Combinations of antibody therapy for treatment of colorectal cancer

By combining the agents that inhibit CD47 with SIRPα and VEGFA/VEGFR, the problem of insufficient response of advanced metastatic colorectal cancer to existing treatments was solved, significantly improving the effect of cancer cell phagocytosis and tumor growth inhibition, especially for KRAS mutations Patients provide more effective treatment options.

CN119013041APending Publication Date: 2024-11-22GILEAD SCIENCES INC
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380029739.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-05
Filing Date
2023-04-03
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Patients with advanced metastatic colorectal cancer have insufficient response to existing targeted therapies and immunotherapy, especially those with KRAS mutations, with poor prognosis and lack of effective biomarkers, which leads to huge treatment challenges.

Method used

As a treatment method, the use of binding agents that inhibit CD47 and SIRPα and binding agents that inhibit vascular endothelial growth factor A (VEGFA) and its homologous receptors, such as molorimab and bevacizumab, is used in combination with the treatment method. To enhance phagocytosis of cancer cells and reduce tumor growth.

Benefits of technology

This method significantly improves the phagocytosis effect of cancer cells and tumor growth inhibition effect, provides a new treatment plan for patients with refractory types such as patients with KRAS mutation, extends survival and improves prognosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013041A_ABST
    Figure CN119013041A_ABST
Patent Text Reader

Abstract

Provided are methods of treating colorectal cancer in a subject, the methods comprising co-administering to the subject an effective amount of: (a) an agent that inhibits binding between CD47 and SIRP alpha (e.g., mololizumab); and (b) an agent (e.g., bevacizumab) that inhibits binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA homologous receptors, optionally further including a chemotherapy regimen (e.g., FOLFIRI).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit under 35 USC § 119(e) of U.S. Provisional Application No. 63 / 327,584, filed on April 5, 2022, which is hereby incorporated by reference in its entirety for all purposes.

[0003] Sequence Listing

[0004] This application contains a sequence listing, which is submitted electronically in .XML file format and is hereby incorporated by reference in its entirety. The XML copy was created on January 14, 2023, is named 1433-WO-PCT_SL.xml, and is 444,843 bytes in size. Background Art

[0005] Metastatic colorectal adenocarcinoma is the second most deadly cancer and the third most common malignancy worldwide. In 2018, 1.8 million new cases and 881,000 deaths were reported, accounting for nearly 10% of new cancer cases and deaths worldwide (Bray et al., CA Cancer J Clin (2018) 68(6):394-424). The number of new cases is expected to increase to nearly 2.5 million in 2035 (Dekker et al., Lancet (2019) 394 (10207):1467-80). In the United States (US), metastatic colorectal cancer (mCRC) is the second leading cause of cancer death (Siegel et al., CA Cancer J Clin (2018) 68 (1):7-30). In 2020, 148,000 new diagnoses and 53,200 deaths were reported, including 17,930 cases and 3,640 deaths in individuals younger than 50 years of age. The 5-year survival rate is approximately 15% (Surveillance Epidemiology and End Results (SEER) 2021; https: / / seer.cancer.gov). Although screening strategies and new treatment modalities have begun to reduce overall CRC mortality, the development of advanced metastatic disease remains associated with poor long-term survival. Recent data have demonstrated a continued decline in morbidity and mortality in patients at least 65 years of age, but an inverse increase in morbidity and mortality in patients younger than 65 years of age. The etiology of this phenomenon has not been determined, and genetic differences may be a factor.

[0006] Colorectal cancer is a heterogeneous disease complicated by the common occurrence of several molecular alterations involving the epidermal growth factor receptor (EGFR) pathway, including mutations in Kirsten rat sarcoma (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and v-raf murine sarcoma viral oncogene homolog B1 (BRAF[V600E]), as well as in the human epidermal growth factor receptor 2 (HER2) and MET receptors. Other molecular alterations include DNA damage repair mechanisms and rare kinase fusions. In addition, tumor laterality is associated with distinct clinical and biological features. Right-sided CRC is more common in women and is associated with Lynch syndrome, mitogen-activated protein kinase (MAPK) signaling, high microsatellite instability (MSI-H), defects in mismatch repair genes, CpG island methylation, and KRAS and BRAF mutations. Left-sided CRC is more common in males and has been associated with familial adenomatous polyposis syndrome, wingless-related integration sites (Wnt) and EGFR signaling, chromosomal instability, v-erb-b2 erythroblastic leukemia viral oncogene homolog 1 (ERBB1) and ERBB2 amplification, adenomatous polyposis coli (APC), p53, and NRAS mutations. These alterations represent oncogenic drivers that coexist in the same tumor with other primary and acquired alterations through a process of clonal selection.

[0007] Advances have been made in the treatment of CRC with therapies that target subgroups with specific mutation profiles. However, resistance to these targeted agents as well as standard chemotherapy based on specific molecular alterations has confounded treatment. Increasingly, enhanced knowledge about tumor biology is driving treatment decision making. The optimal combination and sequencing of these agents continues to evolve. Biologic drugs known to be active against mCRC include drugs targeting vascular endothelial growth factor (VEGF) and its receptor (VEGFR), EGFR, BRAF V600E, HER2, immunotherapy using immune checkpoint inhibitors, and tropomyosin receptor kinase (TRK) inhibitors. Biomarkers have been defined for patients who are candidates for drugs targeting EGFR, HER2, TRK fusions, and immunotherapy, but not yet for other drugs.

[0008] The combination of systemic chemotherapy with anti-EGFR antibodies such as cetuximab and panitumumab has significantly improved prognosis in KRAS wild-type patients (Lee et al., Clin Colorectal Cancer (2015) 14(4):203-18). In addition, patients with MSI-H have demonstrated impressive responses to checkpoint inhibitors such as the anti-programmed cell death-1 (PD-1) agent pembrolizumab (Le et al., N Engl J Med (2015) 372(26):2509-20; Overman et al., Abstract 3501, American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7, 2016; Chicago, Illinois), but this represents only a subset of this tumor type (10% to 15% at diagnosis). On the other hand, certain patient subgroups, such as those with KRAS mutations, which comprise more than 40% of CRCs (Vaughn et al., Genes Chromosomes Cancer (2011) 50(5):307-12), do not respond to anti-EGFR antibody therapy (Allegra et al., J Clin Oncol (2009) 27(12):2091-6). Patients with KRAS mutant mCRC have a poor prognosis with limited available therapies. For most patients who are ineligible or unable to benefit from new targeted therapies or immunotherapies, standard of care (SOC) double or triple chemotherapy-based regimens associated with systemic toxicity, unsatisfactory response rates, unpredictable innate and acquired resistance, and low tumor-specific selectivity are the only available treatment options. Summary of the invention

[0009] In one aspect, a method of treating a subject's previously treated advanced inoperable metastatic colorectal cancer is provided, the method comprising co-administering to the subject an effective amount of: (a) an agent that inhibits binding between CD47 and SIRPα; and (b) an agent that inhibits binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA cognate receptors. In some embodiments, the one or more VEGFA cognate receptors are selected from fms-related receptor tyrosine kinase 1 (FLT1, also known as VEGFR1) and kinase insert domain receptor (KDR, also known as VEGFR2). In some embodiments, the agent that inhibits binding between CD47 and SIRPα comprises an antibody that binds to CD47. In some embodiments, the antibody that binds to CD47 is selected from magrolimab, lemzoparlimab, letaplimab, ligufalimab, AO-176, simridarlimab (IBI-322), gentulizumab, ZL-1201, IMC-002, SRF-231, CC-90002 (also known as INBRX-103), NI-1701 (also known as TG-1801) and STI-6643. In some embodiments, the agent that inhibits the binding between CD47 and SIRPα comprises an antibody that binds to SIRPα. In some embodiments, the antibody that binds to SIRPα is selected from GS-0189 (also known as FSI-189), CC-95251, BI-765063 and APX-700. In some embodiments, the agent that inhibits the binding between CD47 and SIRPα comprises a SIRPα-Fc fusion protein. In some embodiments, the SIRPα-Fc fusion protein is selected from evorpacept (ALX-148), timdarpacept, TTI-621, TTI-622, JMT601 (CPO107) and SL-172154. In some embodiments, the agent that inhibits the binding between VEGFA and one or more VEGFA cognate receptors comprises an antibody that binds to VEGFA. In some embodiments, the antibody that binds to VEGFA is selected from bevacizumab, ranibizumab, brolucizumab, ivonescimab, sevacizumab and faricimab. In some embodiments, the agent that inhibits binding between VEGFA and one or more VEGFA cognate receptors comprises an antibody that binds to VEGFR2.In some embodiments, the antibody that binds to VEGFR2 is ramucirumab. In some embodiments, the agent that inhibits the binding between VEGFA and one or more VEGFA cognate receptors comprises a VEGFA-Fc fusion protein. In some embodiments, the VEGFA-Fc fusion protein is selected from conbercept and aflibercept. In some embodiments, the agent that inhibits the binding between VEGFA and one or more VEGFA cognate receptors comprises a small molecule inhibitor. In some embodiments, the small molecule is selected from surufatinib, catequentinib hydrochloride, fruquintinib, tivozanib, regorafenib, axitinib, vandetanib, chiauranib, pazopanib hydrochloride, sunitinib malate, and pegaptaniboctasodium.

[0010] In another aspect, a method for treating, alleviating, reducing, preventing or delaying recurrence or metastasis of colorectal cancer (CRC) in a subject is provided, the method comprising co-administering an effective amount of mololimab and bevacizumab to the subject. In some embodiments, the cancer is (i) unresectable, locally advanced or (ii) metastatic. In some embodiments, the cancer is unresectable, locally advanced and the subject is untreated. In another aspect, a method for treating a subject's previously treated advanced inoperable metastatic colorectal cancer is provided, the method comprising co-administering an effective amount of: (a) mololimab; and (b) bevacizumab to the subject. In some embodiments, mololimab is first administered at a priming dose of less than 10 mg / kg, and then administered at one or more therapeutic doses of at least 15 mg / kg, for example, at least 30 mg / kg, 45 mg / kg, 60 mg / kg. In some embodiments, mololimab is first administered with a primary immunization dose of less than 5 mg / kg, and then administered with at least 30 mg / kg, for example, one or more therapeutic doses of 45 mg / kg, 60 mg / kg. In some embodiments, mololimab is first administered with a primary immunization dose of 1 mg / kg, then administered with one or more therapeutic doses of 30 mg / kg, and then administered with one or more therapeutic doses of 60 mg / kg. In some embodiments, mololimab is first administered with a primary immunization dose of 1 mg / kg, then administered with one or more therapeutic doses of 20 mg / kg, and then administered with one or more therapeutic doses of 45 mg / kg. In some embodiments, mololimab is first administered with a primary immunization dose of 1 mg / kg, then administered with one or more therapeutic doses of 15 mg / kg, and then administered with one or more therapeutic doses of 30 mg / kg. In some embodiments, mololimab is administered intravenously, subcutaneously, or intratumorally. In some embodiments, bevacizumab is administered at one or more doses in the range of 5 mg / kg to 15 mg / kg, e.g., 5 mg / kg to 7.5 mg / kg or 7.5 mg / kg to 15 mg / kg. In some embodiments, bevacizumab is administered at one or more doses of 5 mg / kg. In some embodiments, bevacizumab is administered intravenously, subcutaneously, or intratumorally.In some embodiments, mololimab and bevacizumab are administered in the first, second, and third 28-day cycles, wherein: (a) for the first 28-day cycle, mololimab is administered at a dose of 1 mg / kg on day 1 and at a dose of 30 mg / kg weekly (QW) starting on day 8; and bevacizumab is administered at a dose of 5 mg / kg on days 1 and 15; (b) for the second 28-day cycle, mololimab is administered at a dose of 30 mg / kg weekly (QW); and bevacizumab is administered at a dose of 5 mg / kg on days 1 and 15; and (c) for the third 28-day cycle, mololimab is administered at a dose of 30 mg / kg Q2W; and bevacizumab is administered at a dose of 5 mg / kg on days 1 and 15. In some embodiments, mololimab and bevacizumab are administered in the first, second, and third 28-day cycles, wherein: (a) for the first 28-day cycle, mololimab is administered at a dose of 1 mg / kg on day 1 and at a dose of 20 mg / kg weekly (QW) starting on day 8; and bevacizumab is administered at a dose of 5 mg / kg on days 1 and 15; (b) for the second 28-day cycle, mololimab is administered at a dose of 20 mg / kg weekly (QW); and bevacizumab is administered at a dose of 5 mg / kg on days 1 and 15; and (c) for the third 28-day cycle, mololimab is administered at a dose of 20 mg / kg Q2W; and bevacizumab is administered at a dose of 5 mg / kg on days 1 and 15. In some embodiments, mololimab and bevacizumab are administered in the first, second, and third 28-day cycles, wherein: (a) for the first 28-day cycle, mololimab is administered at a dose of 1 mg / kg on day 1 and at a dose of 15 mg / kg weekly (QW) starting on day 8; and bevacizumab is administered at a dose of 5 mg / kg on days 1 and 15; (b) for the second 28-day cycle, mololimab is administered at a dose of 15 mg / kg weekly (QW); and bevacizumab is administered at a dose of 5 mg / kg on days 1 and 15; and (c) for the third 28-day cycle, mololimab is administered at a dose of 15 mg / kg Q2W; and bevacizumab is administered at a dose of 5 mg / kg on days 1 and 15.

[0011] With regard to other embodiments of the methods described above and herein, in some embodiments, the method further comprises co-administering a chemotherapy regimen. In some embodiments, the method comprises co-administering a FOLFOX regimen, a FOLFIRI regimen, a XELIRI (also known as CAPIRI) regimen, a FOLFOXIRI regimen, a XELOXIRI regimen, or a FOLFIRINOX regimen. In some embodiments, the method comprises co-administering a FOLFIRI regimen or a XELIRI regimen. In some embodiments, the method comprises co-administering a FOLFIRI regimen. In some embodiments, the cancer has CD47 cell surface expression. In some embodiments, the cancer does not comprise a BRAF V600E mutation. In some embodiments, the cancer does not comprise high or observable or detectable microsatellite instability. In some embodiments, the cancer has one or more KRAS mutations, and the subject does not respond to anti-EGFR antibody therapy (e.g., the cancer progresses or does not regress). In some embodiments, the cancer is an adenocarcinoma originating from the colon or rectum. In some embodiments, the cancer has progressed after one or more previous systemic therapies. In some embodiments, one or more prior therapies include administering one or more agents selected from the group consisting of 5-fluorouracil (5-FU), oxaliplatin, bevacizumab, cetuximab, and panitumumab. In some embodiments, treatment results in a reduction in overall tumor burden of at least 15%, at least 20%, at least 30%, or at least 40%, as determined using a linear dimensional method (e.g., RECIST v1.1). In some embodiments, the method includes reducing the size or eliminating metastases. In some embodiments, the method further includes administering one or more therapeutic antibodies. In some embodiments, the method includes co-administering an antibody that binds to an epidermal growth factor receptor (EGFR). In some embodiments, the antibody that binds to EGFR is selected from cetuximab and panitumumab. In some embodiments, the method further includes co-administering one or more blockers or inhibitors of one or more T cell stimulatory immune checkpoint proteins or receptors. In some embodiments, one or more immune checkpoint inhibitors include protein (e.g., antibody) inhibitors of PD-L1 (CD274), PD-1 (PDCD1), or CTLA4. In some embodiments, the one or more immune checkpoint proteins or receptors are selected from: CD274 (CD274, PDL1, PD-L1) and programmed cell death 1 (PDCD1, PD1, PD-1).In some embodiments, the protein (e.g., antibody) inhibitor of CTLA4 is selected from ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884 (zalifrelimab), BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AG EN-2041, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI-5D3H5, FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4) and AK-104 (CTLA4 / PD-1). In some embodiments, the protein (e.g., antibody) inhibitor of programmed cell death 1 (PDCD1; NCBI Gene ID: 5133; CD279, PD-1, PD1) is selected from sepalizumab (AB122, GLS-010, WBP-3055), pembrolizumab (KEYTRUDA. ® , MK-3475, SCH900475), nivolumab (OPDIVO ® , BMS-936558, MDX-1106), Cimiprilimab (LIBTAYO ® ; Cimiprizumab-rwlc, REGN-2810), pidilizumab (CT-011), AMG-404, MEDI0680 (AMP-514), spartalizumab (PDR001), tislelizumab (BGB-A317), toripalizumab (JS-001), genoluzumab (CBT-501, APL-501, GB 226), SHR-1201, carrelizumab (SHR-1210), sintilimab (TYVYT ®; IBI-308), dotalimumab (TSR-042, WBP-285), lanrolizumab (MK-3475); saxanthlimab (PF-06801591), cilizumab (JNJ-63723283), slulizumab (HLX-10), rivolimab (MGA-012), bastimumab (AGEN2034), palollimumab (BCD 100), buglilimab (ABBV-181), woprelizumab (JTX-4014), AK-103 (HX-008), AK-105, CS 1003, BI-754091, LZM-009, Sym-021, BAT-1306, PD1-PIK, Tepolizumab (MGD013; PD-1 / LAG-3), RO-7247669 (PD-1 / LAG-3), FS-118 (LAG-3 / PD-L1), RO-7121661 (PD 1 / TIM-3), RG7769 (PD-1 / TIM-3), PF-06936308 (PD 1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD 1 / CTLA4), XmAb-20717 (PD 1 / CTLA4), AK-104 (CTLA4 / PD-1), and MEDI-5752 (CTLA4 / PD-1). In some embodiments, a protein (eg, antibody) inhibitor of the CD274 molecule (NCBI Gene ID: Gene ID: 29126; B7-H, B7H1, PD-L1) is selected from atezolizumab (TECENTRIQ ® ), Avelumab (BAVENCIO ® ; MSB0010718C), Envolizumab (ASC22), Durvalumab (IMFINZI ®; MEDI-4736), BMS-936559 (MDX1105), Coxilimab (CK-301), Lodalimab (LY 3300054), Galivizumab (BGBA333), Envolimab (KN035), Oculizumab (HLX 20), Manelimab (BCD 135), CX-072, CBT-502 (TQB2450), MSB-2311, SHR-1316, Sugelimab (CS-1001; WBP3155), A167 (KL-A167, HBM9167), STI-A1015 (IMC-001), FAZ-053, BMS-936559 (MDX1105), INCB086550, GEN-1046 (PD-L1 / 4-1BB), FPT-155 (CTLA4 / PD-L1 / CD28), M7824 (PD-L1 / TGFβ-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM-3 / PDL1), INBRX-105 (4-1BB / PDL1), and GNS-1480 (PD-L1 / EGFR). In some embodiments, the method comprises co-administering an agonist of fms-related receptor tyrosine kinase 3 (FLT3). In some embodiments, the agonist of FLT3 is selected from GS-3583 and CDX-301. In some embodiments, an agent that inhibits binding between CD47 and SIRPα and an agent that inhibits binding between VEGFA and one or more VEGFA cognate receptors are administered in a combined synergistic amount. In some embodiments, the administration of an agent that inhibits the binding between CD47 and SIRPα and an agent that inhibits the binding between VEGFA and one or more VEGFA cognate receptors provides a synergistic effect. In some embodiments, when the effect of the combination is compared with the effect of a single agent that inhibits the binding between CD47 and SIRPα or an agent that inhibits the binding between VEGFA and one or more VEGFA cognate receptors, the synergistic effect is to increase cancer cell death and / or reduce cancer cell growth. In some embodiments, when the effect of the combination is compared with the effect of a single agent that inhibits the binding between CD47 and SIRPα or an agent that inhibits the binding between VEGFA and one or more VEGFA cognate receptors, the synergistic effect is to increase the phagocytosis of cancer cells by macrophages. In some embodiments, when the effect of the combination is compared with the effect of a single agent that inhibits the binding between CD47 and SIRPα or an agent that inhibits the binding between VEGFA and one or more VEGFA cognate receptors, the synergistic effect is to increase or enhance the reduction of tumor burden. In some embodiments, the subject is human.

[0012] In other aspects, a kit is provided, comprising one or more unit doses of: (a) an agent that inhibits binding between CD47 and SIRPα; and (b) an agent that inhibits binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA homologous receptors. In some embodiments, one or more VEGFA homologous receptors are selected from fms-related receptor tyrosine kinase 1 (FLT1, also known as VEGFR1) and kinase insert domain receptor (KDR, also known as VEGFR2). In some embodiments, the kit also comprises one or more unit doses of chemotherapy regimens. In some embodiments, the kit also comprises components (e.g., active agents) for the FOLFOX regimen, the FOLFIRI regimen, the XELIRI (also known as CAPIRI) regimen, the FOLFOXIRI regimen, the XELOXIRI regimen, or the FOLFIRINOX regimen. In some embodiments, the kit comprises components for the FOLFIRI regimen or the XELIRI regimen. In some embodiments, the kit comprises components for the FOLFOX regimen, the FOLFIRI regimen, the XELIRI (also known as CAPIRI) regimen, the FOLFOXIRI regimen, the XELOXIRI regimen, or the FOLFIRINOX regimen. In some embodiments, the kit comprises components for the FOLFIRI regimen or the XELIRI regimen. In some embodiments, the agent that inhibits the binding between CD47 and SIRPα (e.g., mololimab) and the agent that inhibits the binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA homologous receptors (e.g., bevacizumab) are in separate containers. In some embodiments, the separate containers are selected from vials, ampoules, and preloaded syringes. In some embodiments, the agent that inhibits the binding between CD47 and SIRPα comprises an antibody that binds to CD47. In some embodiments, the antibody that binds to CD47 is selected from mololimab, leszolimab, letlimab, lefalimab, AO-176, sirelimab (IBI-322), gintolizumab, ZL-1201, IMC-002, SRF-231, CC-90002 (also known as INBRX-103), NI-1701 (also known as TG-1801) and STI-6643. In some embodiments, the agent that inhibits the binding between CD47 and SIRPα comprises an antibody that binds to SIRPα. In some embodiments, the antibody that binds to SIRPα is selected from GS-0189 (also known as FSI-189), CC-95251, BI-765063 and APX-700. In some embodiments, the agent that inhibits the binding between CD47 and SIRPα comprises a SIRPα-Fc fusion protein.In some embodiments, the SIRPα-Fc fusion protein is selected from ALX-148, TTI-621, TTI-622, JMT601 (CPO107) and SL-172154. In some embodiments, the kit further comprises one or more unit doses of one or more therapeutic antibodies. In some embodiments, the kit further comprises one or more blockers or inhibitors of one or more T cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the kit includes a protein (e.g., antibody) inhibitor of PD-L1 (CD274), PD-1 (PDCD1), or CTLA4. In some embodiments, the kit includes a protein (e.g., antibody) inhibitor of PD-L1 (CD274) or PD-1 (PDCD1). In some embodiments, the protein (e.g., antibody) inhibitor of CTLA4 is selected from ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884 (zeflimab), BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN2041, JHL-1155, KN-0 44, CG-0161, ATOR-1144, PBI-5D3H5, FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4) and AK-104 (CTLA4 / PD-1). In some embodiments, the protein (e.g., antibody) inhibitor of programmed cell death 1 (PDCD1; NCBI gene ID: 5133; CD279, PD-1, PD1) is selected from sepalizumab (AB122, GLS-010, WBP-3055), pembrolizumab (KEYTRUDA. ® , MK-3475, SCH900475), nivolumab (OPDIVO ® , BMS-936558, MDX-1106), Cimiprilimab (LIBTAYO ®; Cimiprizumab-rwlc, REGN-2810), pidilizumab (CT-011), AMG-404, MEDI0680 (AMP-514), spartalizumab (PDR001), tislelizumab (BGB-A317), toripalizumab (JS-001), genoluzumab (CBT-501, APL-501, GB 226), SHR-1201, carrelizumab (SHR-1210), sintilimab (TYVYT ® ; IBI-308), dotalimumab (TSR-042, WBP-285), lanrolizumab (MK-3475); saxanthlimab (PF-06801591), cilizumab (JNJ-63723283), slulizumab (HLX-10), rivolimab (MGA-012), bastimumab (AGEN2034), palollimumab (BCD 100), buglilimab (ABBV-181), woprelizumab (JTX-4014), AK-103 (HX-008), AK-105, CS 1003, BI-754091, LZM-009, Sym-021, BAT-1306, PD1-PIK, Tepolizumab (MGD013; PD-1 / LAG-3), RO-7247669 (PD-1 / LAG-3), FS-118 (LAG-3 / PD-L1), RO-7121661 (PD 1 / TIM-3), RG7769 (PD-1 / TIM-3), PF-06936308 (PD 1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD 1 / CTLA4), XmAb-20717 (PD 1 / CTLA4), AK-104 (CTLA4 / PD-1), and MEDI-5752 (CTLA4 / PD-1). In some embodiments, a protein (eg, antibody) inhibitor of the CD274 molecule (NCBI Gene ID: Gene ID: 29126; B7-H, B7H1, PD-L1) is selected from atezolizumab (TECENTRIQ ® ), Avelumab (BAVENCIO ® ; MSB0010718C), Envolizumab (ASC22), Durvalumab (IMFINZI ®; MEDI-4736), BMS-936559 (MDX1105), coxilimab (CK-301), lodalimab (LY3300054), galifoliumab (BGB A333), envolimab (KN035), oclimab (HLX 20), manelimab (BCD 135), CX-072, CBT-502 (TQB2450), MSB-2311, SHR-1316, sugemalimab (CS-1001; WBP3155), A167 (KL-A167, HBM 9167), STI-A1015 (IMC-001), FAZ-053, BMS-936559 (MDX1105), INCB086550, GEN-1046 (PD-L1 / 4-1BB), FPT-155 (CTLA4 / PD-L1 / CD28), M7824 (PD-L1 / TGFβ-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM-3 / PDL1), INBRX-105 (4-1BB / PDL1), and GNS-1480 (PD-L1 / EGFR). In some embodiments, the kit further comprises co-administering an agonist of fms-related receptor tyrosine kinase 3 (FLT3). In some embodiments, the agonist of FLT3 is selected from GS 3583 and CDX-301. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 The protocol for the clinical study described in this article is described. 5-FU = 5-fluorouracil; CRC = colorectal cancer; EU = European Union; FOLFIRI = 5-fluorouracil, irinotecan, and leucovorin; KRAS = Kirsten rat sarcoma; KRASmt = KRAS mutant; KRASwt = KRAS wild-type; ROW = rest of the world; US = United States; FOLFIRI: irinotecan 180 mg / m 2 , leucovorin 400 mg / m 2 , fluorouracil 400 mg / m 2 .

[0014] Figures 2A-2B illustrate that irinotecan upregulates the expression of prophagocytic receptors and promotes in vitro phagocytosis of colorectal cancer cells. A. LS 174T cells were incubated with titrations of irinotecan for 24 hours, washed, and stained for CALR and PS. Flow cytometry was used to analyze and quantify the frequency of stained cells. The shaded area indicates the reported IC50 for each drug. B. LS-174T or HCT-116 cells were pretreated with irinotecan or oxaliplatin at the indicated concentrations for 24 hours. Tumor cells were washed, CFSE-labeled, and co-cultured with monocyte-derived macrophages at a 2:1 target to effector ratio for 2 hours. The phagocytic index (defined as the percentage of macrophages that phagocytized tumor cells to total macrophages) was quantified using flow cytometry. 5F9, Magro = magrolimab; CALR = calreticulin; CFSE = carboxyfluorescein succinimidyl ester; hr = hours; IC50 = half maximal inhibitory concentration; MFI = median fluorescence intensity; PBS = phosphate-buffered saline; PS = phosphatidylserine; SN 38 = irinotecan.

[0015] Figure 3 Colorectal cancer cells growth inhibition with irinotecan and oxaliplatin are described. Tumor cells were treated with titrations of irinotecan, oxaliplatin, or vehicle control and their growth was monitored 24, 48, and 72 hours after drug treatment. Commercially available reagents (Promega, Cell-titer Glo ® ) is an indirect assay for cell growth, which measures intracellular adenosine triphosphate (ATP) levels and directly correlates to the number of viable cells. Treated cells are normalized to dimethyl sulfoxide-treated control samples to determine the percentage of growth inhibition. DMSO = dimethyl sulfoxide; Oxa = oxaliplatin; SN-38 = irinotecan.

[0016] Figure 4 The combination of irinotecan and magrolimab provides additive therapeutic efficacy in the chlordiazepoxide (CDX) model of colorectal cancer (CRC). IP = intraperitoneal; Magro = magrolimab. NOD scid γ mice were implanted subcutaneously with 3 million HT-29 cells. When the mean tumor volume reached 60 120 mm3, mice were randomized into groups of 8 and treated with isotype or magrolimab by IP injection (250 µg, 3 times per week). Irinotecan (20 mg / kg, 3 times per week) and oxaliplatin (5 mg / kg, twice per week) were also administered by IP injection. The resulting tumor volume was measured using a caliper and reported during the duration of the study. DETAILED DESCRIPTION

[0017] 1. Introduction

[0018] Provided is a method of treating a subject's previously treated advanced inoperable metastatic colorectal cancer, the method comprising co-administering to the subject an effective amount of: (a) an agent that inhibits binding between CD47 and SIRPα (e.g., mololimab); and (b) an agent that inhibits binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA cognate receptors (e.g., bevacizumab). Surprisingly, the combined administration of an agent that inhibits binding between CD47 and SIRPα (e.g., mololimab) and an agent that inhibits binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA cognate receptors (e.g., bevacizumab) results in synergistic (i.e., more than additive) phagocytosis of colorectal cancer cells and a reduction in tumor growth.

[0019] The role of chemotherapy in the treatment of metastatic colorectal cancer

[0020] Despite the well-known genetic differences in the disease, chemotherapy treatment for CRC remains largely consistent. Patients with newly diagnosed mCRC are typically treated with 5-fluorouracil (5 FU)-based regimens such as FOLFOX (5-FU, oxaliplatin, and leucovorin [LV]) or FOLFIRI (5-fluorouracil, irinotecan, and leucovorin) alone or in combination with therapies that block EGFR or VEGF signaling.

[0021] A meta-analysis of seven phase 3 studies evaluating regimens associated with 5-FU / LV, oxaliplatin, and irinotecan showed that patients receiving the three drugs showed prolonged survival compared with patients receiving a single dual regimen, regardless of the first dual regimen used (Grothey et al., J Clin Oncol (2004) 22(7):1209-14). However, capecitabine showed equivalence to 5-FU and represents a well-tolerated alternative combination to irinotecan or oxaliplatin. After disease progression, crossover second-line regimens combining fluoropyrimidine / oxaliplatin or fluoropyrimidine / irinotecan with another agent showed satisfactory response rates and stable disease over a period of several months (Tournigand et al., J Clin Oncol (2004) 22(2):229-37). The combination of FOLFIRI and FOLFOX6 was evaluated as a crossover first- or second-line therapy after progression. Both groups showed similar response rates (first-line treatment: FOLFIRI 56% vs. FOLFOX 54%, second-line treatment: FOLFIRI 4% vs. FOLFOX 15%). There were no significant differences in progression-free survival (PFS) (first-line treatment: FOLFIRI 8.5 months vs. FOLFOX 8.0 months and second-line treatment FOLFIRI 2.5 months vs. FOLFOX 4.2 months) or overall survival (OS) (FOLFIRI-FOLFOX: 21.5 months vs. FOLFOX FOLFIRI 20.6 months).

[0022] Rationale for combination therapy co-targeting CD47 and VEGFA

[0023] Cluster of differentiation 47 (CD47; NCBI Gene ID: 961) is a molecule that mediates cancer cell evasion of innate immune surveillance. CD47 expression is a well-characterized mechanism by which cancer cells (including cancer stem cells) overcome phagocytosis due to intrinsic expression of prophagocytic "eat me" signals (Jaiswal et al., Cell (2009) 138(2):271-85; Majeti et al., Cell (2009) 138(2):286-99). Progression from normal cells to cancer cells involves changes in genes and / or gene expression that trigger programmed cell death and programmed cell clearance (Chao et al., Nat Rev Cancer. (2012) 12(1):58-67). Many steps in cancer progression subvert the various mechanisms of programmed cell death, and expression of the dominant anti-phagocytic signal CD47 may represent an important checkpoint (Chao et al., 2012, supra). Increased CD47 expression was first identified on leukemic stem cells in human acute myeloid leukemia (AML) (Majeti et al., 2009, supra), and has since been found to be increased on the surface of cancer cells in a diverse group of human tumor types.

[0024] In mouse xenograft models, monoclonal antibodies (mAbs) blocking CD47 inhibit human xenograft tumor growth and metastasis by enabling phagocytosis and elimination of cancer cells from various hematological malignancies and solid tumors (Chao et al., Cancer Res (2011) 71(4):1374-84; Chao et al., Cell (2010) 142:699-713; Chao et al., Blood (2011) 118(18):4890-901; Edris et al., Proc Natl Acad Sci USA (2012) 109(17):6656-61; Kim et al., Proc Natl Acad Sci USA (2012) 109(17):6656-61; Majeti et al., supra; Willingham et al., Proc Natl Acad Sci USA (2012) 109(17):6662-7). Binding of CD47 expressed by cancer cells to its ligand, signal regulatory protein α (SIRPα), expressed on phagocytic cells results in inhibition of tumor cell phagocytosis. Thus, blocking the CD47 SIRPα signaling pathway by anti-CD47 antibodies results in phagocytosis and elimination of tumor cells. Selective targeting of tumor cells by anti-CD47 antibodies is due to the presence of pro-phagocytic signals that are primarily expressed on tumor cells and not on normal cell counterparts (Chao et al., Sci Transl Med (2010) 2(63):63ra94). In addition, after tumor cell phagocytosis, anti-CD47 antibodies can induce anti-cancer T cell responses by cross-presenting tumor antigens by macrophages and antigen-presenting cells (Liu et al., Nat Med (2015) 21(10):1209-15, Tseng et al., Proc Natl Acad Sci USA (2013) 110(27):11103-8).

[0025] Magrolimab is a humanized anti-CD47 mAb that blocks the interaction of CD47 with its receptor and enables phagocytosis of human cancer cells (Liu et al., PLoS One. (2015) 10 (9): e0137345). The activity of magrolimab depends primarily on blocking the binding of CD47 to SIRPα and is independent of the recruitment of fragment crystallizable (Fc)-dependent effector functions, although the presence of the immunoglobulin G4 (IgG4) Fc domain is required for its full activity. To this end, magrolimab was engineered with the human IgG4 isotype, which is relatively inefficient in recruiting Fc-dependent effector functions that may enhance toxic effects on cells that normally express CD47 (Liu et al., PLoS One. (2015), supra). Nonclinical studies using xenograft cancer models have provided convincing evidence that magrolimab triggers phagocytosis and elimination of cancer cells from human solid tumors and hematological malignancies. Based on this mechanism of action (MOA) and its potent nonclinical activity, mololimab is being developed as a therapeutic candidate for both solid tumors and hematological malignancies.

[0026] Vascular endothelial growth factor A (VEGFA, NCBI gene ID: 7422; also referred to herein as VEGF) is a factor involved in tumor angiogenesis, permeability, and survival of tumor vascularization (Gerber et al., Cancer Res (2005) 65 (3): 671-80). VEGF inhibition induces disruption of newly formed microvascularization and endothelial cell apoptosis (Erber et al., FASEB J (2004) 18 (2): 338-40; Ferrara et al., Endocrine Rev (2004) 25 (4): 581-611).

[0027] One VEGF pathway inhibitor is bevacizumab, a humanized monoclonal antibody that targets circulating VEGF and prevents tumor angiogenesis. Binding of bevacizumab to VEGF prevents the latter from binding to its endothelial cell membrane receptors, Flt-1 and kinase insert domain receptor (KDR). In models of angiogenesis, interaction of VEGF with its receptor induces tumor growth and neovascularization. In addition to antiangiogenic properties, targeting the VEGF pathway with bevacizumab has been reported to reduce the infiltration of immunosuppressive monocyte-derived suppressor cells and regulatory T cells and upregulate cytotoxic T cells into the tumor microenvironment.

[0028] Randomized clinical studies have shown that bevacizumab combined with fluoropyrimidine-based chemotherapy is an effective treatment for patients with mCRC, and such combinations are now considered standard of care in the first-line and second-line settings (Hurwitz et al., N Engl J Med (2004) 350(23):2335-42; Saltz et al., J Clin Oncol (2008) 26(12):2013-9; Tebbutt et al., J Clin Oncol (2010) 28(19):3191-8). Various studies have validated the efficacy of bevacizumab in patients without prior exposure or treatment with bevacizumab. In the bevacizumab-naive second-line setting, for patients with CRC who progressed after FOLFOX therapy, longer PFS (7.3 vs. 4.7 months, hazard ratio [HR] = 0.61, P value < 0.001) and OS (12.9 vs. 10.8 months, HR = 0.75, P value = 0.0011), as well as better response rates (22.7% vs. 8.6%, P value = 0.0001) were observed in the E3200 study comparing the combination of FOLFOX and bevacizumab with FOLFOX alone (Giantonio et al., J Clin Oncol (2007) 25(12):1539-44).

[0029] The ML18147 study (Bennouna et al., Lancet Oncol (2013) 14(1):29-37) and the BEBYP study (Masi et al., Abstract LBA17, Ann Oncol. (2012) doi.org / 10.1016 / S0923-7534(20)34318-0) indicated that continued VEGF inhibition beyond first disease progression with bevacizumab plus standard second-line chemotherapy (switch from first-line regimen) significantly prolonged OS and PFS in patients with mCRC. Continuing bevacizumab for those who progressed after first-line chemotherapy still contributed to improvements in PFS (5.7 vs. 4.1 months, HR = 0.68, P value < 0.001) and OS (11.2 vs. 9.9 months, HR = 0.81, P value = 0.0062) compared with standard chemotherapy alone.

[0030] Rationale for dose selection of mololimab

[0031] The rationale for dosing of mololimab proposed in this study was derived from safety, efficacy, and PK / pharmacodynamic (PD) data and modeling and simulation analyses based on data obtained from all ongoing and completed clinical studies using mololimab in patients with solid tumors, non-Hodgkin's lymphoma (NHL), and acute myeloid leukemia (AML) / myelodysplastic syndrome (MDS). In addition, nonclinical studies have demonstrated activity against human solid tumors (e.g., breast cancer, ovarian cancer, pancreatic cancer, colon cancer, leiomyosarcoma, bladder cancer, prostate cancer, etc.) and hematological malignancies (acute myeloid leukemia (AML), acute lymphoblastic leukemia, non-Hodgkin's lymphoma (NHL), myeloma, myelodysplastic syndrome (MDS), etc.).

[0032] In the first-in-human study of mololimab in patients with solid tumors and lymphomas, mololimab was tested as a monotherapy at weekly doses of up to 45 mg / kg after an initial priming dose of 1 mg / kg on the first day. The use of an initial 1 mg / kg priming dose was integrated into the dosing regimen to alleviate on-target anemia induced by CD47 blockade. The initial priming dose resulted in the elimination of aged RBCs that were sensitive to CD47 blockade and triggered reticulocytosis of young RBCs that were not affected by CD47 blockade (Chen et al., Blood (ASH Annual Meeting Abstracts) (2018) 132 (Suppl 1): 2327). The use of the priming dose results in an initial, transient, and mild anemia that generally normalizes back to baseline within a few weeks, even in the presence of repeated therapeutic doses of mololimab (Advani et al., N Engl J Med (2018) 379 (18): 1711-21; Liu et al., PLoS One. (2015) 10 (9): e0137345; Sikic et al., J Clin Oncol (2019) 37 (12): 946-53). Based on PK-PD modeling, a maintenance dose of 30 mg / kg every 2 weeks is expected to provide more than 90% CD47 receptor occupancy in peripheral blood and tumor tissue, and is therefore expected to provide maximum efficacy while maintaining adequate safety. In solid tumors where combination therapy is given according to a 3-week cycle, dosing mololimab every 3 weeks optimizes patient and caregiver convenience. Mololimab 60 mg / kg every 3 weeks is expected to provide similar trough concentrations and receptor occupancy (RO) as 30 mg / kg dosing every 2 weeks, which is used in Phase 3 studies for AML and MDS. Updated pharmacokinetic (PK) modeling from study 5F9005 (NCT03248479) showed that a mololimab dose of 45 mg / kg every 3 weeks was suboptimal in maintaining trough concentrations compared to 30 mg / kg every 2 weeks and 60 mg / kg every 3 weeks. Maintaining adequate trough concentrations may be necessary for optimal efficacy, given that some patients may experience dose delays due to toxicity. In addition, PK / pharmacodynamic (PD) modeling also indicates that RO will be maintained at maximal levels (>90%) in peripheral blood and tumor tissues under these extended interval dosing regimens. Based on the full safety data in a variety of tumor populations, the mololimab dosing regimen proposed in this study is expected to have an acceptable safety profile as a monotherapy and in combination with other tumor-targeted antibodies and chemotherapeutic agents.

[0033] 2. Agents that inhibit the binding between CD47 and SIRPα

[0034] a. Antibodies or antigen-binding fragments thereof that bind to CD47

[0035] In various embodiments, the agent that inhibits the binding between CD47 and SIRPα is an antibody or antigen-binding fragment thereof that binds to CD47 (also known as IAP, MER6, OA3; NCBI gene ID: 961; UniProt Q08722). In various embodiments, the antibody that binds to CD47 has an Fc with effector function. In various embodiments, the antibody that binds to CD47 is IgG4 or IgG1. Examples of anti-CD47 antibodies used include, but are not limited to, mololimab, leszolimab, leterlimab (AK117), AO-176, sirelimab (IBI-322), gentolizumab, ZL-1201, IMC-002, SRF-231, CC-90002 (also known as INBRX-103), NI-1701 (also known as TG-1801), STI-6643 (Vx-1004), CNTO-7108, RCT-1938, RRx-001, DSP-107, VT-1021, and SGN-CD47M.

[0036] In various embodiments, the antibody targeting CD47 is a bispecific antibody. Examples of bispecific antibodies targeting CD47 include, but are not limited to, IBI-322 (CD47 / PD-L1), IMM-0306 (CD47 / CD20), TJ-L1C4 (CD47 / PD-L1), HX-009 (CD47 / PD-1), PMC-122 (CD47 / PD-L1), PT-217 (CD47 / DLL3), IMM-26011 (CD47 / FLT3), IMM-0207 (CD47 / VEGF), IMM-2902 (CD47 / HER2), BH29xx (CD47 / PD-L1), IMM-03 (CD47 / CD20), IMM-2502 (CD47 / PD-L1), HMBD-004B (CD47 / BCMA), HMBD-004A (CD47 / CD33). Examples of anti-CD47 antibodies include IBI-188, TJC-4, SHR-1603, HLX-24, LQ-001, IMC-002, ZL-1201, IMM-01, B6H12, GenSci-059, TAY-018, PT-240, 1F8-GMCSF, SY-102, and KD-015.

[0037] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to Kabat):

[0038] ●SEQ ID NO: 1, 2, 3, 4, 5 and 6;

[0039] ●SEQ ID NO: 7, 8, 9, 10, 11 and 12;

[0040] ●SEQ ID NO: 13, 14, 15, 16, 17 and 18;

[0041] ●SEQ ID NO: 19, 20, 21, 22, 23 and 24;

[0042] SEQ ID NOs: 210, 211, 212, 213, 214 and 215;

[0043] ●SEQ ID NO: 216, 217, 218, 219, 220 and 221; or

[0044] ●SEQ ID NO: 345, 346, 347, 348, 23 and 349.

[0045] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to IMGT):

[0046] ●SEQ ID NO: 25, 26, 27, 28, 29 and 6;

[0047] ●SEQ ID NO: 30, 31, 32, 33, 34 and 12;

[0048] ●SEQ ID NO: 35, 36, 37, 38, 39 and 18;

[0049] ●SEQ ID NO: 40, 41, 42, 43, 44 and 24;

[0050] ●SEQ ID NO: 222, 223, 224, 225, 226 and 215;

[0051] ●SEQ ID NO: 227, 228, 229, 230, 231 and 221; or

[0052] ●SEQ ID NO: 350, 351, 352, 353, 44 and 354.

[0053] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to Chothia):

[0054] ●SEQ ID NO: 45, 46, 47, 48, 29 and 49;

[0055] ●SEQ ID NO: 50, 51, 52, 53, 34 and 54;

[0056] ●SEQ ID NO: 55, 56, 57, 58, 39 and 59;

[0057] ●SEQ ID NO: 60, 61, 62, 62, 44 and 64;

[0058] ●SEQ ID NO: 232, 233, 234, 235, 226 and 236;

[0059] ●SEQ ID NO: 232, 237, 238, 239, 231 and 240; or

[0060] ●SEQ ID NO: 355, 356, 357, 358, 44 and 359.

[0061] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to Honegger):

[0062] ●SEQ ID NO: 65, 66, 67, 68, 69 and 49;

[0063] ●SEQ ID NO: 70, 71, 72, 73, 74 and 54;

[0064] ●SEQ ID NO: 75, 76, 77, 78, 79 and 59;

[0065] ●SEQ ID NO: 80, 81, 82, 83, 84 and 64;

[0066] ●SEQ ID NO: 241, 242, 243, 244, 245 and 246;

[0067] ●SEQ ID NO: 247, 248, 249, 239, 250 and 251;

[0068] ●SEQ ID NO: 342, 81, 82, 83, 84 and 64; or

[0069] ●SEQ ID NO: 360, 361, 362, 363, 84 and 359.

[0070] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0071] SEQ ID NOs: 1, 2, 3, 4, 5 and 6 (according to Kabat);

[0072] SEQ ID NOs: 25, 26, 27, 28, 29 and 6 (according to IMGT);

[0073] ●SEQ ID NO: 45, 46, 47, 48, 29 and 49 (according to Chothia); or

[0074] ●SEQ ID NO: 65, 66, 67, 68, 69 and 49 (according to Honegger).

[0075] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0076] SEQ ID NOs: 7, 8, 9, 10, 11 and 12 (according to Kabat);

[0077] SEQ ID NOs: 30, 31, 32, 33, 34 and 12 (according to IMGT);

[0078] ●SEQ ID NO: 50, 51, 52, 53, 34 and 54 (according to Chothia); or

[0079] ●SEQ ID NO: 70, 71, 72, 73, 74 and 54 (according to Honegger).

[0080] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0081] SEQ ID NOs: 13, 14, 15, 16, 17 and 18 (according to Kabat);

[0082] SEQ ID NOs: 35, 36, 37, 38, 39 and 18 (according to IMGT);

[0083] ●SEQ ID NO: 55, 56, 57, 58, 39 and 59 (according to Chothia); or

[0084] ●SEQ ID NO: 80, 81, 82, 83, 84 and 64 (according to Honegger).

[0085] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0086] SEQ ID NOs: 19, 20, 21, 22, 23 and 24 (according to Kabat);

[0087] SEQ ID NOs: 40, 41, 42, 43, 44 and 24 (according to IMGT);

[0088] ●SEQ ID NO: 60, 61, 62, 62, 44 and 64 (according to Chothia); or

[0089] ●SEQ ID NO: 80, 81, 82, 83, 84 and 64 (according to Honegger).

[0090] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0091] SEQ ID NOs: 210, 211, 212, 213, 214 and 215 (according to Kabat);

[0092] SEQ ID NOs: 222, 223, 224, 225, 226 and 215 (according to IMGT);

[0093] ● SEQ ID NO: 232, 233, 234, 235, 226 and 236 (according to Chothia); or

[0094] ●SEQ ID NO: 241, 242, 243, 244, 245 and 246 (according to Honegger).

[0095] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0096] SEQ ID NOs: 216, 217, 218, 219, 220 and 221 (according to Kabat);

[0097] SEQ ID NOs: 227, 228, 229, 230, 231 and 221 (according to IMGT);

[0098] SEQ ID NOs: 232, 237, 238, 239, 231 and 240 (according to Chothia); or

[0099] ●SEQ ID NO: 247, 248, 249, 239, 250 and 251 (according to Honegger).

[0100] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0101] SEQ ID NOs: 339, 20, 21, 22, 23 and 24 (according to Kabat);

[0102] SEQ ID NOs: 340, 41, 42, 43, 44 and 24 (according to IMGT);

[0103] ●SEQ ID NO: 341, 61, 62, 63, 44 and 64 (according to Chothia); or

[0104] ●SEQ ID NO: 342, 81, 82, 83, 84 and 64 (according to Honegger).

[0105] In various embodiments, the antibody targeting CD47 comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0106] SEQ ID NOs: 345, 346, 347, 348, 23 and 349 (according to Kabat);

[0107] SEQ ID NOs: 350, 351, 352, 353, 44 and 354 (according to IMGT);

[0108] ●SEQ ID NO: 355, 356, 357, 358, 44 and 359 (according to Chothia); or

[0109] ●SEQ ID NO: 360, 361, 362, 363, 84 and 359 (according to Honegger).

[0110] In various embodiments, the antibody targeting CD47 comprises a VH and a VL, each comprising an amino acid sequence as shown below, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence as shown below:

[0111] ●SEQ ID NO: 85 and 86;

[0112] ●SEQ ID NO: 87 and 88;

[0113] ●SEQ ID NO: 89 and 90;

[0114] ●SEQ ID NO: 91 and 92;

[0115] ●SEQ ID NO: 252 and 253;

[0116] ●SEQ ID NO: 254 and 255;

[0117] ●SEQ ID NO: 343 and 344; or

[0118] • SEQ ID NO: 364 and 365. Sequence identity can be determined according to the BLAST algorithm (blast.ncbi.nlm.nih.gov / Blast.cgi) using default settings.

[0119] The amino acid sequences of the CDRs and variable regions (VH / VL) of illustrative anti-CD47 antibodies useful in the methods of the invention are described in Tables A1, A2, A3, A4, and B.

[0120]

[0121]

[0122]

[0123]

[0124] Additional anti-CD47 antibodies for use in the present methods include WO199727873, WO199940940, WO2002092784, WO2005044857, WO2009046541, WO2010070047, WO2011143624, WO2012170250, WO2013109752, WO2013119714, WO2014087248, WO2015191861, W O2016022971, WO2016023040, WO2016024021, WO2016081423, WO2016109415, WO2016141328, WO20161884 49. WO2017027422, WO2017049251, WO2017053423, WO2017121771, WO2017194634, WO2017196793, WO20172 15585, WO2018075857, WO2018075960, WO2018089508, WO2018095428, WO2018137705, WO2018233575, WO2 019027903, WO2019034895, WO2019042119, WO2019042285, WO2019042470, WO2019086573, WO2019108733, Those described in WO2019138367, WO2019144895, WO2019157843, WO2019179366, WO2019184912, WO2019185717, WO2019201236, WO2019238012, WO2019241732, WO2020019135, WO2020036977, WO2020043188 and WO2020009725.

[0125] b. Antibodies or antigen-binding fragments thereof that bind to SIRPα

[0126] In various embodiments, the agent that inhibits binding between CD47 and SIRPα CD47 is an antibody or antigen-binding fragment thereof that binds to signal regulatory protein α (SIRPα) (NCBI gene ID: 140885; UniProt P78324). Illustrative antibodies that bind to SIRPα include, but are not limited to, GS-0189 (FSI-189), ES-004, BI765063, ADU1805, and CC-95251.

[0127] In certain embodiments, the antibody may comprise one or more CDRs of 1H9. In some embodiments, the antibody may comprise all CDRs of 1H9. In some embodiments, the antibody may comprise one or more variable sequences of 1H9. In some embodiments, the antibody may comprise each variable sequence of 1H9. In some embodiments, the antibody may comprise the heavy chain of 1H9. In some embodiments, the antibody may comprise the light chain of 1H9. In some embodiments, the antibody may comprise the heavy chain and light chain of 1H9. In some embodiments, the antibody is 1H9.

[0128] In certain embodiments, the antibody may comprise one or more CDRs of 3C2. In some embodiments, the antibody may comprise all CDRs of 3C2. In some embodiments, the antibody may comprise one or more variable sequences of 3C2. In some embodiments, the antibody may comprise each variable sequence of 3C2. In some embodiments, the antibody may comprise the heavy chain of 3C2. In some embodiments, the antibody may comprise the light chain of 3C2. In some embodiments, the antibody may comprise the heavy chain and light chain of 3C2. In some embodiments, the antibody is 3C2.

[0129] In some embodiments, the antibody may comprise one or more CDRs of 9B11. In some embodiments, the antibody may comprise all CDRs of 9B11. In some embodiments, the antibody may comprise one or more variable sequences of 9B11. In some embodiments, the antibody may comprise each variable sequence of 9B11. In some embodiments, the antibody may comprise the heavy chain of 9B11. In some embodiments, the antibody may comprise the light chain of 9B11. In some embodiments, the antibody may comprise the heavy chain and light chain of 9B11. In some embodiments, the antibody is 9B11.

[0130] In some embodiments, the antibody may comprise one or more CDRs of 7E11. In some embodiments, the antibody may comprise all CDRs of 7E11. In some embodiments, the antibody may comprise one or more variable sequences of 7E11. In some embodiments, the antibody may comprise each variable sequence of 7E11. In some embodiments, the antibody may comprise the heavy chain of 7E11. In some embodiments, the antibody may comprise the light chain of 7E11. In some embodiments, the antibody may comprise the heavy chain and light chain of 7E11. In some embodiments, the antibody is 7E11.

[0131] Additional anti-SIRPα antibodies for use in the present method include WO200140307, ​​WO2002092784, WO2007133811, WO2009046541, WO2010083253, WO2011076781, WO2013056352, WO2015138600, WO2016179399, WO2016205042, WO2017178653 , WO2018026600, WO2018057669, WO2018107058, WO2018190719, WO2018210793, WO2019023347, WO2019042470, WO2019175218, WO2019183266, WO2020013170, WO2020068752 and WO2020088580.

[0132] In various embodiments, the antibody targeting SIRPα comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to Kabat):

[0133] ●SEQ ID NO: 93, 94, 95, 96, 97 and 98;

[0134] ●SEQ ID NO: 99, 100, 101, 102, 103 and 104;

[0135] ●SEQ ID NO: 99, 100, 105, 102, 103 and 106;

[0136] SEQ ID NOs: 107, 108, 109, 110, 111 and 112;

[0137] ●SEQ ID NO: 113, 114, 115, 116, 117 and 118; or

[0138] ●SEQ ID NO: 119, 120, 121, 122, 123 and 124.

[0139] In various embodiments, the antibody targeting SIRPα comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to IMGT):

[0140] ●SEQ ID NO: 125, 126, 127, 128, 129 and 98;

[0141] ●SEQ ID NO: 125, 130, 131, 132, 29 and 104;

[0142] ●SEQ ID NO: 125, 130, 133, 132, 29 and 106;

[0143] ●SEQ ID NO: 134, 135, 136, 137, 138 and 112;

[0144] ●SEQ ID NO: 139, 130, 140, 141, 142 and 118; or

[0145] ●SEQ ID NO: 143, 144, 145, 146, 44 and 124.

[0146] In various embodiments, the antibody targeting SIRPα comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to Chothia):

[0147] ●SEQ ID NO: 147, 148, 149, 150, 129 and 151;

[0148] ●SEQ ID NO: 147, 152, 153, 154, 29 and 155;

[0149] ●SEQ ID NO: 147, 152, 156, 154, 29 and 157;

[0150] ●SEQ ID NO: 158, 159, 160, 161, 138 and 162;

[0151] ●SEQ ID NO: 163, 152, 164, 165, 142 and 166; or

[0152] ●SEQ ID NO: 167, 168, 169, 170, 44 and 171.

[0153] In various embodiments, the antibody targeting SIRPα comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to Honegger):

[0154] ●SEQ ID NO: 172, 173, 174, 175, 176 and 151;

[0155] ●SEQ ID NO: 172, 177, 178, 179, 180 and 155;

[0156] ●SEQ ID NO: 172, 181, 182, 179, 180 and 157;

[0157] ●SEQ ID NO: 183, 184, 185, 186, 187 and 162;

[0158] ●SEQ ID NO: 188, 189, 190, 191, 192 and 166; or

[0159] ●SEQ ID NO: 193, 194, 195, 196, 197 and 171.

[0160] In various embodiments, the antibody targeting SIRPα comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0161] SEQ ID NOs: 93, 94, 95, 96, 97 and 98 (according to Kabat);

[0162] SEQ ID NOs: 125, 126, 127, 128, 129 and 98 (according to IMGT);

[0163] ● SEQ ID NO: 147, 148, 149, 150, 129 and 151 (according to Chothia); or

[0164] ●SEQ ID NO: 172, 173, 174, 175, 176 and 151 (according to Honegger).

[0165] In various embodiments, the antibody targeting SIRPα comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0166] SEQ ID NOs: 99, 100, 101, 102, 103 and 104 (according to Kabat);

[0167] SEQ ID NOs: 125, 130, 131, 132, 29 and 104 (according to IMGT);

[0168] ●SEQ ID NO: 147, 152, 153, 154, 29 and 155 (according to Chothia); or

[0169] ●SEQ ID NO: 172, 177, 178, 179, 180 and 155 (according to Honegger).

[0170] In various embodiments, the antibody targeting SIRPα comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0171] SEQ ID NOs: 99, 100, 105, 102, 103 and 106 (according to Kabat);

[0172] SEQ ID NOs: 125, 130, 133, 132, 29 and 106 (according to IMGT);

[0173] ● SEQ ID NO: 147, 152, 156, 154, 29 and 157 (according to Chothia); or

[0174] ●SEQ ID NO: 172, 181, 182, 179, 180 and 157 (according to Honegger).

[0175] In various embodiments, the antibody targeting SIRPα comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0176] SEQ ID NOs: 107, 108, 109, 110, 111 and 112 (according to Kabat);

[0177] SEQ ID NOs: 134, 135, 136, 137, 138 and 112 (according to IMGT);

[0178] ● SEQ ID NO: 158, 159, 160, 161, 138 and 162 (according to Chothia); or

[0179] ●SEQ ID NO: 183, 184, 185, 186, 187 and 162 (according to Honegger).

[0180] In various embodiments, the antibody targeting SIRPα comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0181] SEQ ID NOs: 113, 114, 115, 116, 117 and 118 (according to Kabat);

[0182] SEQ ID NOs: 139, 130, 140, 141, 142 and 118 (according to IMGT);

[0183] ● SEQ ID NO: 163, 152, 164, 165, 142 and 166 (according to Chothia); or

[0184] ●SEQ ID NO: 188, 189, 190, 191, 192 and 166 (according to Honegger).

[0185] In various embodiments, the antibody targeting SIRPα comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0186] SEQ ID NOs: 119, 120, 121, 122, 123 and 124 (according to Kabat);

[0187] SEQ ID NOs: 143, 144, 145, 146, 44 and 124 (according to IMGT);

[0188] ●SEQ ID NO: 167, 168, 169, 170, 44 and 171 (according to Chothia); or

[0189] ●SEQ ID NO: 193, 194, 195, 196, 197 and 171 (according to Honegger).

[0190] In various embodiments, the antibody targeting SIRPα comprises a VH and a VL, each comprising an amino acid sequence as shown below, or an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence as shown below:

[0191] ●SEQ ID NO: 198 and 199;

[0192] ●SEQ ID NO: 200 and 201;

[0193] ●SEQ ID NO: 202 and 203;

[0194] ●SEQ ID NO: 204 and 205;

[0195] ●SEQ ID NO: 206 and 207; or

[0196] • SEQ ID NO: 208 and 209. Sequence identity can be determined according to the BLAST algorithm (blast.ncbi.nlm.nih.gov / Blast.cgi) using default settings.

[0197] The amino acid sequences of the CDRs and variable regions (VH / VL) of illustrative anti-SIRPα antibodies useful in the methods of the invention are described in Tables C1, C2, C3, C4, and D.

[0198]

[0199]

[0200]

[0201]

[0202] c. SIRPα-Fc fusion protein

[0203] In various embodiments, the agent that inhibits the binding between CD47 and SIRPα CD47 is a SIRPα-Fc fusion protein or a "high-affinity SIRPα agent," which includes SIRPα-derived polypeptides and analogs thereof. High-affinity SIRPα agents are described in International Application WO2013109752A1, which is hereby expressly incorporated by reference. High-affinity SIRPα agents are variants of natural SIRPα proteins. In some embodiments, the high-affinity SIRPα agent is soluble, wherein the polypeptide lacks the SIRPα transmembrane domain and comprises at least one amino acid change relative to the wild-type SIRPα sequence, and wherein the amino acid change increases the affinity of the SIRPα polypeptide for binding to CD47, for example by reducing the dissociation rate by at least 10 times, at least 20 times, at least 50 times, at least 100 times, at least 500 times, or more.

[0204] The high-affinity SIRPα agent comprises a portion of SIRPα sufficient to bind to CD47 with a recognizable affinity (e.g., high affinity) (the portion is generally located between the signal sequence and the transmembrane domain), or a fragment thereof that retains binding activity. The high-affinity SIRPα agent will generally comprise at least the d1 domain of SIRPα, which has modified amino acid residues to increase affinity. In some embodiments, the SIRPα variant is a fusion protein, for example, a fusion protein fused in-frame with a second polypeptide. In some embodiments, the second polypeptide is capable of increasing the size of the fusion protein, for example, so that the fusion protein will not be rapidly cleared from the circulation. In some embodiments, the second polypeptide is part or all of the Fc region of an immunoglobulin. The Fc region assists phagocytosis by providing an "eat me" signal, which enhances the blocking of the "don't eat me" signal provided by the high-affinity SIRPα agent. In other embodiments, the second polypeptide is any suitable polypeptide substantially similar to Fc, for example, providing an increased size, a multimerization domain, and / or additional binding or interaction with an Ig molecule. The amino acid changes that provide increased affinity are located in the d1 domain, so the high-affinity SIRPα agent comprises the d1 domain of human SIRPα, which has at least one amino acid change relative to the wild-type sequence in the d1 domain. Such high-affinity SIRPα agents optionally include: additional amino acid sequences, such as antibody Fc sequences; portions of wild-type human SIRPα protein other than the d1 domain (including but not limited to residues 150 to 374 of the native protein or a fragment thereof), which are generally fragments adjacent to the d1 domain; etc. The high-affinity SIRPα agent can be a monomer or a multimer, i.e., a dimer, trimer, tetramer, etc.

[0205] Illustrative SIRPα-Fc fusion proteins used include ALX-148 (also known as evorpacept, described in WO2013109752), tedapeptide, TTI-621 or TTI-622 (described in WO2014094122), SIRPα-F8, JY002-M2G1 (N297A), JMT601 (CPO107), SS002M91, SIRPα-lgG4-Fc-Fc, and hCD172a(SIRPα)-Fc-LIGHT.

[0206] 3. Drugs that inhibit the binding of vascular endothelial growth factor A (VEGFA) to one or more VEGFA cognate receptors Agent

[0207] The methods described herein involve co-administering an agent that inhibits binding between CD47 and SIRPα and an agent that inhibits binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA cognate receptors (VEGFA / VEFGR inhibitors). VEGFA has the alternative acronyms VEGF, MVCD1, VPF, and is designated as NCBI Gene ID: 7422; Uniprot P15692. VEGFA cognate receptors include VEGFR1 (fms-related receptor tyrosine kinase 1 (FLT1; NCBI Gene ID: 2321)) and VEGFR2 (kinase insert domain receptor (KDR; also known as CD309, FLK1; NCBI Gene ID: 3791).

[0208] Illustrative examples of agents that inhibit binding between VEGFA and one or more VEGFA cognate receptors include, but are not limited to, antibodies that bind to VEGFA, antibodies that bind to VEGFR2, VEGFA-Fc fusion proteins, and small molecule inhibitors.

[0209] Exemplary antibodies that bind to VEGFA for use in the methods of the invention include, but are not limited to, bevacizumab, ranibizumab, brucelluzumab, evocizumab, suvicitumab, and faricitumab. In some embodiments, the antibody that binds to VEGFA is bevacizumab.

[0210] Exemplary antibodies that bind to VEGFR2 for use in the methods of the invention include, but are not limited to, ramucirumab.

[0211] Exemplary VEGFA-Fc fusion proteins for use in the methods of the invention include, but are not limited to, conbercept and aflibercept.

[0212] Exemplary small molecule inhibitors of VEGFA and one or more VEGFA cognate receptors for use in the methods of the invention include, but are not limited to, surufatinib, anlotinib hydrochloride, fruquintinib, tivozanib, regorafenib, axitinib, vandetanib, sioronib, pazopanib hydrochloride, sunitinib malate, and pegaptanib sodium.

[0213] In various embodiments, the antibody that binds to VEGFA comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to Kabat):

[0214] ●SEQ ID NO: 258, 259, 260, 261, 262 and 263;

[0215] ●SEQ ID NO: 264, 259, 265, 261, 262 and 263;

[0216] ●SEQ ID NO: 266, 267, 268, 269, 270 and 271; or

[0217] ●SEQ ID NO: 272, 273, 274, 275, 276 and 277.

[0218] In various embodiments, the antibody that binds to VEGFA comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to IMGT):

[0219] ●SEQ ID NO: 278, 279, 280, 281, 282 and 263;

[0220] ●SEQ ID NO: 283, 279, 284, 281, 282 and 263;

[0221] ●SEQ ID NO: 285, 286, 287, 288, 289 and 271; or

[0222] ●SEQ ID NO: 290, 291, 292, 293, 294 and 277.

[0223] In various embodiments, the antibody that binds to VEGFA comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to Chothia):

[0224] ●SEQ ID NO: 295, 296, 297, 298, 282 and 299;

[0225] ●SEQ ID NO: 300, 296, 301, 298, 282 and 299;

[0226] ●SEQ ID NO: 302, 303, 304, 305, 289 and 306; or

[0227] ●SEQ ID NO: 307, 308, 309, 310, 294 and 311.

[0228] In various embodiments, the antibody that binds to VEGFA comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences (according to Honegger):

[0229] ●SEQ ID NO: 312, 313, 314, 315, 316 and 299;

[0230] ●SEQ ID NO: 317, 313, 318, 315, 316 and 299;

[0231] ●SEQ ID NO: 319, 320, 321, 322, 323 and 306; or

[0232] ●SEQ ID NO: 324, 325, 326, 327, 328 and 311.

[0233] In various embodiments, the antibody that binds to VEGFA comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0234] SEQ ID NOs: 258, 259, 260, 261, 262 and 263 (according to Kabat);

[0235] SEQ ID NOs: 278, 279, 280, 281, 282 and 263 (according to IMGT);

[0236] ● SEQ ID NO: 295, 296, 297, 298, 282 and 299 (according to Chothia); or

[0237] ●SEQ ID NO: 312, 313, 314, 315, 316 and 299 (according to Honegger).

[0238] In various embodiments, the antibody that binds to VEGFA comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0239] SEQ ID NOs: 264, 259, 265, 261, 262 and 263 (according to Kabat);

[0240] SEQ ID NOs: 283, 279, 284, 281, 282 and 263 (according to IMGT);

[0241] ●SEQ ID NO: 300, 296, 301, 298, 282 and 299 (according to Chothia); or

[0242] ●SEQ ID NO: 317, 313, 318, 315, 316 and 299 (according to Honegger).

[0243] In various embodiments, the antibody that binds to VEGFA comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0244] SEQ ID NOs: 266, 267, 268, 269, 270 and 271 (according to Kabat);

[0245] SEQ ID NOs: 285, 286, 287, 288, 289 and 271 (according to IMGT);

[0246] ●SEQ ID NO: 302, 303, 304, 305, 289 and 306 (according to Chothia); or

[0247] ●SEQ ID NO: 319, 320, 321, 322, 323 and 306 (according to Honegger).

[0248] In various embodiments, the antibody that binds to VEGFA comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, respectively comprising the following amino acid sequences:

[0249] SEQ ID NOs: 272, 273, 274, 275, 276 and 277 (according to Kabat);

[0250] SEQ ID NOs: 290, 291, 292, 293, 294 and 277 (according to IMGT);

[0251] ●SEQ ID NO: 307, 308, 309, 310, 294 and 311 (according to Chothia); or

[0252] ●SEQ ID NO: 324, 325, 326, 327, 328 and 311 (according to Honegger).

[0253] In various embodiments, an antibody that binds to VEGFA comprises a VH and a VL, each comprising an amino acid sequence as shown below, or an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to an amino acid sequence as shown below:

[0254] - SEQ ID NO: 329, 330, 331, 332, 333, 334, 335, 336, 337 or 338. Sequence identity can be determined according to the BLAST algorithm (blast.ncbi.nlm.nih.gov / Blast.cgi) using default settings.

[0255] The amino acid sequences of the CDRs and variable regions (VH / VL) of illustrative anti-VEGFA antibodies useful in the methods of the invention are described in Tables E1, E2, E3, E4, and F.

[0256]

[0257]

[0258] 4. Additional combination medicines

[0259] Additional agents suitable for treating hematological malignancies (such as small molecules, antibodies, adoptive cell therapy and chimeric antigen receptor T cells (CAR-T), checkpoint inhibitors and vaccines) can be combined with agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab). Additional immunotherapeutic agents for hematological malignancies are described in Dong et al., J Life Sci (Westlake Village). 2019 June; 1(1): 46–52; and Cuesta-Mateos et al., Front. Immunol. 8: 1936. doi: 10.3389 / fimmu.2017.01936, each of which is hereby incorporated by reference in its entirety for all purposes.

[0260] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with one or more additional therapeutic agents, such as inhibitory immune checkpoint blockers or inhibitors, stimulatory immune checkpoint stimulators, agonists or activators, chemotherapeutic agents, anticancer agents, radiotherapeutic agents, antitumor agents, antiproliferative agents, antiangiogenic agents, anti-inflammatory agents, immunotherapeutic agents, therapeutic antigen binding molecules (monospecific and multispecific antibodies and fragments thereof in any form (e.g., including but not limited to DARTs) ® 、Duobodies ® 、BiTEs ® , BiKEs, TriKEs, XmAbs ® 、TandAbs ® , scFvs, Fab, Fab derivatives), bispecific antibodies, non-immunoglobulin antibody mimetics (e.g., including but not limited to adnectin, affibody molecules, affilin, affimer, affitin, alphabody, anticalin, peptide aptamers, armadillo repeat proteins (ARM), atrimer, avimer, designed ankyrin repeat proteins (DARPins) ® ), fynomers, knottins, Kunitz domain peptides, monobodies and nanoCLAMPs), antibody-drug conjugates (ADCs), antibody-peptide conjugates), oncolytic viruses, gene modifiers or editors, cells containing chimeric antigen receptors (CARs) (e.g., including T cell immunotherapeutics, NK cell immunotherapeutics, or macrophage immunotherapeutics), cells containing engineered T cell receptors (TCR-T), or any combination thereof.

[0261] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with one or more additional therapeutic agents, including but not limited to inhibitors, agonists, antagonists, ligands, modulators, stimulators, blockers, activators or repressors of targets (e.g., polypeptides or polynucleotides), including but not limited to: Eberson murine leukemia viral oncogene homolog 1 gene (ABL, such as ABL1), acetyl-CoA carboxylase (such as ACC1 / 2), activated CDC kinase (ACK, such as ACK1), adenosine deaminase, adenosine receptor ( such as A2BR, A2aR, A3aR), adenylate cyclase, ADP-ribosyl cyclase-1, adrenocorticotropic hormone receptor (ACTH), aeromonas lysin, AKT1 gene, Alk-5 protein kinase, alkaline phosphatase, alpha 1 adrenal receptor, alpha 2 adrenal receptor, alpha-ketoglutarate dehydrogenase (KGDH), aminopeptidase N, AMP-activated protein kinase, anaplastic lymphoma kinase (ALK, such as ALK1), androgen receptor, angiopoietin (such as ligand-1, ligand-2), angiotensinogen (AGT) gene, murine thymoma viral oncogene homolog 1 (AKT) protein kinase (such as AKT1, AKT2, AKT3), apolipoprotein AI (APOA1) gene, apoptosis-inducing factor, apoptosis protein (such as 1, 2), apoptosis signal-regulating kinase (ASK, such as ASK1), arginase (I), arginine deiminase, aromatase, steroid homolog 1 (ASTE1) gene, ataxia telangiectasia and Rad3-related (ATR) serine / threonine protein kinase, Aurora protein kinase (such as 1, 2), Axl tyrosine kinase receptor, 4-1BB ligand (CD137L), baculovirus IAP repeat-containing protein 5 (BIRC5) gene, Basigin, B cell lymphoma 2 (BCL2) gene, Bcl2 binding component 3, Bcl2 protein, BCL2L11 gene genes, BCR (cleft cluster region) proteins and genes, beta-adrenergic receptor, beta-catenin, B-lymphocyte antigen CD19, B-lymphocyte antigen CD20, B-lymphocyte adhesion molecule, B-lymphocyte stimulator ligand, bone morphogenetic protein-10 ligand, bone morphogenetic protein-9 ligand regulator, Brachyury protein, Bradykinin receptor, B-Raf proto-oncogene (BRAF), Brc-Abl tyrosine kinase, bromodomain- and extracellular domain (BET) bromodomain-containing proteins (such as BRD2, BRD3, BRD4), Bruton's tyrosine kinase (BTK), calmodulin, calmodulin-dependent protein kinase (CaMK,, such as CAMKII), cancer / testis antigen 2, cancer / testis antigen NY-ESO-1, cancer / testis antigen 1B (CTAG1) gene, cannabinoid receptors (such as CB1, CB2), carbonic anhydrase, casein kinase (CK, such as CKI, CKII), caspases (such as caspase-3, caspase-7, caspase-9), caspase 8 apoptosis-related cysteine ​​peptidase CASP8-FADD-like regulator, caspase recruitment domain protein-15, cathepsin G, CCR5 gene, CDK activation kinase kinase (CAK), checkpoint kinases (such as CHK1, CHK2), chemokine (CC motif) receptors (such as CCR2, CCR4, CCR5, CCR8), chemokine (CXC motif) receptors (such as CXCR1, CXCR2, CXCR3 and CXCR4), chemokine CC21 ligand, cholecystokinin CCK2 receptor, chorionic gonadotropin, c-Kit (tyrosine-protein kinase Kit or CD117), CISH (cytokine-inducible SH2-containing protein), occludens (such as 6, 18), cluster of differentiation (CD ) (such as CD4, CD27, CD29, CD30, CD33, CD37, CD40, CD40 ligand receptor, CD40 ligand, CD40LG gene, CD44, CD45, CD47, CD49b, CD51, CD52, CD55, CD58, CD66e (CEACAM6), CD70 gene, CD74, CD79, CD79b, CD79B gene, CD80, CD95, CD99, CD117, CD122, CDw123, CD134, CDw137, C D158a, CD158b1, CD158b2, CD223, CD276 antigens); clusterin (CLU) gene, clusterin, c-Met (hepatocyte growth factor receptor (HGFR)), complement C3, connective tissue growth factor, COP9 signalosome subunit 5, CSF-1 (colony stimulating factor 1 receptor), CSF2, CTLA-4 (cytotoxic T lymphocyte protein 4), C-type lectin domain protein 9A (CLEC9A), cyclin D1, cyclin G1, cyclin-dependent kinase (CDK,Such as CDK1, CDK12, CDK1B, CDK2-9), cyclooxygenase (such as COX1, COX2), CYP2B1 gene, cysteine ​​palmitoyltransferase porcupine, cytochrome P450 11B2, cytochrome P450 17, cytochrome P450 17A1, cytochrome P450 2D6, cytochrome P4503A4, cytochrome P450 reductase, cytokine signaling-1, cytokine signaling-3, cytoplasmic isocitrate dehydrogenase, cytosine deaminase, cytosine DNA methyltransferase, cytotoxic T lymphocyte protein-4, DDR2 gene, DEAD-box helicase 6 (DDX6), death receptor 5 (DR5, TRAILR2), death receptor 4 (DR4, TRAILR1), Delta-like protein ligand (such as 3, 4), deoxyribonuclease, deubiquitinase (DUB), Dickkopf-1 ligand, dihydrofolate reductase (DHFR), dihydropyridine Dehydrogenase, dipeptidyl peptidase IV, discoidin domain receptor (DDR, such as DDR1), diacylglycerol kinase ζ (DGKZ), DNA binding protein (such as HU-β), DNA dependent protein kinase, DNA gyrase, DNA methyltransferase, DNA polymerase (such as α), DNA primase, dUTP pyrophosphatase, L-dopachrome isozyme, E3 ubiquitin protein ligase (such as RNF128, CBL-B), echinoderm microtubule-like protein 4, epidermal growth factor receptor tyrosine kinase receptor, elastase, elongation factor 1α2, elongation factor 2, endoglin, endonuclease, endoplasmic reticulum aminopeptidase (ERAP,such as ERAP 1, ERAP2), endosialin, endosialin, endostatin, endothelin (such as ET-A, ET-B), Enhancer of Zeste homolog 2 (EZH2), ephrin (EPH) tyrosine kinase (such as Epha3, Ephb4), ephrin B2 ligand, epidermal growth factor, epidermal growth factor receptor (EGFR), epidermal growth factor receptor (EGFR gene, Epigen, epithelial cell adhesion molecule (EpCAM), Erb-b2 (v-erb-b2 avian erythrocytic leukemia virus oncogene homolog 2) tyrosine kinase receptor, Erb-b3 tyrosine kinase receptor , Erb-b4 tyrosine kinase receptor, E-selectin, estradiol 17β-dehydrogenase, estrogen receptor (such as α, β), estrogen-related receptor, eukaryotic translation initiation factor 5A (EIF5A) gene, exportin 1, extracellular signal-related kinase (such as 1, 2), extracellular signal-regulated kinase (ERK), hypoxia-inducible factor prolyl hydroxylase (HIF-PH or EGLN), factor (such as Xa, VIIa), estrogen x receptor (FXR), Fas ligand, fatty acid synthase (FASN), ferritin, FGF-2 ligand, FGF-5 ligand, fibroblast growth factor (FGF, such as such as FGF1, FGF2, FGF4), fibronectin, focal adhesion kinase (FAK, such as FAK2), folate hydrolase prostate-specific membrane antigen 1 (FOLH1), folate receptor (such as α), folic acid, folate transporter 1, FYN tyrosine kinase, paired alkaline amino acid lyase (FURIN), β-glucuronidase, galactosyltransferase, galectin-3, ganglioside GD2, glucocorticoids, glucocorticoid-induced TNFR-related protein GITR receptor, glutamate carboxypeptidase II, glutaminase, glutathione S-transferase P, glycogen synthase kinase (GSK, such as 3-β), phosphorylation GPC3, gonadotropin-releasing hormone (GNRH), granulocyte macrophage colony-stimulating factor (GM-CSF) receptor, granulocyte colony-stimulating factor (GCSF) ligand, growth factor receptor binding protein 2 (GRB2), Grp78 (78kDa glucose-regulated protein) calcium-binding protein, molecular chaperone groEL2 gene, heme oxygenase 1 (HO1), heme oxygenase 2 (HO2), heat shock protein (such as 27, 70, 90α, β), heat shock protein gene, heat-stable enterotoxin receptor, hedgehog protein, liver enzyme, hepatocyte growth factor, HERV-H LTR-associated protein 2, hexokinase, histamine H2 receptor, histone methyltransferase (DOT1L), histone deacetylase (HDAC,Such as 1, 2, 3, 6, 10, 11), histone H1, histone H3, HLA class I antigen (A-2α), HLA class II antigen, HLA Class I antigen αG (HLA-G), non-HLA class, homeobox protein NANOG, HSPB1 gene, human leukocyte antigen (HLA), human papillomavirus (such as E6, E7) protein, hyaluronic acid, hyaluronidase, hypoxia-inducible factor-1α (HIF1α), imprinted maternal expressed transcript (H19) gene, mitogen-activated protein kinase 1 (MAP4K1), tyrosine protein kinase HCK, I-κ-B kinase (IKK, such as IKKbe), IL-1α, IL-1β, IL-12, IL-12 gene, IL-15, IL-17, IL-2 gene, IL-2 receptor α subunit, IL-2, IL-3 receptor, IL-4, IL-6, IL-7, IL-8, immunoglobulins (such as G, G1, G2, K, M), immunoglobulin Fc receptor, immunoglobulin gamma Fc receptor (such as I, III, III A), indoleamine 2,3-dioxygenase (IDO, such as IDO1 and IDO2), indoleamine pyrrole 2,3-dioxygenase 1 inhibitor, insulin receptor, insulin-like growth factor (such as 1, 2), integrin α-4 / β-1, integrin α-4 / β-7, integrin α-5 / β-1, integrin α-V / β-3, integrin α-V / β-5, integrin α-V / β-6, intercellular adhesion molecule 1 (ICAM-1 ), interferons (such as α, α2, β, γ), interferon-induced protein 2 (AIM2) deleted in melanoma, interferon type I receptor, interleukin 1 ligand, interleukin 13 receptor α2, interleukin 2 ligand, interleukin-1 receptor associated kinase 4 (IRAK4), interleukin-2, interleukin-29 ligand, interleukin 35 (IL-35), isocitrate dehydrogenase (such as IDH1, IDH2), Janus kinase (JAK,Such as JAK1, JAK2), Jun N-terminal kinase, kallikrein-related peptidase 3 (KLK3) gene, killer cell Ig-like receptor, kinase insert domain receptor (KDR), kinesin-like protein KIF11, rat sarcoma viral oncogene homolog (KRAS) gene, kisspeptin (KiSS-1) receptor, KIT gene, v-kitHardy-Zuckerman4 feline sarcoma viral oncogene homolog (KIT) tyrosine kinase, lactoferrin, lanosterol-14 demethylase, LDL receptor guanyin-1, leukocyte immunoglobulin-like receptor B subfamily member 1 (ILT2), leukocyte immunoglobulin-like receptor B subfamily member 2 (ILT4), leukotriene A4 hydrolase, listerin, L-selectin, luteinizing hormone receptor, lyase, lymphocyte activation gene 3 protein (LAG-3), lymphocyte antigen 75, lymphocyte function antigen-3 receptor, lymphocyte-specific protein tyrosine kinase (LCK), lymphocyte chemoattractant protein, Lyn (Lck / Yes novel) tyrosine kinase, lysine demethylase (such as KDM1, KDM2, KDM4, KDM5, KDM6, A / B / C / D), lysophosphatidic acid-1 receptor, lysosomal associated membrane protein family (LAMP) gene, lysosomal oxidase homolog 2, lysosomal oxidase protein (LOX), 5-lipoxygenase (5-LOX), hematopoietic progenitor cell kinase 1 (HPK1), hepatocyte growth factor receptor (MET) gene, macrophage colony stimulating factor (MCSF) ligand, macrophage migration inhibitory factor, MAGEC1 gene, MAGEC2 gene, major vault protein, MAPK-activated protein kinase (such as MK2), Mas-related G protein-coupled receptor, matrix metalloproteinase (MMP, such as MMP2, MMP9), Mcl-1 differentiation protein, Mdm2 p53 binding protein, Mdm4 protein, Melan-A (MART-1) melanoma antigen, melanocyte protein Pmel 17. Melanocyte stimulating hormone ligand, melanoma antigen family A3 (MAGEA3) gene, melanoma associated antigens (such as 1, 2, 3, 6), membrane copper amine oxidase, mesothelin, MET tyrosine kinase, metabotropic glutamate receptor 1, metalloreductase STEAP1 (prostate six transmembrane epithelial antigen 1), transferase, methionine aminopeptidase-2, methyltransferase, mitochondrial 3-ketoacyl-CoA thiolase, mitogen-activated protein kinase (MAPK), mitogen-activated protein kinase (MEK, such as MEK1, MEK2), mTOR (mechanistic target of rapamycin (serine / threonine kinase)), mTOR complex (such as 1, 2), mucin (such as 1, 5A, 16), mutT homolog (MTH,Such as MTH1), Myc proto-oncogene protein, myeloid cell leukemia 1 (MCL1) gene, myristoylated alanine-rich protein kinase C substrate (MARCKS) protein, NAD ADP ribosyltransferase, natriuretic peptide receptor C, neural cell adhesion molecule 1, neurokinin 1 (NK1) receptor, neurokinin receptor, neurokinin kinase 2, NFκB activated protein, NIMA-related kinase 9 (NEK9), nitric oxide synthase, NK cell receptor, NK3 receptor, NKG2 AB activated NK receptor, NLRP3 (NACHT LRRPYD domain protein 3) regulator, norepinephrine transporter, Notch (such as Notch-2 receptor, Notch-3 receptor, Notch-4 receptor), nuclear erythroid 2-related factor 2, nuclear factor (NF) κB, nucleoprotein, nucleolar phosphatidylcholine, riboprotein-asexual lymphoma kinase (NPM-ALK), 2-oxoglutarate dehydrogenase, 2,5-ol adenylate synthetase, O-methylguanine DNA methyltransferase, opioid receptor (such as delta), ornithine decarboxylase, ornithine phosphoribosyltransferase, orphan nuclear hormone receptor NR4A1, osteocalcin, osteoclast differentiation factor, osteocalcin, OX-40 (tumor necrosis factor receptor superfamily member 4 TNFRSF4, or CD134) receptor, P3 protein, p38 kinase, p38 MAP kinase, p53 tumor suppressor protein, parathyroid hormone ligand, peroxisome proliferator-activated receptor (PPAR, such as α, δ, γ), P-glycoprotein (such as 1), phosphatase and tencel homolog (PTEN), phosphatidylinositol 3-kinase (PI3K), phosphoinositide 3-kinase (PI3K, such as α, δ, γ), phosphorylase kinase (PK), PKN3 gene, placental growth factor, platelet-derived growth factor (PDGF, such as α, β), platelet-derived growth factor (PDGF, such as α, β), multi-drug resistance transporter, plexin B1, PLK1 gene, polo-like kinase (PLK), Polo-like kinase 1, poly (ADP-ribose) polymerase (PAR P, such as PARP1, PARP2 and PARP3, PARP7 and single PARP), melanoma preferentially expressed antigen (PRAME) gene, prenyl binding protein (PrPB), possible transcription factor PML, progesterone receptor, programmed cell death 1 (PD-1), programmed cell death ligand 1 inhibitor (PD-L1), prostaglandin (PSAP) gene, prostaglandin receptor (EP4), prostaglandin E2 synthase, prostate specific antigen, prostatic acid phosphatase, proteasome, protein E7, protein farnesyl transferase, protein kinase (PK, such as A, B, C), protein tyrosine kinase, protein tyrosine phosphatase β, proto-oncogene serine / threonine protein kinase (PIM,such as PIM-1, PIM-2, PIM-3), P-selectin, purine nucleoside phosphorylase, purinergic receptor P2X ligand-gated ion channel 7 (P2X7), pyruvate dehydrogenase (PDH), pyruvate dehydrogenase kinase, pyruvate kinase (PYK), 5-α-reductase, Raf protein kinase (such as 1, B), RAF1 gene, Ras gene, Ras GTPase, RET gene, Ret tyrosine kinase receptor, retinoblastoma-associated protein, retinoic acid receptor (such as γ), retinol X receptor, Rheb (Ras homolog enriched in brain) GTPase, Rho (Ras homolog) associated protein kinase 2, ribonuclease, ribonucleotide reductase (such as M2 subunit), ribosomal protein S6 kinase, RNA polymerase (such as I, II), Ron (Recepteur d'Origine Nantais) tyrosine kinase, ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) gene, Ros1 tyrosine kinase, Runt-related transcription factor 3, γ-secretase, S100 calcium-binding protein A9, sarcoplasmic reticulum calcium ATPase, second mitochondria-derived caspase activator (SMAC) protein, secreted wrinkle-associated protein-2, secreted phospholipase A2, brain semaphorin-4D, serine protease, serine / threonine kinase (STK), serine / threonine protein kinase (TBK, such as TBK1), signal transduction and transcription (STAT,Such as STAT-1, STAT-3, STAT-5), signaling lymphocyte activation molecule (SLAM) family member 7, prostate six membrane epithelial antigen (STEAP) gene, SL cytokine ligand, smoothened (SMO) receptor, sodium iodide cotransporter, sodium hydrogen phosphate cotransporter 2B, somatostatin receptor (such as 1, 2, 3, 4, 5), sonic hedgehog protein, son of no seven (SOS), specificity protein 1 (Sp1) transcription factor, globus sphaeroides synthase, globus sphaeroides kinase (such as 1, 2), globus sphaeroides-1-phosphate receptor-1, spleen tyrosine kinase (SYK), SRC gene, Src tyrosine kinase, stable protein-1 (STAB1 ), STAT3 gene, steroid sulfatase, stimulator of interferon genes (STING) receptor, stimulator of interferon genes protein, stromal cell-derived factor 1 ligand, SUMO (small ubiquitin-like modifier), superoxide dismutase, inhibitory regulators of cytokine signaling (SOCS), survivin protein, synapsin 3, syndecan-1, synuclein α, T cell surface glycoprotein CD28, tank binding kinase (TBK), TATA box binding protein-associated factor RNA polymerase I subunit B (TAF1B) gene, T cell CD3 glycoprotein ζ chain, T cell differentiation antigen CD6, T cell immunoglobulin and mucin domain-containing-3 (TIM- 3), T cell surface glycoprotein CD8, Tec protein tyrosine kinase, Tek tyrosine kinase receptor, telomerase, telomerase reverse transcriptase (TERT) gene, tenascin, three-element repair exonuclease 1 (TREX1), three-element repair exonuclease 2 (TREX2), thrombopoietin receptor, thymidine kinase, thymine phosphorylase, thymidylate synthase, thymosin (such as α1), thyroid hormone receptor, thyroid stimulating hormone receptor, tissue factor, TNF-related apoptosis-inducing ligand, TNFR1-related death domain protein, TNF-related apoptosis-inducing ligand (TRAIL) receptor, TNFSF11 gene, TNFSF9 gene, Toll-like receptor ( TLR, such as 1-13), topoisomerase (such as I, II, III), transcription factor, transferrin (TF), transforming growth factor alpha (TGFα), transforming growth factor beta (TGFB) and its isoforms, TGFβ2 ligand, transforming growth factor TGF-β receptor kinase, transglutaminase, transport-related protein, transmembrane glycoprotein NMB, Trop-2 calcium signal transducer, trophoblast glycoprotein (TPBG) gene, trophoblast glycoprotein, myosin receptor kinase (Trk) receptor (such as TrkA, TrkB, TrkC), tryptophan 2,3-dioxygenase (TDO), tryptophan 5-hydroxylase, tubulin, tumor necrosis factor (TNF,Such as α, β), tumor necrosis factor 13C receptor, tumor progression locus 2 (TPL2), tumor protein 53 (TP53) gene, tumor suppressor candidate gene 2 (TUSC2), tumor-specific neoantigens, tyrosinase, tyrosine hydroxylase, tyrosine kinase (TK), tyrosine kinase receptor, tyrosine kinase with immunoglobulin-like and EGF-like domains (TIE) receptor, tyrosine protein kinase ABL1 inhibitor, ubiquitin, ubiquitin carboxyl hydrolase isozyme L5, ubiquitin thioesterase-14, ubiquitin conjugating enzyme E2I (UBE2I, UBC9), ubiquitin-specific processing protease 7 (USP7), urease, urokinase plasminogen activator, uterine myoglobin, vanilloid VR1, vascular cell adhesion molecule Attachment 1, vascular endothelial growth factor receptor (VEGFR), V-domain Ig inhibitor of T-cell activation (VISTA), VEGF-1 receptor, VEGF-2 receptor, VEGF-3 receptor, VEGF-A, VEGF-B, vimentin, vitamin D3 receptor, proto-oncogene tyrosine protein kinase, Mer (Mer tyrosine kinase receptor modulator), YAP (Yes-associated protein modulator), Wee-1 protein kinase, Werner syndrome RecQ-like helicase (WRN), Wilms tumor antigen 1, Wilms tumor protein, WW domain-containing transcription regulator protein 1 (TAZ), X-linked inhibitor of apoptosis protein, zinc finger protein transcription factor, or any combination thereof.

[0262] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are combined with one or more additional therapeutic agents, which can be classified into the following groups according to their mechanism of action: antimetabolites / anticancer agents, such as pyrimidine analogs floxuridine, capecitabine, cytarabine, CPX-351 (liposomal cytarabine, daunorubicin), and TAS-118; α1-adrenergic receptor / α2-adrenergic receptor antagonists, such as phenoxybenzamine hydrochloride (injectable, pheochromocytoma); androgen receptor antagonists, such as nilutamide; anti-cadherin antibodies, such as HKT-288; anti-leucine-rich repeat-containing protein 15 (LRRC15) antibodies, such as ABBV-085, ARGX-110; angiotensin receptor blockers, nitric oxide donors; antisense oligonucleotides, such as AEG35156, ION IS-KRAS-2.5Rx, EZN-3042, RX-0201, IONIS-AR-2.5Rx, BP-100 (prexigebersen), IONIS-STAT3-2.5Rx; anti-angiopoietin (ANG)-2 antibodies, such as MEDI3617 and LY3127804; anti-ANG-1 / ANG-2 antibodies, such as AMG-780; anti-CSF1R antibodies, such as emactuzumab, LY3022855, AMG-820, FPA-008 (cabiralizumab); anti-endoglin antibodies, such as TRC105 (carotuximab); anti-ERBB antibodies, such as CDX-3379, HLX-02, seribantumab; anti-HER2 antibodies, such as HERCEPTIN ®(trastuzumab), trastuzumab biosimilars, magituximab, MEDI4276, BAT-8001, pertuzumab (Perjeta), RG6264, ZW25 (a bispecific HER2-directed antibody targeting extracellular domains 2 and 4; Cancer Discov. 2019 Jan;9(1):8; PMID: 30504239); anti-HLA-DR antibodies, such as IMMU-114; anti-IL-3 antibodies, such as JNJ-56022473; anti-TNF receptor superfamily member 18 (TNFRSF18, GITR; NCBI Gene ID: 8784) antibodies, such as MK-4166, MEDI1873, FPA-154, INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323; and, for example, in International Patent Publication Nos. WO 2017 / 096179, WO 2017 / 096276, WO 2017 / 096189; and WO Those described in 2018 / 089628; anti-EphA3 antibodies, such as KB-004; anti-CD37 antibodies, such as otlertuzumab (TRU-016); anti-FGFR-3 antibodies, such as LY3076226, B-701; anti-FGFR-2 antibodies, such as GAL-F2; anti-C5 antibodies, such as ALXN-1210; anti-EpCAM antibodies, such as VB4-845; anti-CEA antibodies, such as RG-7813; anti-carcinoembryonic antigen-related cell adhesion molecule-6 (CEACAM6, CD66C) antibodies, such as BAY-1834942, NEO-201 (CEACAM 5 / 6); anti-GD2 antibodies, such as APN-301; anti-IL-17 antibodies, such as CJM-112; anti-IL-1β antibodies, such as canakinumab (ACZ885), VPM087; anti-carbonic anhydrase 9 (CA9, CAIX) antibodies, such as TX-250; anti-mucin 1 (MUC1) antibodies, such as gatipotuzumab, Mab-AR-20.5; anti-KMA antibodies, such as MDX-1097; anti-CD55 antibodies, such as PAT-SC1; anti-c-Met antibodies, such as ABBV-399; anti-PSMA antibodies, such as ATL-101; anti-CD100 antibodies, such as VX-15; anti-EPHA3 antibodies, such as fibatuzumab; anti-APRIL antibodies, such as BION-1301; anti-fibroblast activation protein (FAP) / IL-2R antibodies, such as R G7461; anti-fibroblast activation protein (FAP) / TRAIL-R2 antibodies, such as RG7386; anti-fucosyl-GM1 antibodies, such as BMS-986012; anti-IL-8 (interleukin-8) antibodies, such as HuMax-Inflam; anti-myostatin inhibitors, such as landogrozumab; anti-delta-like protein ligand 3 (DDL3) antibodies, such as rovalpituzumab; tesirine); anti-DLL4 (delta-like ligand 4) antibodies, such as demcizumab; anti-clusterin antibodies, such as AB-16B5; anti-ephrin-A4 (EFNA4) antibodies, such as PF-06647263; anti-mesothelin antibodies, such as BMS-986148, anti-MSLN-MMAE; anti-sodium phosphate cotransporter 2B (NaP2B) antibodies, such as lifastuzumab; anti-TGFβ antibodies, such as SAR439459; anti-transforming growth factor-β (TGF-β) antibodies, such as ABBV-151, LY3022859, NIS793, XOMA 089; purine analogs, folate antagonists (such as pralatrexate), cladribine, pentostatin, fludarabine, and related inhibitors; antiproliferative / antimitotic agents, including natural products such as vinca alkaloids (vinblastine, vincristine); and microtubule disrupting agents such as taxanes (paclitaxel, docetaxel), vinblastine, nocodazole, epothilones, vinorelbine (NAVELBINE. ®) and epipodophyllotoxins (etoposide, teniposide); DNA damaging agents such as actinomycin, amsacrine, busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide (CYTOXAN ® ), dactinomycin, daunorubicin, doxorubicin, DEBDOX, epirubicin, ifosfamide, melphalan, merchlorethamine, mitomycin C, mitoxantrone, nitrosoureas, procarbazine, taxol, Taxotere, teniposide, etoposide, and triethylenethiophosphoramide; DNA hypomethylating agents such as guadecitabine (SGI-110), oral decitabine ( decitabine) and cedazuridine (ASTX727); antibiotics such as dactinomycin, daunorubicin, doxorubicin, idarubicin, anthracyclines, mitoxantrone, bleomycin, plicamycin (mithramycin); enzymes such as L-asparaginase, which systemically metabolizes L-asparagine and deprives cells of the ability to synthesize their own asparagine; DNAi oligonucleotides targeting Bcl-2, such as PNT2258; agents that activate or reactivate latent human immunodeficiency virus (HIV), such as panobinostat and romidepsin; asparaginase stimulators, such as crisantaspase (Erwinase ® ) and GRASPA (ERY-001, ERY-ASP), calaspargase pegol, pegaspargase; pan-Trk, ROS1, and ALK inhibitors such as entrectinib, TPX-0005; anaplastic lymphoma kinase (ALK) inhibitors such as alectinib, ceritinib, alecensa (RG7853), ALUNBRIG ®(brigatinib); antiproliferative / antimitotic alkylating agents such as nitrogen mustard cyclophosphamide and analogs (e.g., melphalan, chlorambucil, hexamethonium, thiotepa), alkylnitrosoureas (e.g., carmustine) and analogs, streptozotocin, and triazenes (e.g., dacarbazine); antiproliferative / antimitotic antimetabolites such as folic acid analogs (methotrexate); platinum coordination complexes (e.g., cisplatin, oxaliplatinim, and carboplatin), procarbazine, hydroxyurea, mitotane, and aminoglutethimide; hormones, hormone analogs (e.g., estrogens, tamoxifen, goserelin, bicalutamide, and nilutamide), and aromatase inhibitors preparations (e.g., letrozole and anastrozole); antiplatelet agents; anticoagulants such as heparin, synthetic heparin salts, and other inhibitors of thrombin; fibrinolytic agents such as tissue plasminogen activator, streptokinase, urokinase, aspirin, dipyridamole, ticlopidine, and clopidogrel; antimigratory agents; antisecretory agents (e.g., breveldin); immunosuppressants such as tacrolimus, sirolimus, azathioprine, and mycophenolate mofetil; growth factor inhibitors and vascular endothelial growth factor inhibitors; fibroblast growth factor inhibitors such as FPA14; AMP-activated protein kinase stimulators such as metformin hydrochloride; ADP-ribosyl cyclase-1 inhibitors such as daratumumab (DARZALEX ®); caspase recruitment domain protein-15 stimulators, such as mifatin (liposomes); CCR5 chemokine antagonists, such as MK-7690 (vicriviroc); CDC7 protein kinase inhibitors, such as TAK-931; cholesterol side chain cleavage enzyme inhibitors, such as ODM-209; dihydropyrimidine dehydrogenase / orotate phosphoribosyltransferase inhibitors, such as Cefesone (tegafur + gimeracil + oteracil potassium); DNA polymerase / ribonucleotide reductase inhibitors, such as clofarabine; DNA interfering oligonucleotides, such as PNT2258, AZD-9150; estrogen receptor modulators, such as bazedoxifene; estrogen receptor agonists / progesterone receptor antagonists, such as TRI-CYCLEN LO (norethindrone + ethinyl estradiol); HLA class I antigen A-2 α modulators, such as FH-MCVA2TCR; HLA class I antigen A-2 α / MART-1 melanoma antigen modulators, such as MART-1 F5 TCR engineered PBMC; human granulocyte colony stimulating factor, such as PF-06881894; GNRH receptor agonists, such as leuprolide acetate, leuprolide acetate extended release depot (ATRIGEL), triptorelin pamoate, goserelin acetate; GNRH receptor antagonists, such as elagolix, relugolix, degarelix; endoplasmic protein modulators, such as anlotinib; H+ K+ ATPase inhibitors, such as omeprazole, esomeprazole; ICAM-1 / CD55 modulators, such as cavatak (V-937); IL-15 / IL-12 modulators, such as SAR441000; interleukin 23A inhibitors, such as guselkumab; lysine-specific histone demethylase 1 inhibitors, such as CC-90011; IL-12 mRNA, such as MEDI1191; RIG-I modulators, such as RGT-100; NOD2 modulators, such as SB-9200 and IR-103; progesterone receptor agonists, such as levonorgestrel; cereblon protein modulators, such as CC-92480, CC-90009; cereblon protein modulators / DNA binding protein Ikaros inhibitors / zinc finger binding protein Aiolos inhibitors, such as iberdomide; Retinoid X receptor modulators, such as alitretinoin, bexarotene (oral preparations); RIP-1 kinase inhibitors, such as GSK-3145095; selective estrogen receptor degraders, such as AZD9833; SUMO inhibitors, such as TAK-981;Thrombopoietin receptor agonists, such as eltrombopag; thyroid hormone receptor agonists, such as levothyroxine sodium; TNF agonists, such as tasonamine; tyrosine phosphatase substrate 1 inhibitors, such as CC-95251; HER2 inhibitors, such as neratinib, tucatinib (ONT-380); EGFR / ErbB2 / Ephb4 inhibitors, such as tesevatinib; EGFR / HER2 inhibitors, such as TAK-788; EGFR family tyrosine kinase inhibitors, such as DZD-9008 ; EGFR / ErbB-2 inhibitors, such as varlitinib; mutant-selective EGFR inhibitors, such as PF-06747775, EGF816 (nazartinib), ASP8273, ACEA-0010, BI-1482694; epha2 inhibitors, such as MM-310; polycomb protein (EED) inhibitors, such as MAK683; DHFR inhibitors / folate transporter 1 modulators / folate receptor antagonists, such as pralatrexate; DHFR / GAR transformylase / thymidylate synthase / transferase inhibitors, such as pemetrexed disodium; p38 MAP kinase inhibitors, such as ralimetinib; PRMT inhibitors, such as MS203, PF-06939999, GSK3368715, GSK3326595; sphingosine kinase 2 (SK2) inhibitors, such as opaganib; erythroid 2-related factor 2 stimulators, such as omasorolone (RTA-408); tropomyosin receptor kinase (TRK) inhibitors, such as LOXO-195, ONO-7579; mucin 1 inhibitors, such as GO-203-2C; MARCKS protein inhibitors, such as BIO-11006; folate antagonists, such as arfolitixorin; galectin-3 inhibitors, such as GR-MD-02; phosphorylated P68 inhibitors, such as RX-5902; CD95 / TNF modulators, such as ofranergene obadenovec); pan-PIM kinase inhibitors, such as INCB-053914; IL-12 gene stimulators, such as EGEN-001, tavokinogene telseplasmid; heat shock protein HSP90 inhibitors, such as TAS-116, PEN-866; VEGF / HGF antagonists, such as MP-0250; VEGF ligand inhibitors, such as bevacizumab biosimilars; VEGF receptor antagonists / VEGF ligand inhibitors, such as ramucirumab;VEGF-1 / VEGF-2 / VEGF-3 receptor antagonists, such as fruquintinib; VEGF-1 / VEGF-2 receptor modulators, such as HLA-A2402 / HLA-A0201 restricted epitope peptide vaccines; placental growth factor ligand inhibitors / VEGF-A ligand inhibitors, such as aflibercept; SYK tyrosine kinase / JAK tyrosine kinase inhibitors, such as ASN-002; Trk tyrosine kinase inhibitors, such as larotrectinib sulfate; JAK3 / JAK1 / TBK1 kinase inhibitors, such as CS-12912; IL-24 antagonists, such as AD-IL24; NLRP3 (NACHT LRRPYD domain protein 3) modulators, such as BMS-986299; RIG-I agonists, such as RGT-100; Aeromonas lysin stimulators, such as topsalysin; P-glycoprotein 1 inhibitors, such as HM-30181A; CSF-1 antagonists, such as ARRY-382, BLZ-945; CCR8 inhibitors, such as JTX-1811, I-309, SB-649701, HG-1013, RAP-3 10; anti-mesothelin antibodies, such as SEL-403; thymidine kinase stimulators, such as aglatimagene besadenovec; Polo-like kinase 1 inhibitors, such as PCM-075, onvansertib; NAE inhibitors, such as pevonedistat (MLN-4924); Trop-2 inhibitors, such as saccharotuzumab-govitecan (TRODELVY; ®), TAS-4464; pleiotropic pathway modulators, such as avadomide (CC-122); amyloid binding protein-1 inhibitors / ubiquitin ligase modulators; FoxM1 inhibitors, such as thiostrepton; UBA1 inhibitors, such as TAK-243; Src tyrosine kinase inhibitors, such as VAL-201; VDAC / HK inhibitors, such as VDA-1102; Elf4a inhibitors, such as rohinitib, eFT226; TP53 gene stimulators, such as ad-p53; retinoic acid receptor agonists, such as tretinoin; retinoic acid receptor alpha (RARα) inhibitors, such as SY-1425; SIRT3 inhibitors, such as YC8-02; stromal cell-derived factor 1 ligand inhibitors, such as olaptesed pegol, NOX-A12); IL-4 receptor modulators, such as MDNA-55; arginase-I stimulators, such as pegzilarginase; topoisomerase I inhibitors, such as irinotecan hydrochloride, Onivyde; topoisomerase I inhibitors / hypoxia-inducible factor-1α inhibitors, such as PEG-SN38 (firtecan pegol); hypoxia-inducible factor-1α inhibitors such as PT-2977, PT-2385; CD122 (IL-2 receptor) agonists such as proleukin, aldesleukin, IL-2; pegylated IL-2 (e.g., NKTR-214); modified variants of IL-2 (e.g., THOR-707); TLR7 / TLR8 agonists such as NKTR-262; TLR7 agonists such as DS-0509, GS-9620, LHC-165, TMX-101 (imiquimod); p53 tumor suppressor protein stimulators such as kevetrin; Mdm4 / Mdm2 p53 binding protein inhibitors, such as ALRN-6924; kinesin spindle protein (KSP) inhibitors, such as filanisib (ARRY-520); CD80-Fc fusion protein inhibitors, such as FPT-155; multiple endocrine oncoprotein and mixed lineage leukemia (MLL) inhibitors, such as KO-539; liver x receptor agonists, such as RGX-104; IL-10 agonists, such as Pegilodecakin (AM-0010); VEGFR / PDGFR inhibitors, such as vorolanib; IRAK4 inhibitors, such as CA-4948; anti-TLR-2 antibodies, such as OPN-305; calmodulin modulators, such as CBP-501.

[0263] Glucocorticoid receptor antagonists, such as relacorilant (CORT-125134); second mitochondrial-derived caspase activator (SMAC) protein inhibitors, such as BI-891065; lactoferrin modulators, such as LTX-315; KIT proto-oncogene, receptor tyrosine kinase (KIT) inhibitors, such as PLX-9486; platelet-derived growth factor alpha (PDGFRA) / KIT proto-oncogene, receptor tyrosine kinase (KIT) mutant-specific antagonists / inhibitors, such as BLU-285, DCC-2618; exportin 1 inhibitors, such as eptanesole (eltanexor); CHST15 gene inhibitors, such as STNM-01; somatostatin receptor antagonists, such as OPS-201; CEBPA gene stimulators, such as MTL-501; DKK3 gene modulators, such as MTG-201; chemokine (CXCR1 / CXCR2) inhibitors, such as SX-682; p70s6k inhibitors, such as MSC2363318A; methionine aminopeptidase 2 (MetAP2) inhibitors, such as M8891, APL-1202; arginine N-methyltransferase 5 inhibitors, such as GSK-3326595; CD71 modulators, such as Such as CX-2029 (ABBV-2029); ATM (ataxia telangiectasia) inhibitors, such as AZD0156, AZD1390; CHK1 inhibitors, such as GDC-0575, LY2606368 (prexasertib), SRA737, RG7741 (CHK1 / 2); CXCR4 antagonists, such as BL-8040, LY2510924, burixafor (TG-0054), X4P-002, X4P-001-IO, plerixafor; EXH2 inhibitors, such as GSK28161 26; KDM1 inhibitors, such as ORY-1001, IMG-7289, INCB-59872, GSK-2879552; CXCR2 antagonists, such as AZD-5069; DNA-dependent protein kinase inhibitors, such as MSC2490484A (nedisertib), VX-984, AsiDNA (DT-01); protein kinase C (PKC) inhibitors, such as LXS-196, sotrastaurin; selective estrogen receptor downregulators (SERDs), such as fulvestrant (Faslodex ®), RG6046, RG6047, RG6171, elacestrant (RAD-1901), SAR439859 and AZD9496; selective estrogen receptor covalent antagonists (SERCAs), such as H3B-6545; selective androgen receptor modulators (SARMs), such as GTX-024, darolutamide; transforming growth factor-β (TGF-β) kinase antagonists, such as galunisertib, LY3200882; WO TGF-β inhibitors as described in 2019 / 103203; TGF-β receptor 1 inhibitors, such as PF-06952229; bispecific antibodies, such as ABT-165 (DLL4 / VEGF), MM-141 (IGF-1 / ErbB3), MM-111 (Erb2 / Erb3), JNJ-64052781 (CD19 / CD3), PRS-343 (CD-137 / HER2), AFM26 (BCMA / CD16A), JNJ-61186372 (EGFR / c MET), AMG-211 (CEA / CD3), RG7802 (CEA / CD3), ERY-974 (CD3 / GPC3), vancizumab (angiogenin / VEGF), PF-06671008 (cadherin / CD3), AFM-13 (CD16 / CD30), APVO436 (CD123 / CD3), flutezumab (CD123 / CD3), REGN-1979 (CD20 / CD3), MCLA-117 (CD3 / CLEC12A), MC LA-128 (HER2 / HER3), JNJ-0819, JNJ-7564 (CD3 / heme), AMG-757 (DLL3-CD3), MGD-013 (PD-1 / LAG-3), FS-118 (LAG-3 / PD- L1), MGD-019 (PD-1 / CTLA-4), KN-046 (PD-1 / CTLA-4), MEDI-5752 (CTLA-4 / PD-1), RO-7121661 (PD-1 / TIM-3), XmAb-207 17 (PD-1 / CTLA-4), AK-104 (CTLA-4 / PD-1), AMG-420 (BCMA / CD3), BI-836880 (VEFG / ANG2), JNJ-63709178 (CD123 / CD3), MGD-007 (CD3 / gpA33), MGD-009 (CD3 / B7H3), AGEN1223, IMCgp100 (CD3 / gp100), AGEN-1423, ATOR-1015 (CTLA-4 / OX40),LY-3415244 (TIM-3 / PDL1), INHIBRX-105 (4-1BB / PDL1), faricimab (VEGF-A / ANG-2), FAP-4-IBBL (4-1BB / FAP), XmAb-13676 (CD3 / CD20), TAK-252 (PD-1 / OX40L), TG-1801 (CD19 / CD47), XmAb-18087 (SSTR2 / CD3), catumaxomab (CD3 / EpCAM), SAR-156597 (IL4 / IL 13), EMB-01 (EGFR / cMET), REGN-4018 (MUC16 / CD3), REGN-1979 (CD20 / CD3), RG-7828 (CD20 / CD3), CC-93269 (CD3 / BCMA), REGN-545 8 (CD3 / BCMA), navicixizumab (DLL4 / VEGF), GRB-1302 (CD3 / Erbb2), vanucizumab (VEGF-A / ANG-2), GRB-1342 (CD38 / CD3) , GEM-333 (CD3 / CD33), IMM-0306 (CD47 / CD20), RG6076, MEDI5752 (PD-1 / CTLA-4), LY3164530 (MET / EGFR); α-ketoglutarate dehydrogenase (KGDH) inhibitors, such as CPI-613; XPO1 inhibitors, such as selinexor (KPT-330); isocitrate dehydrogenase 2 (IDH2) inhibitors, such as enanib (AG-221); IDH1 inhibitors, such as AG-120 and AG-881 (IDH1 and ID H2), IDH-305, BAY-1436032; IDH1 gene inhibitors, such as ivosidenib; interleukin-3 (IL-3R) modulators, such as SL-401; arginine deiminase stimulators, such as arginine deiminase (pegargiminase, ADI-PEG-20); occludin-18 inhibitors, such as claudiximab; β-catenin inhibitors, such as CWP-291; chemokine receptor 2 (CCR) inhibitors, such as PF-04136309, CCX-872,BMS-813160 (CCR2 / CCR5); thymidylate synthase inhibitors such as ONX-0801; ALK / ROS1 inhibitors such as lorlatinib; tankyrase inhibitors such as G007-LK; triggering receptor expressed on myeloid cells 1 (TREM1; NCBI Gene ID: 54210), such as PY159; triggering receptor expressed on myeloid cells 2 (TREM2; NCBI Gene ID: 54209), such as PY314; Mdm2 p53 binding protein inhibitors such as CMG-097, HDM-201; c-PIM inhibitors such as PIM447; sphingosine kinase-2 (SK2) inhibitors such as Yeliva, ® (ABC294640); DNA polymerase inhibitors such as sapacitabine; cell cycle / microtubule inhibitors such as eribulin mesylate; c-MET inhibitors such as AMG-337, savolitinib, tivantinib (ARQ-197), capmatinib and tepotinib, ABT-700, AG213, AMG-208, JNJ-38877618 (OMO-1), merestinib, HQP-8361; c-Met / VEGFR inhibitors such as BMS-817378, TAS-115; c-Met / RON inhibitors such as BMS-777607; BCR / ABL inhibitors such as rebastinib, asciminib, ponatinib (ICLUSIG ®); MNK1 / MNK2 inhibitors, such as eFT-508; cytochrome P450 11B2 / cytochrome P450 17 / AKT protein kinase inhibitors, such as LAE-201; cytochrome P450 3A4 stimulators, such as mitotane; lysine-specific demethylase-1 (LSD1) inhibitors, such as CC-90011; CSF1R / KIT and FLT3 inhibitors, such as pexidartinib (PLX3397); Flt3 tyrosine kinase / Kit tyrosine kinase inhibitors and PDGF receptor antagonists, such as quizartinib dihydrochloride (quizartinib dihydrochloride); kinase inhibitors such as vandetanib; E-selectin antagonists such as GMI-1271; differentiation inducers such as retinoic acid; epidermal growth factor receptor (EGFR) inhibitors such as osimertinib (AZD-9291), cetuximab; topoisomerase inhibitors such as doxorubicin, doxorubicin, daunorubicin, dactinomycin, DaunoXome, Caelyx, eniposide, epirubicin, etoposide, idarubicin, irinotecan, mitoxantrone, pisantrone, sobuzosane, topotecan, irinotecan, MM-398 (liposomal irinotecan), vosarosin and GPX-150, adorubicin, AR-67, mavelertinib, AS T-2818, avitinib (ACEA-0010), ilofofen (MGI-114); corticosteroids such as cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, prednisolone; growth factor signaling kinase inhibitors; nucleoside analogs such as DFP-10917; Axl inhibitors such as BGB-324 (bemcentinib), SLC-0211; Axl / Flt3 inhibitors such as gilteritinib; inhibitors of bromodomain and extra-terminal motif (BET) proteins, including ABBV-744, BRD2 (NCBI Gene ID: 6046), BRD3 (NCBI Gene ID: 8019), BRD4 (NCBI Gene ID: 23476), and bromodomain testis-specific protein (BRDT;NCBI gene ID: 676), such as INCB-054329, INCB057643, TEN-010, AZD-5153, ABT-767, BMS-986158, CC-90010, GSK525762 (molibresib), NHWD-870, ODM-207, GSK-2820151, GSK-1210151A, ZBC246, ZBC260, Z EN3694, FT-1101, RG-6146, CC-90010, CC-95775, mivebresib, BI-894999, PLX-2853, PLX-51107, CPI-0610, GS-5829; PARP inhibitors, such as pamiparib, fuzuloparib, talazoparib tosylate tosylate, niraparib tosylate monohydrate, rucaparib camsylate, olaparib, veliparib, ABT-767, BGB-290, bendamustine hydrochloride; PARP / tankyrase inhibitors such as 2X-121 (e-7499); IMP-4297, SC-10914, IDX-1197, HWH-340, CK-102, simmiparib; proteasome inhibitors such as ixazomib (NINLARO; ® ), carfilzomib (Kyprolis ®), marizomib, bortezomib; glutamine inhibitors such as CB-839 (telaglenastat), bis-2-(5-phenylacetylamino-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES); mitochondrial complex I inhibitors such as metformin, phenformin; vaccines such as peptide vaccines TG-01 (RAS), GALE-301, GALE-302, nelipepimut-s, SurVaxM, DSP-7888, TPIV-200, PVX-410, VXL-100, DPX-E7, ISA-101, 6MHP, OSE-2101, galinpepimut-S, SVN53-67 / M57-KLH, IMU-131, peptide subunit vaccines (acute lymphoblastic leukemia, University Children's Hospital Tübingen) Tuebingen); bacterial vector vaccines such as CRS-207 / GVAX, axalimogene filolisbac (ADXS11-001); adenovirus vector vaccines such as nadofaragene firadenovec; autologous Gp96 vaccine; dendritic cell vaccines such as CVactm, stapuldencel-T, eltrapuldencel-T, rocapuldencel-T (AGS-003), DCVAC, SL-701, BSK01TM, ADXS31-142, autologous dendritic cell vaccine (metastatic malignant melanoma, intradermal / intravenous, Universitatsklinikum Erlangen); oncolytic vaccines such as talimogene laherparepvec, pexastimogene devacirepvec, GL-ONC1, MG1-MA3, parvovirus H-1, ProstAtak, enadenotucirev, MG1MA3, ASN-002 (TG-1042); therapeutic vaccines such as CVAC-301, CMP-001, CreaVax-BC, PF-06753512, VBI-1901, TG-4010, ProscaVax ™ ; Tumor cell vaccines, such as Vigil ®(IND-14205), Oncoquest-L vaccine; live attenuated recombinant serotype 1 poliovirus vaccines, such as PVS-RIPO; Adagloxad simolenin; MEDI-0457; DPV-001 tumor-derived autophagosome-enriched cancer vaccine; RNA vaccines, such as CV-9209, LV-305; DNA vaccines, such as MEDI-0457, MVI-816, INO-5401; modified vaccinia virus Ankara vaccine expressing p53, such as MVA-p53; DPX-Survivac; BriaVax ™ ; GI-6301; GI-6207; GI-4000; IO-103; Neoantigen peptide vaccines, such as AGEN-2017, GEN-010, NeoVax, RG-6180, GEN-009, PGV-001 (TLR-3 agonist), GRANITE-001, NEO-PV-01; Peptide vaccines targeting heat shock proteins, such as PhosphoSynVax ™ ; Vitespen (HSPPC-96-C), NANT colorectal cancer vaccine with aldoxorubicin, autologous tumor cell vaccine + systemic CpG-B + IFN-α (cancer), IO-120 + IO-103 (PD-L1 / PD-L2 vaccine), HB-201, HB-202, HB-301, TheraT-based ® Vaccines. TLR-3 agonists / interferon inducers, such as Poly-ICLC (NSC-301463); STAT-3 inhibitors, such as Nababukacin (BBI-608); ATPase p97 inhibitors, such as CB-5083; Smoothened (SMO) receptor inhibitors, such as Odomzo ®(sonidegib, formerly LDE-225), LEQ506, vismodegib (GDC-0449), BMS-833923, glasdegib (PF-04449913), LY2940680, and itraconazole; interferon alpha ligand modulators, such as interferon alpha-2b, interferon alpha-2a biosimilars (Biogenomics), ropeg interferon alpha-2b (AOP-2014, P-1101, PEG IFN alpha-2b), Multiferon (Alfanative, Viragen), interferon alpha 1b, Roferon-A (Canferon, Ro-25-3036), interferon alpha-2a follow-on biologics (Biosidus) (Inmutag, Inter 2A), interferon alpha-2b follow-on biologics (Biosidus) -Bioferon, Citopheron, Ganapar, Beijing Kawin Technology – Kaferon), Alfaferone, pegylated interferon alpha-1b, pegylated interferon alpha-2b follow-on biologic (Amega), recombinant human interferon alpha-1b, recombinant human interferon alpha-2a, recombinant human interferon alpha-2b, veltuzumab-IFNα 2b conjugates, Dynavax (SD-101), and interferon α-n1 (Humoferon, SM-10500, Sumiferon); interferon γ ligand modulators, such as interferon γ (OH-6000, Oγ100); telomerase modulators, such as tertomotide (GV-1001, HR-2802, Riavax) and imetelstat (GRN-163, JNJ-63935937); DNA methyltransferase inhibitors, such as temozolomide (CCRG-81045), decitabine, oral decitabine, and cedaruridine (ASTX72 7), guadecitabine (S-110, SGI-110), KRX-0402, RX-3117, RRx-001 and azacytidine (CC-486); DNA gyrase inhibitors, such as pisantron and sobuzoxan; DNA gyrase inhibitors / topoisomerase II inhibitors, such as amrubicin; Bcl-2 family protein inhibitors, such as ABT-263, venetola (ABT-199), obaclava mesylate, pasitola, ABT-737, RG7601 and AT-101; Bcl-2 / Bcl-XL inhibitors, such as navitola (ABT-263; RG-7433);Notch inhibitors, such as LY3039478 (crenigacestat), tarextumab (anti-Notch2 / 3), BMS-906024; hyaluronidase stimulators, such as PEGPH-20; Erbb2 tyrosine kinase inhibitors / hyaluronidase stimulators, such as Herceptin Hylecta; Wnt pathway inhibitors, such as SM-04755, PRI-724, WNT-974; γ-secretase inhibitors, such as PF-03084014, MK-0752, RO-4929097; Grb-2 (growth factor receptor binding protein-2) inhibitors TRAIL inhibitors, such as BP1001; TRAIL pathway inducing compounds, such as ONC201, ABBV-621; TRAIL modulators, such as SCB-313; focal adhesion kinase inhibitors, such as VS-4718, defactinib, GSK2256098; hedgehog inhibitors, such as saridegib, sonidegib (LDE225), glasdegib; Aurora kinase inhibitors, such as alisertib (MLN-8237) and AZD-2811, AMG-900, barasert ib), ENMD-2076; HSPB1 modulators (heat shock protein 27, HSP27), such as brivudine, apatorsen; ATR inhibitors, such as BAY-937, AZD6738, AZD6783, VX-803, VX-970 (berzosertib) and VX-970; Hsp90 inhibitors, such as AUY922, onalespib (AT13387), SNX-2112, SNX5422; mouse double minute (mdm2) oncogene inhibitors, such as DS-3032b, RG7775 , AMG-232, HDM201 and idasanutlin (RG7388); CD137 agonists such as urelumab, utomilumab (PF-05082566), AGEN2373, ADG-106, BT-7480, QL1806; STING agonists such as ADU-S100 (MIW-815), SB-11285, MK-1454, SR-8291, AdVCA0848, GSK-532, SYN-STING, MSA-1, SR-8291, GSK3745417;FGFR inhibitors, such as FGF-401, INCB-054828, BAY-1163877, AZD4547, JNJ-42756493, LY2874455, Debio-1347; fatty acid synthase (FASN) inhibitors, such as TVB-2640; CD44 binders, such as A6; protein phosphatase 2A (PP2A) inhibitors, such as LB-100; CYP17 inhibitors, such as seviteronel (VT-464), ASN-001, ODM-204, CFG920, abiraterone acetate; RXR agonists, such as IRX4204; hedgehog / smoothened (hh / Smo) antagonists, such as taladegib, patidegib, b), vismodegib; complement C3 modulators, such as ImprimePGG; IL-15 agonists, such as ALT-803, NKTR-255, interleukin-15 / Fc fusion protein, AM-0015, NIZ-985, and hetIL-15; EZH2 (Zeste homolog enhancer 2) inhibitors, such as tazemetostat, CPI-1205, GSK-2816126, PF-06821497; oncolytic viruses, such as pelareorep, CG-0070, MV-NIS therapy, HSV-1716, DS-1647, VCN-01, ONCOS-102, TBI-1401, tasadenoturev (DNX-2401), and vocimagene amiretrorepvec), RP-1, CVA21, Celyvir, LOAd-703, OBP-301, IMLYGIC; ®; DOT1L (histone methyltransferase) inhibitors, such as pinostat (EPZ-5676); toxins, such as cholera toxin, ricin, Pseudomonas exotoxin, Bordetella pertussis adenylate cyclase toxin, diphtheria toxin, and caspase activators; DNA plasmids, such as BC-819; PLK PLK inhibitors of 1, 2 and 3, such as volasertib (PLK1); WEE1 inhibitors, such as AZD-1775 (adavosertib); Rho kinase (ROCK) inhibitors, such as AT13148, KD025; inhibitors of apoptosis protein (IAP) inhibitors, such as ASTX660, debio-1143, birinapant, APG-1387, LCL-161; RNA polymerase inhibitors, such as lurbinectedin (PM-1183), CX-5461; microtubule inhibitors, such as PM- 184, BAL-101553 (lisavanbulin) and OXI-4503, fluorapacin (AC-0001), plinabulin, vinflunine; Toll-like receptor 4 (TLR-4) agonists such as G100, GSK1795091 and PEPA-10; elongation factor 1α2 inhibitors such as plitidepsin; elongation factor 2 inhibitors / interleukin-2 ligands / NADADP-ribosyltransferase stimulators such as denileukin-toxin conjugates; diftitox); CD95 inhibitors such as APG-101, APO-010, asunercept; WT1 inhibitors such as DSP-7888; splicing factor 3B subunit 1 (SF3B1) inhibitors such as H3B-8800; retinoid Z receptor γ (RORγ) agonists such as LYC-55716; and microbiome modulators such as SER-401, EDP-1503, MRx-0518.

[0264] In various embodiments, the agents described herein that inhibit binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with one or more additional therapeutic agents, including inhibitors or antagonists of: myeloid cell leukemia sequence 1 (MCL1) apoptosis regulator (NCBI gene ID: 4170); mitogen-activated protein kinase 1 (MAP4K1) (also known as hematopoietic progenitor cell kinase 1 (HPK1), NCBI gene ID: 11184); diacylglycerol kinase alpha (DGKA, DAGK, DAGK1 or DGK-α; NCBI gene ID: 1606); '-ectonucleotidase (NT5E or CD73; NCBI Gene ID: 4907); ectonucleotide triphosphate diphosphohydrolase 1 (ENTPD1 or CD39; NCBI Gene ID: 593); transforming growth factor β1 (TGFB1 or TGFβ; NCBI Gene ID: 7040); heme oxygenase 1 (HMOX1, HO-1 or HO1; NCBI Gene ID: 3162); heme oxygenase 2 (HMOX2, HO-2 or HO2; NCBI Gene ID: 3163); vascular endothelial growth factor A (VEGFA or VEGF; NCBI Gene ID: 7422); erb-b2 receptor tyrosine kinase 2 (ERBB2, HER2 , HER2 / neu or CD340; NCBI Gene ID: 2064), epidermal growth factor receptor (EGFR, ERBB, ERBB1 or HER1; NCBI Gene ID: 1956); ALK receptor tyrosine kinase (ALK, CD246; NCBI Gene ID: 238); poly (ADP-ribose) polymerase 1 (PARP1; NCBI Gene ID: 142); poly (ADP-ribose) polymerase 2 (PARP2; NCBI Gene ID: 10038); TCDD-inducible poly (ADP-ribose) polymerase (TIPARP, PARP7; NCBI Gene ID: 25976); cyclin-dependent kinase 4 (CDK4; NC BI gene ID: 1019); cyclin-dependent kinase 6 (CDK6; NCBI gene ID: 1021); TNF receptor superfamily member 14 (TNFRSF14, HVEM, CD270; NCBI gene ID: 8764); T cell immunoreceptor with Ig and ITIM domains (TIGIT; NCBI gene ID: 201633); X-linked inhibitor of apoptosis (XIAP, BIRC4, IAP-3; NCBI gene ID: 331); baculovirus IAP repeat-containing protein 2 (BIRC2, cIAP1; NCBI gene ID: 329); baculovirus IAP repeat-containing protein 3 (BIRC3, cIAP2;NCBI gene ID: 330); baculovirus IAP repeat-containing protein 5 (BIRC5, survivin; NCBI gene ID: 332); CC motif chemokine receptor 2 (CCR2, CD192; NCBI gene ID: 729230); CC motif chemokine receptor 5 (CCR5, CD195; NCBI gene ID: 1234); CC motif chemokine receptor 8 (CCR8, CDw198; NCBI gene ID: 1237); CXC motif chemokine receptor 2 (CXCR2, CD182; NCBI gene ID: 3579); CXC motif chemokine receptor 3 (CXCR3, CD1 82, CD183; NCBI gene ID: 2833); CXC motif chemokine receptor 4 (CXCR4, CD184; NCBI gene ID: 7852); arginase (ARG1 (NCBI gene ID: 383), ARG2 (NCBI gene ID: 384)), carbonic anhydrase (CA1 (NCBI gene ID: 759), CA2 (NCBI gene ID: 760), CA3 (NCBI gene ID: 761), CA4 (NCBI gene ID: 762), CA5A (NCBI gene ID: 763), CA5B (NCBI gene ID: 11238), CA6 (NCBI gene ID: 11239), CA7 (NCBI gene ID: 11247), CA8 (NCBI gene ID: 11254), CA9 (NCBI gene ID: 11263), CA10 (NCBI gene ID: 11264), CA11 (NCBI gene ID: 11265), CA12 (NCBI gene ID: 11266), CA13 (NCBI gene ID: 11267), CA14 (NCBI gene ID: 11268), CA15 (NCBI gene ID: 11269), CA16 (NCBI gene ID: 11270), CA17 (NCBI gene ID: 11271), CA18 (NCBI gene ID: 11267), CA19 (NCBI gene ID: 11268), CA20 (NCBI gene ID: 11269), CA3 Gene ID: 765), CA7 (NCBI Gene ID: 766), CA8 (NCBI Gene ID: 767), CA9 (NCBI Gene ID: 768), CA10 (NCBI Gene ID: 56934), CA11 (NCBI Gene ID: 770), CA12 (NCBI Gene ID: 771), CA13 (NCBI Gene ID: 377677), CA14 (NCBI Gene ID: 23632), prostaglandin-endoperoxide synthase 1 (PTGS1, COX-1; NCBI Gene ID: 5742), prostaglandin-endoperoxide synthase 2 (PTGS2, COX-2; NCBI gene ID: 5743), secreted phospholipase A2, prostaglandin E synthase (PTGES, PGES; gene ID: 9536), arachidonic acid 5-lipoxygenase (ALOX5, 5-LOX; NCBI gene ID: 240), and / or soluble epoxide hydrolase 2 (EPHX2, SEH; NCBI gene ID: 2053); secreted phospholipase A2 (e.g., PLA2G1B (NCBI gene ID: 5319); PLA2G7 (NCBI gene ID: 7941), PLA2G3 (NCBI gene ID: 50487), PLA2G2A (NCBI gene ID: 5320);PLA2G4A (NCBI Gene ID: 5321), PLA2G12A (NCBI Gene ID: 81579), PLA2G12B (NCBI Gene ID: 84647), PLA2G10 (NCBI Gene ID: 8399), PLA2G5 (NCBI Gene ID: 5322), PLA2G2D (NCBI Gene ID: 26279), PLA2G15 (NCBI Gene ID: 23659); indoleamine 2,3-dioxygenase 1 (IDO1; NCBI Gene ID: 3620); indoleamine 2,3-dioxygenase 2 (IDO2; NCBI Gene ID: 16935 5); hypoxia-inducible factor 1 subunit alpha (HIF1A; NCBI Gene ID: 3091); angiopoietin 1 (ANGPT1; NCBI Gene ID: 284); endothelial TEK tyrosine kinase (TIE-2, TEK, CD202B; NCBI Gene ID: 7010); Janus kinase 1 (JAK1; NCBI Gene ID: 3716); catenin beta 1 (CTNNB1; NCBI Gene ID: 1499); histone deacetylase 9 (HDAC9; NCBI Gene ID: 9734) and / or 5'-3' exoribonuclease 1 (XRN1; NCBI Gene ID: 54464). ;

[0265] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with agonists of: fms-related receptor tyrosine kinase 3 (FLT3); FLK2; STK1; CD135; FLK-2; NCBI gene ID: 2322). Examples of FLT3 agonists include, but are not limited to, CDX-301 and GS-3583. GS-3583 is described, for example, in WO 2020 / 263830, which is hereby incorporated by reference in its entirety for all purposes.

[0266] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD19 agents or antibodies. Examples of anti-CD19 agents or antibodies that can be co-administered include, but are not limited to: blinatumomab, tafacitumomab, XmAb5574 (Xencor), AFM-11, inelizumab, lantuximab, MEDI 551 (Cellective Therapeutics); and MDX-1342 (Medarex).

[0267] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD20 agents or antibodies. Examples of anti-CD20 agents or antibodies that can be co-administered include, but are not limited to, IGN-002, PF-05280586; rituximab (Rituxan / Biogen Idec), ofatumumab (Arzerra / Genmab), obinutuzumab (Gazyva / RocheGlycart Biotech), alemtuzumab, veltuzumab, veltuzumab, ocrelizumab (Ocrevus / Biogen Idec; Genentech), ocatumumab and urituximab, and LFB-R603 (LFB Biotech.; rEVOBiologics).

[0268] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD22 agents or antibodies. Examples of anti-CD22 agents or antibodies that can be co-administered include, but are not limited to, epratuzumab, AMG-412, IMMU-103 (Immunomedics).

[0269] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD30 agents or antibodies. Examples of anti-CD30 agents or antibodies that can be co-administered include, but are not limited to, vebutin (Seattle Genetics).

[0270] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD33 agents or antibodies. Examples of anti-CD33 agents or antibodies that can be co-administered include, but are not limited to, gemtuzumab, lintuzumab, vadatuximab, CIK-CAR.CD33; CD33CART, AMG-330 (CD33 / CD3), AMG-673 (CD33 / CD3) and GEM-333 (CD3 / CD33), and IMGN-779.

[0271] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD37 agents or antibodies. Examples of anti-CD37 agents or antibodies that can be co-administered include, but are not limited to: BI836826 (Boehringer Ingelheim), Otuzumab, and TRU-016 (Trubion Pharmaceuticals).

[0272] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD38 agents or antibodies. Examples of anti-CD38 agents or antibodies that can be co-administered include, but are not limited to: CD38, such as T-007, UCART-38; Darzalex (Genmab), daratumumab, JNJ-54767414 (Darzalex / Genmab), Isatuximab, SAR650984 (ImmunoGen), MOR202, MOR03087 (MorphoSys), TAK-079; and anti-CD38-attenukine, such as TAK573.

[0273] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD52 agents or antibodies. Examples of anti-CD52 agents or antibodies that can be co-administered include, but are not limited to, anti-CD52 antibodies such as alemtuzumab (Campath / Cambridge University).

[0274] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD98 (4F2, FRP-1) agents or antibodies. Examples of anti-CD98 agents or antibodies that can be co-administered include, but are not limited to: IGN523 (Igenica).

[0275] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD157 (BST-1) agents or antibodies. Examples of anti-CD157 agents or antibodies that can be co-administered include, but are not limited to: OBT357, MEN1112 (Menarini; Oxford BioTherapeutics).

[0276] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-DKK-1 agents or antibodies. Examples of anti-DKK-1 agents or antibodies that can be co-administered include, but are not limited to: BHQ880 (MorphoSys; Novartis) and DKN-01, LY-2812176 (Eli Lilly).

[0277] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-GRP78 (BiP) agents or antibodies. Examples of anti-GRP78 agents or antibodies that can be co-administered include, but are not limited to: PAT-SM6 (OncoMab GmbH).

[0278] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-NOTCH1 agents or antibodies. Examples of anti-NOTCH1 agents or antibodies that can be co-administered include, but are not limited to: Brontictuzumab, OMP-52M51 (OncoMed Pharmaceuticals).

[0279] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-ROR1 agents or antibodies. Examples of anti-ROR1 agents or antibodies that can be co-administered include, but are not limited to, mapatumumab, TRM1, and HGS-1012 (Cambridge Antibody Technology).

[0280] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., moglizumab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-SLAMF7 (CS1, CD319) agents or antibodies. Examples of anti-SLAMF7 agents or antibodies that can be co-administered include, but are not limited to, elotuzumab, HuLuc63, BMS-901608 (Empliciti / PDL BioPharma), moglizumab (KW-0761).

[0281] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-TNFRSF10A (DR4; APO2; CD261; TRAILR1; TRAILR-1) agents or antibodies. Examples of anti-TNFRSF10A agents or antibodies that can be co-administered include, but are not limited to, mapatumumab, TRM1, and HGS-1012 (Cambridge Antibody Technology).

[0282] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-transferrin receptor (TFRC; CD71) agents or antibodies. Examples of anti-transferrin receptor agents or antibodies that can be co-administered include, but are not limited to: E2.3 / A27.15 (University of Arizona).

[0283] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-EPHA3 agents or antibodies. Examples of anti-EPHA3 agents or antibodies that can be co-administered include, but are not limited to, Ifabotuzumab, KB004 (Ludwig Institute for Cancer Research).

[0284] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., moglizumab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CCR4 agents or antibodies. Examples of anti-CCR4 agents or antibodies that can be co-administered include, but are not limited to, moglizumab, KW-0761 (Poteligeo / Kyowa Hakko Kirin Co.).

[0285] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CXCR4 agents or antibodies. Examples of anti-CXCR4 agents or antibodies that can be co-administered include, but are not limited to, ululumab, BMS-936564, MDX-1338 (Medarex), and PF-06747143 (Pfizer).

[0286] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-BAFF agents or antibodies. Examples of anti-BAFF agents or antibodies that can be co-administered include, but are not limited to, tabecirumab, LY2127399 (Eli Lilly).

[0287] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-BAFF receptor (BAFF-R) agents or antibodies. Examples of anti-BAFF-R agents or antibodies that can be co-administered include, but are not limited to: VAY736 (MorphoSys; Novartis).

[0288] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-RANKL agents or antibodies. Examples of anti-RANKL agents or antibodies that can be co-administered include, but are not limited to, denosumab, AMG-162 (Prolia; Ranmark; Xgeva / Amgen).

[0289] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-IL-6 agents or antibodies. Examples of anti-IL-6 agents or antibodies that can be co-administered include, but are not limited to, siltuximab, CNTO-328 (Sylvant / Centocor).

[0290] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-IL-6 receptor (IL-6R) agents or antibodies. Examples of anti-IL-6R agents or antibodies that can be co-administered include, but are not limited to, tocilizumab, R-1569 (Actemra / Chugai Pharmaceutical; Osaka University), or AS-101 (CB-06-02, IVX-Q-101).

[0291] In various embodiments, the agents described herein that inhibit binding between CD47 and SIRPα (eg, mololimab); and VEGFA / VEGFR inhibitors (eg, bevacizumab) are further combined with an anti-IL3RA (CD123) agent or antibody. Examples of anti-IL3RA (CD123) agents or antibodies that can be co-administered include, but are not limited to, tagraxofusp, talacotuzumab (JNJ-56022473; CSL362 (CSL)), pivekimab sunirine (IMGN632), MB-102 (Mustang Bio), CSL360 (CSL); victozumab (XmAb14045; Xencor); KHK2823 (KyowaHakko Kirin Co.); MGD-024 (CD123 / CD3; Macrogenics), APVO436 (CD123 / CD3); flutezumab (CD123 / CD3); JNJ-63709178 (CD123 / CD3); and XmAb-14045 (CD123 / CD3) (Xencor).

[0292] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-IL2RA (CD25) agents or antibodies. Examples of anti-IL2RA agents or antibodies that can be co-administered include, but are not limited to, basiliximab, SDZ-CHI-621 (Simulect / Novartis), and daclizumab.

[0293] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-IGF-1R (CD221) agents or antibodies. Examples of anti-IGF-1R agents or antibodies that can be co-administered include, but are not limited to: ganituzumab, AMG-479 (Amgen); ganituzumab, AMG-479 (Amgen), darotozumab, MK-0646 (Pierre Fabre), and AVE1642 (ImmunoGen).

[0294] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-GM-CSF (CSF2) agents or antibodies. Examples of anti-GM-CSF agents or antibodies that can be co-administered include, but are not limited to, Lenzilumab (also known as KB003; KaloBios Pharmaceuticals).

[0295] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-HGF agents or antibodies. Examples of anti-HGF agents or antibodies that can be co-administered include, but are not limited to, non-catuzumab, AV-299 (AVEO Pharmaceuticals).

[0296] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD44 agents or antibodies. Examples of anti-CD44 agents or antibodies that can be co-administered include, but are not limited to: RG7356, RO5429083 (Chugai Biopharmaceuticals; Roche).

[0297] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-VLA-4 (CD49d) agents or antibodies. Examples of anti-VLA-4 agents or antibodies that can be co-administered include, but are not limited to: natalizumab, BG-0002-E (Tysabri / Elan Corporation).

[0298] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-ICAM-1 (CD54) agents or antibodies. Examples of anti-ICAM-1 agents or antibodies that can be co-administered include, but are not limited to: BI-505 (BioInvent International).

[0299] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-VEGF-A agents or antibodies. Examples of anti-VEGF-A agents or antibodies that can be co-administered include, but are not limited to, bevacizumab (Avastin / Genentech; Hackensack University Medical Center).

[0300] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-endosialoprotein (CD248, TEM1) agents or antibodies. Examples of anti-endosialoprotein agents or antibodies that can be co-administered include, but are not limited to: Ontecizumab, MORAB-004 (Ludwig Institute for Cancer Research; Morphotek).

[0301] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-CD79 agents or antibodies. Examples of anti-CD79 agents or antibodies that can be co-administered include, but are not limited to: polotuzumab, DCDS4501A, RG7596 (Genentech).

[0302] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-isocitrate dehydrogenase (IDH) agents or antibodies. Examples of anti-IDH agents or antibodies that can be co-administered include, but are not limited to, the IDH1 inhibitor ivertinib (Tibsovo; Agios) and the IDH2 inhibitor ensidipine (Idhifa; Celgene / Agios).

[0303] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with antibodies targeting tumor-associated calcium signal transducer 2 (TACSTD2) (NCBI gene ID: 4070; EGP-1, EGP1, GA733-1, GA7331, GP50, M1S1, TROP2), such as sacituzumab, for example, sacituzumab-govetecan (TRODELVY ™ )combination.

[0304] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an anti-class I, class G major histocompatibility complex (HLA-G; NCBI Gene ID: 3135) antibody (such as TTX-080).

[0305] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an anti-leukocyte immunoglobulin-like receptor B2 (LILRB2, also known as CD85D, ILT4; NCBI Gene ID: 10288) antibody (such as JTX-8064 or MK-4830).

[0306] TNF receptor superfamily (TNFRSF) member agonists or activators

[0307] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an agonist of one or more TNF receptor superfamily (TNFRSF) members, such as an agonist of one or more of the following: TNFRSF1A (NCBI gene ID: 7132), TNFRSF1B (NCBI gene ID: 7133), TNFRSF4 (OX40, CD134; NCBI gene ID: 7293), TNFRSF5 ( CD40; NCBI gene ID: 958), TNFRSF6 (FAS, NCBI gene ID: 355), TNFRSF7 (CD27, NCBI gene ID: 939), TNFRSF8 (CD30, NCBI gene ID: 943), TNFRSF9 (4-1BB, CD137, NCBI gene ID: 3604), TNFRSF10A (CD261, DR4, TRAILR1, NCBI gene ID: 8797), TNFRSF10B (CD262, DR5, TRAILR2, NCBI gene ID: 87 95), TNFRSF10C (CD263, TRAILR3, NCBI gene ID: 8794), TNFRSF10D (CD264, TRAILR4, NCBI gene ID: 8793), TNFRSF11A (CD265, RANK, NCBI gene ID: 8792), TNFRSF11B (NCBI gene ID: 4982), TNFRSF12A (CD266, NCBI gene ID: 51330), TNFRSF13B (CD267, NCBI gene ID: 23495), TNFRSF13C (CD268, NCBI Gene ID: 115650), TNFRSF16 (NGFR, CD271, NCBI Gene ID: 4804), TNFRSF17 (BCMA, CD269, NCBI Gene ID: 608), TNFRSF18 (GITR, CD357, NCBI Gene ID: 8784), TNFRSF19 (NCBI Gene ID: 55504), TNFRSF21 (CD358, DR6, NCBI Gene ID: 27242), and TNFRSF25 (DR3, NCBI Gene ID: 8718).

[0308] Examples of anti-TNFRSF4 (OX40) antibodies that can be co-administered include, but are not limited to, MEDI6469, MEDI6383, MEDI0562 (tavolizumab), MOXR0916, PF-04518600, RG-7888, GSK-3174998, INCAGN1949, BMS-986178, GBR-8383, ABBV-368, and those described in WO2016179517, WO2017096179, WO2017096182, WO2017096281, and WO2018089628, each of which is hereby incorporated by reference in its entirety.

[0309] Examples of anti-TNF receptor superfamily member 10b (TNFRSF10B, DR5, TRAILR2) antibodies that may be co-administered include, but are not limited to, antibodies such as DS-8273, CTB-006, INBRX-109, and GEN-1029.

[0310] Examples of anti-TNFRSF5 (CD40) antibodies that may be co-administered include, but are not limited to, selumetumab (RO7009789), mitazalimab (also known as vanalimab), ADC-1013, JNJ-64457107, RG7876, SEA-CD40, APX-005M, and ABBV-428, ABBV-927, and JNJ-64457107.

[0311] Examples of anti-TNFRSF7 (CD27) that may be co-administered include, but are not limited to, varilumab (CDX-1127).

[0312] Examples of anti-TNFRSF9 (4-1BB, CD137) antibodies that may be co-administered include, but are not limited to, Urelumab, Utolumab (PF-05082566), AGEN2373, and ADG-106, BT-7480, and QL1806.

[0313] Examples of anti-TNFRSF17 (BCMA) that may be co-administered include, but are not limited to, GSK-2857916.

[0314] Examples of anti-TNFRSF18 (GITR) antibodies that can be co-administered include, but are not limited to, MEDI1873, FPA-154, INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323, and those described in WO2017096179, WO2017096276, WO2017096189, and WO2018089628. In some embodiments, antibodies or fragments thereof that co-target TNFRSF4 (OX40) and TNFRSF18 (GITR) are co-administered. Such antibodies are described, for example, in WO2017096179 and WO2018089628, each of which is hereby incorporated by reference in its entirety.

[0315] Examples of anti-TRAILR1 antibodies, anti-TRAILR2 antibodies, anti-TRAILR3 antibodies, anti-TRAILR4 antibodies that can be co-administered include, but are not limited to, ABBV-621.

[0316] Examples of bispecific antibodies targeting TNFRSF family members that can be co-administered include, but are not limited to, PRS-343 (CD-137 / HER2), AFM26 (BCMA / CD16A), AFM-13 (CD16 / CD30), REGN-1979 (CD20 / CD3), AMG-420 (BCMA / CD3), INHIBRX-105 (4-1BB / PDL1), FAP-4-IBBL (4-1BB / FAP), XmAb-13676 (CD3 / CD20), RG-7828 (CD20 / CD3), CC-93269 (CD3 / BCMA), REGN-5458 (CD3 / BCMA), IMM-0306 (CD47 / CD20), and AMG-424 (CD38.CD3).

[0317] Examples of PVR-related immunoglobulin domain (PVRIG, CD112R) containing inhibitors that may be co-administered include, but are not limited to, COM-701.

[0318] Examples of inhibitors of T cell immunoreceptor with Ig and ITIM domains (TIGIT; NCBI Gene ID: 201633) that can be co-administered include, but are not limited to, BMS-986207, RG-6058, AGEN-1307 and COM-902, etigilimab, tisleliumab (also known as MTIG-7192A; RG-6058; RO 7092284), AGEN1777, IBI-939, AB154, MG1131, and EOS884448 (EOS-448).

[0319] Examples of inhibitors of hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM-3) that may be co-administered include, but are not limited to, cobilimab (TSR-022), LY-3321367, sabatuzumab (MBG-453), INCAGN-2390, RO-7121661 (PD-1 / TIM-3), LY-3415244 (TIM-3 / PDL1), and RG7769 (PD-1 / TIM-3).

[0320] Examples of inhibitors of lymphocyte activation 3 (LAG-3, CD223) that may be co-administered include, but are not limited to, relatlimab (ONO-4482), LAG-525, MK-4280, REGN-3767, INCAGN2385, TSR-033, MGD-013 (PD-1 / LAG-3), and FS-118 (LAG-3 / PD-L1).

[0321] Examples of anti-killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1; KIR; NCBI Gene ID: 3811) monoclonal antibodies, such as lirilumab (IPH-2102) and IPH-4102.

[0322] Examples of anti-NKG2a antibodies that can be co-administered include, but are not limited to, monalizumab.

[0323] Examples of anti-V-set immunomodulatory receptor (VSIR, B7H5, VISTA) antibodies that can be co-administered include, but are not limited to: HMBD-002 and CA-170 (PD-L1 / VISTA).

[0324] Examples of anti-CD70 antibodies that may be co-administered include, but are not limited to, AMG-172.

[0325] Examples of anti-ICOS antibodies that can be co-administered include, but are not limited to, JTX-2011, GSK3359609.

[0326] Examples of ICOS agonists that may be co-administered include, but are not limited to: ICOS-L.COMP (Gariepy et al. 106th Annual Meeting of the American Association of Immunologists (AAI) (May 9-13, 2019, San Diego), Abstract 71.5).

[0327] Immune checkpoint inhibitors

[0328] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with one or more immune checkpoint inhibitors. In some embodiments, one or more immune checkpoint inhibitors are proteinaceous (e.g., antibodies or fragments thereof, or antibody mimetics) inhibitors of PD-L1 (CD274), PD-1 (PDCD1), or CTLA4. In some embodiments, one or more immune checkpoint inhibitors include organic small molecule inhibitors of PD-L1 (CD274), PD-1 (PDCD1), or CTLA4.

[0329] Examples of CTLA4 inhibitors that can be co-administered include, but are not limited to, ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, CG- -0161, ATOR-1144, PBI-5D3H5, BPI-002, HBM-4003, and the multispecific inhibitors FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4), and AK-104 (CTLA4 / PD-1).

[0330] Examples of inhibitors / antibodies of PD-L1 (CD274) or PD-1 (PDCD1) that may be co-administered include, but are not limited to, sepalizumab, pembrolizumab (KEYTRUDA ® , MK-3477), nivolumab (OPDIVO ®, BMS-936558, MDX-1106), cemiprilimab, pidilizumab, spartalizumab (PDR-001), atezolizumab (RG-7446; TECENTRIQ, MPDL3280A), durvalumab (MEDI-4736), avelumab (MSB0010718C), tislelizumab (BGB-A317), toripalizumab (JS-001), genoluzumab (CBT-501), carrelizumab (SHR- 1210), dotalimumab (TSR-042), sintilimab (IBI-308), tislelizumab (BGB-A317), cemiplizumab (REGN-2810), lanlorizumab (CAS registration number: 1374853-91-4), AMG-404, AMP-224, MEDI0680 (AMP-514), BMS-936559, CK-301, PF-06801591, GEN-1046 (PD-L1 / 4-1 BB), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JNJ -63723283, LZM-009, BCD-100, LY-3300054, SHR-1201, Sym-021, ABBV-181, PD1-PIK, BAT-1306, CX-072, CBT -502, MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, GS-4224, GS-4416, INCB086550, MAX10181,As well as the multispecific inhibitors FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-013 (PD-1 / LAG-3), RO-7247669 (PD-1 / LAG-3), FS-118 (LAG-3 / PD-L1) MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), RO-7121661 (PD-1 / TIM-3), XmAb-20717 (PD-1 / CTLA4), AK-104 (CTLA4 / PD -1), M7824 (PD-L1 / TGFβ-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM-3 / PDL1), RG7769 (PD-1 / TIM-3) and INBRX-105 (4-1BB / PDL1), GNS-1480 (PD-L1 / EGFR), SCH-900475, PF-06801591, AGEN-2034, AK-105, PD1-PIK, BAT-1306, BMS-936559, CK-301, MEDI-0680, PDR001 + Tafinlar, ® + Mekinist ® , and those described, for example, in International Patent Publication Nos. WO2018195321, WO2020014643, WO2019160882, and WO2018195321.

[0331] In various embodiments, an anti-CD47 agent as described herein is combined with an inhibitor of MCL1 apoptosis regulator (BCL2 family member) (MCL1, TM; EAT; MCL1L; MCL1S; Mcl-1; BCL2L3; MCL1-ES; bcl2-L-3; mcl1 / EAT; NCBI Gene ID: 4170). Examples of MCL1 inhibitors include AMG-176, AMG-397, S-64315, and AZD-5991, 483-LM, A-1210477, UMI-77, JKY-5-037, and those described in WO2018183418, WO2016033486, and WO2017147410.

[0332] Toll-like receptor (TLR) agonists

[0333] In various embodiments, an anti-CD47 agent or an anti-SIRPα agent as described herein is combined with an agonist of a toll-like receptor (TLR), such as an agonist of TLR1 (NCBI gene ID: 7096), TLR2 (NCBI gene ID: 7097), TLR3 (NCBI gene ID: 7098), TLR4 (NCBI gene ID: 7099), TLR5 (NCBI gene ID: 7100), TLR6 (NCBI gene ID: 10333), TLR7 (NCBI gene ID: 51284), TLR8 (NCBI gene ID: 51311), TLR9 (NCBI gene ID: 54106) and / or TLR10 (NCBI gene ID: 81793).Exemplary TLR7 agonists that can be co-administered include, but are not limited to, DS-0509, GS-9620, LHC-165, TMX-101 (imiquimod), GSK-2245035, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, MEDI-9197, 3M-051, SB-9922, 3M-052, Limtop, TMX-30X, TMX-202, RG-7863, RG-7795, and US20100143301 (Gilead Sciences), US20110098248 (Gilead Sciences), and US20090047249 (Gilead Sciences), US20140045849 (Janssen), US20140073642 (Janssen), WO2014 / 056953 (Janssen), WO2014 / 076221 (Ja nssen), WO2014 / 128189 (Janssen), US20140350031 (Janssen), WO2014 / 023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics) and US20130251673 (Novira Therapeutics). The TLR7 / TLR8 agonist that can be co-administered is NKTR-262.Exemplary TLR8 agonists that can be co-administered include, but are not limited to, E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, GS-9688, VTX-1463, VTX-763, 3M-051, 3M-052, and US20140045849 (Janssen), US20140073642 (Janssen), WO2014 / 056953 (Janssen), WO2014 / 076221 (Janssen), WO2014 / 128189 (Janssen), US20140350031 (Janssen), WO2014 / 023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (VentirxPharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics) and US20130251673 (Novira Therapeutics). Example TLR9 agonists that can be co-administered include, but are not limited to, AST-008, CMP-001, IMO-2055, IMO-2125, litenimod, MGN-1601, BB-001, BB-006, IMO-3100, IMO-8400, IR-103, IMO-9200, agatolimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, leftolimod (MGN-1703), CYT-003, CYT-003-QbG10, and PUL-042. Examples of TLR3 agonists include retasimide, polyICLC, RIBOXXON. ® 、Apoxxim、RIBOXXIM ® , IPH-33, MCT-465, MCT-475 and ND-1.1.

[0334] Examples of TLR8 inhibitors include, but are not limited to, E-6887, IMO-8400, IMO-9200, and VTX-763.

[0335] Examples of TLR8 agonists include, but are not limited to, MCT-465, Motomod, GS-9688, and VTX-1463.

[0336] Examples of TLR9 agonists include, but are not limited to, AST-008, IMO-2055, IMO-2125, lefitolimod, linimod, MGN-1601, and PUL-042.

[0337] Examples of TLR7 / TLR8 agonists include, but are not limited to, NKTR-262, IMO-4200, MEDI-9197 (telratolimod), and resiquimod.

[0338] Examples of TLR agonists include, but are not limited to, lefitimod, tilsotolimod, retamod, DSP-0509, AL-034, G-100, cobitolimod, AST-008, motomod, GSK-1795091, GSK-2245035, VTX-1463, GS-9688, LHC-165, BDB-001, RG-7854, tiramid.

[0339] In some embodiments, the therapeutic agent is a stimulator of interferon genes (STING). In some embodiments, the STING receptor agonist or activator is selected from ADU-S100 (MIW-815), SB-11285, MK-1454, SR-8291, AdVCA0848, GSK-532, SYN-STING, MSA-1, SR-8291, 5,6-dimethylxanthone-4-acetic acid (DMXAA), cyclic GAMP (cGAMP) and cyclic diAMP.

[0340] TCR signaling modulators

[0341] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with one or more agonists or antagonists of T cell receptor (TCR) signaling regulators. T cell activation by TCR is essential for thymocyte development and effector T cell function. TCR activation promotes signaling cascades that ultimately determine the fate of cells by regulating cytokine production, cell survival, proliferation, and differentiation. Examples of TCR signaling modulators include, but are not limited to, CD2 (cluster of differentiation 2, LFA-2, T11, LFA-3 receptor), CD3 (cluster of differentiation 3), CD4 (cluster of differentiation 4), CD8 (cluster of differentiation 8), CD28 (cluster of differentiation 28), CD45 (PTPRC, B220, GP180), LAT (adaptor for activated T cells, LAT1), Lck, LFA-1 (ITGB2, CD18, LAD, LCAMB), Src, Zap-70, SLP-76, DGKα, CBL-b, CISH, HPK1. Examples of agonists of cluster of differentiation 3 (CD3) that can be co-administered include, but are not limited to MGD015.

[0342] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with one or more blockers or inhibitors of inhibitory immune checkpoint proteins or receptors and / or with one or more stimulators, activators, or agonists of one or more stimulatory immune checkpoint proteins or receptors. Blocking or inhibition of inhibitory immune checkpoints can positively regulate T cell or NK cell activation and prevent immune escape of cancer cells within the tumor microenvironment. Activation or stimulation of stimulatory immune checkpoints can enhance the effect of immune checkpoint inhibitors in cancer treatment. In various embodiments, immune checkpoint proteins or receptors regulate T cell responses (e.g., Xu et al., J Exp Clin Cancer Res. (2018) 37: 110). In various embodiments, the immune checkpoint protein or receptor modulates NK cell responses (e.g., as reviewed in Davis et al., Semin Immunol. (2017) 31:64–75; and Chiossone et al., Nat Rev Immunol. (2018) 18(11):671-688).

[0343] Examples of immune checkpoint proteins or receptors include, but are not limited to, CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), transmembrane and immunoglobulin domain-containing 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunomodulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR-associated 2 (HHLA2, B7H7); inducible T cell co-stimulator (ICOS, CD278); inducible T cell co-stimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137 ), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC Class I polypeptide-related sequence A (MICA); MHC class I polypeptide-related sequence B (MICB); CD274 (PDL1, PD-L1); programmed cell death 1 (PDCD1, PD-1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); T cell immunoreceptor with Ig and ITIM domains (TIGIT); T cell immunoglobulin and mucin domain-containing protein 4 (TIMD4; TIM4); hepatitis A virus cell receptor 2 (HAVCR2, TIMD3, TIM-3); galectin 9 (LGALS9); lymphocyte activation 3 (LAG-3, CD223);Signal transducer lymphocyte activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding protein 1 (ULBP1); UL16 binding protein 2 (ULBP2); UL16 binding protein 3 (ULBP3); retinoic acid early transcript 1E (RAET1E; ULBP4); retinoic acid early transcript 1G (RAET1G; ULBP5); retinoic acid early transcript 1L (RAET1L; ULBP6); lymphocyte activation 3 (CD223); killer cell immunoglobulin-like receptor (KIR); killer cell lectin-like receptor C1 (KLRC1, NKG 2A, CD159A); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); killer cell lectin-like receptor C2 (KLRC2, CD159c, NKG2C); killer cell lectin-like receptor C3 (KLRC3, NKG2E); killer cell lectin-like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor D1 (KLRD1). ;

[0344] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with one or more blockers or inhibitors of one or more T cell inhibitory immune checkpoint proteins or receptors. Exemplary T cell inhibitory immune checkpoint proteins or receptors include, but are not limited to, CD274 (PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte-associated (BTLA)); Contains PVR-related immunoglobulin domains (PVRIG, CD112R); T-cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activation 3 (LAG-3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM-3); galectin 9 (LGALS9); killer cell immunoglobulin-like receptor (KIR); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1).

[0345] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with one or more agonists or activators of one or more T cell stimulatory immune checkpoint proteins or receptors. Exemplary T cell stimulatory immune checkpoint proteins or receptors include, but are not limited to, CD27, CD70; CD40, CD40LG; inducible T cell co-stimulator (ICOS, CD278); inducible T cell co-stimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); CD244 (2B4, SLAMF4), poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). See, e.g., Xu et al., J Exp Clin Cancer Res. (2018) 37:110.

[0346] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with one or more blockers or inhibitors of one or more NK cell inhibitory immune checkpoint proteins or receptors. Exemplary NK cell inhibitory immune checkpoint proteins or receptors include, but are not limited to, killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); and killer cell lectin-like receptor D1 (KLRD1, CD94).

[0347] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with one or more agonists or activators of one or more NK cell stimulatory immune checkpoint proteins or receptors. Exemplary NK cell stimulatory immune checkpoint proteins or receptors include, but are not limited to, CD16, CD226 (DNAM-1); CD244 (2B4, SLAMF4); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); SLAM family member 7 (SLAMF7). See, e.g., Davis et al., Semin Immunol. (2017) 31: 64–75; Fang et al., Semin Immunol. (2017) 31: 37-54; and Chiossone et al., Nat Rev Immunol. (2018) 18 (11): 671-688.

[0348] Adenosine production and signaling

[0349] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with agonists or antagonists of A1R, A2AR, A2BR, A3R, CD73, CD39, CD26; the agonist or antagonist is, for example, an adenosine A3 receptor (A3R) agonist, such as namodenoson (CF102); an A2aR / A2bR antagonist, such as AB928; an anti-CD73 antibody, such as MEDI-9447 (oleclumab), CPX-00 6. IPH-53, BMS-986179, NZV-930, CPI-006; CD73 inhibitors such as AB-680, PSB-12379, PSB-12441, PSB-12425, CB-708 and those described in International Patent Publication No. WO19173692; CD39 / CD73 inhibitors such as PBF-1662; anti-CD39 antibodies such as TTX-030; adenosine A2A receptor antagonists such as CPI-444, AZD-4635, preladenant, PBF-509; and adenosine deaminase inhibitors such as pentostatin and cladribine.

[0350] Bispecific T cell engagers

[0351] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with a bispecific T cell engager (e.g., without Fc) or an anti-CD3 bispecific antibody (e.g., with Fc). Illustrative anti-CD3 bispecific antibodies or BiTEs that can be co-administered include: AMG-160 (PSMA / CD3), AMG-212 (PSMA / CD3), AMG-330 (CD33 / CD3), AMG-420 (BCMA / CD3), AMG-427 (FLT3 / CD3), AMG-562 (CD19 / CD3), AMG-596 (EGFRvIII / CD3), AMG-701 (BCMA / CD3), AMG-757 (DLL3 / CD3), JNJ-64052781 (CD19 / CD3), AMG-211 (CEA / CD3), BLINCYTO ®(CD19 / CD3), RG7802 (CEA / CD3), ERY-974 (CD3 / GPC3), huGD2-BsAb (CD3 / GD2), PF-06671008 (cadherin / CD3), APVO436 (CD123 / CD3), ERY974, flutezumab (CD123 / CD3), GEM333 (CD3 / CD33), GEMoab (CD3 / PSCA), REGN-1979 (CD20 / CD3), REGN-5678 (PSMA / CD28), MCLA-117 (CD3 / CLEC12A), JNJ-0819, JNJ-7564 (CD3 / heme), JNJ-63709178 (CD123 / CD3), MGD-007 (CD3 / gpA33), MG D-009 (CD3 / B7H3), IMCgp100 (CD3 / gp100), XmAb-14045 (CD123 / CD3), XmAb-13676 (CD3 / CD 20), 76. RG6194, RG-7828 (CD20 / CD3), CC-93269 (CD3 / BCMA), REGN-5458 (CD3 / BCMA), GRB-1302 (CD3 / Erbb2), GRB-1342 (CD38 / CD3), PF-06863135 (BCMA / CD3), SAR440234 (CD3 / CDw123). The anti-CD3 binding bispecific molecule may or may not have an Fc, as appropriate. Exemplary bispecific T cell engagers that may be co-administered target CD3 and a tumor-associated antigen as described herein, including, for example, CD19 (e.g., blinatumomab); CD33 (e.g., AMG330); CEA (e.g., MEDI-565); receptor tyrosine kinase-like orphan receptor 1 (ROR1) (Gohil et al., Oncoimmunology. (2017) May 17; 6(7): e1326437); PD-L1 (Horn et al., Oncotarget. 2017 Aug 3; 8(35): 57964-57980); and EGFRvIII (Yang et al., Cancer Lett. 2017 Sep 10; 403: 224-230).

[0352] Bispecific and trispecific natural killer (NK) cell engagers

[0353] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with a bispecific NK cell engager (BiKE) or a trispecific NK cell engager (TriKE) (e.g., without Fc) or a bispecific antibody (e.g., with Fc) against: NK cell activation receptors, such as CD16A, C-type lectin receptors (CD94 / NKG2C , NKG2D, NKG2E / H and NKG2F), natural cytotoxicity receptors (NKp30, NKp44 and NKp46), killer cell C-type lectin-like receptors (NKp65, NKp80), Fc receptor FcγR (which mediates antibody-dependent cellular cytotoxicity), SLAM family receptors (e.g., 2B4, SLAM6 and SLAM7), killer cell immunoglobulin-like receptors (KIR) (KIR-2DS and KIR-3DS), DNAM-1 and CD137 (41BB). Exemplary anti-CD16 bispecific antibodies, BiKEs or TriKEs that can be co-administered include AFM26 (BCMA / CD16A) and AFM-13 (CD16 / CD30). The anti-CD16 binding bispecific molecule may or may not have an Fc, as appropriate. Exemplary bispecific NK cell engagers that can be co-administered target CD16 and one or more tumor-associated antigens as described herein, including, for example, CD19, CD20, CD22, CD30, CD33, CD123, EGFR, EpCAM, ganglioside GD2, HER2 / neu, HLA class II, and FOLR1. BiKE and TriKE are described, for example, in Felices et al., Methods Mol Biol. (2016) 1441: 333–346; Fang et al., Semin Immunol. (2017) 31: 37-54.

[0354] Hematopoietic progenitor kinase 1 (HPK1) inhibitors

[0355] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an inhibitor of mitogen-activated protein kinase kinase kinase kinase kinase 1 (MAP4K1, HPK1; NCBI Gene ID: 11184). Examples of hematopoietic progenitor kinase 1 (HPK1) inhibitors include, but are not limited to, those described in WO-2018183956, WO-2018183964, WO-2018167147, WO-2018183964, WO-2016205942, WO-2018049214, WO-2018049200, WO-2018049191, WO-2018102366, WO-2018049152, WO2020092528, WO2020092621, and WO-2016090300.

[0356] Apoptosis signal-regulating kinase (ASK) inhibitors

[0357] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an ASK inhibitor, e.g., an inhibitor of mitogen-activated protein kinase kinase kinase 5 (MAP3K5; ASK1, MAPKKK5, MEKK5; NCBI gene ID: 4217). Examples of ASK1 inhibitors include, but are not limited to, those described in WO 2011 / 008709 (Gilead Sciences) and WO 2013 / 112741 (Gilead Sciences).

[0358] Bruton's tyrosine kinase (BTK) inhibitors

[0359] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an inhibitor of Bruton's tyrosine kinase (BTK, AGMX1, AT, ATK, BPK, IGHD3, IMD1, PSCTK1, XLA; NCBI Gene ID: 695). Examples of BTK inhibitors include, but are not limited to: (S)-6-amino-9-(1-(but-2-ynyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one, acalabrutinib (ACP-196), BGB-3111, CB988, HM71224, ibrutinib (Imbruvica), M-2951 (evobrutinib), M7583, tirabrutinib (ONO-4059), PRN-1008, sepretinib (CC-292), TAK-020, vecabrutinib, ARQ-531, SHR-1459, DTRMWXHS-12, TAS-5315, Calquence + AZD6738, Calquence + danvatirsen.

[0360] Cyclin-dependent kinase (CDK) inhibitors

[0361] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of: cyclin-dependent kinase 1 (CDK1, CDC2; CDC28A; p34CDC2; NCBI gene ID: 983); cyclin-dependent kinase 2 (CDK2, CDKN2; p33 (CDK2); NCBI gene ID: 1017); cyclin-dependent kinase 3 (CDK3; NCBI gene ID: 1018); cell Cyclin-dependent kinase 4 (CDK4, CMM3; PSK-J3; NCBI Gene ID: 1019); cyclin-dependent kinase 6 (CDK6, MCPH12; PLSTIRE; NCBI Gene ID: 1021); cyclin-dependent kinase 7 (CDK7, CAK; CAK1; HCAK; MO15; STK1; CDKN7; p39MO15; NCBI Gene ID: 1022); cyclin-dependent kinase 9 (CDK9, TAK; C-2k; CTK1; CDC2L4; PITALRE; NCBI Gene ID: 1025). Inhibitors of CDK 1, 2, 3, 4, 6, 7 and / or 9 include, but are not limited to, abemaciclib, alvocidib (HMR-1275, flavopiridol), AT-7519, dinaciclib, ibrance, FLX-925, LEE001, palbociclib, ribociclib, rigosertib, selinexor, UCN-01, SY1365, CT-7001, SY-1365, G1T38, milciclib, trilaciclib, PF-06873600, AZD4573, and TG-02.

[0362] Discoidin domain receptor (DDR) inhibitors

[0363] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of the following: discoidin domain receptor tyrosine kinase 1 (DDR1, CAK, CD167, DDR, EDDR1, HGK2, MCK10, NEP, NTRK4, PTK3, PTK3A, RTK6, TRKE; NCBI gene ID: 780); and / or discoidin domain receptor tyrosine kinase 2 (DDR2, MIG20a, NTRKR3, TKT, TYRO10, WRCN; NCBI gene ID: 4921). Examples of DDR inhibitors include, but are not limited to, dasatinib, and those disclosed in WO 2014 / 047624 (Gilead Sciences), US 2009-0142345 (Takeda Pharmaceutical), US 2011-0287011 (Oncomed Pharmaceuticals), WO 2013 / 027802 (Chugai Pharmaceutical), and WO 2013 / 034933 (Imperial Innovations).

[0364] Histone deacetylase (HDAC) inhibitors

[0365] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an inhibitor of histone deacetylase, such as histone deacetylase 9 (HDAC9, HD7, HD7b, HD9, HDAC, HDAC7, HDAC7B, HDAC9B, HDAC9FL, HDRP, MITR; Gene ID: 9734). Examples of HDAC inhibitors include, but are not limited to, abexinostat, ACY-241, AR-42, BEBT-908, belinostat, CKD-581, CS-055 (HBI-8000), CUDC-907 (fimepinostat), entinostat, givinostat, mocetinostat, panobinostat, pracinostat, quisinostat (JNJ-26481585), resminostat, ricolinostat, SHP-141, valproic acid (VAL-001), vorinostat, tinostamustine, remetinostat, entinostat, romidepsin, tucidinostat.

[0366] Indoleamine-pyrrole-2,3-dioxygenase (IDO1) inhibitors

[0367] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1; NCBI gene ID: 3620). Examples of IDO1 inhibitors include, but are not limited to, BLV-0801, icadolstat, F-001287, GBV-1012, GBV-1028, GDC-0919, indomod, NKTR-218, NLG-919-based vaccines, PF-06840003, pyranonaphthoquinone derivatives (SN-35837), resminostat, SBLK-200802, BMS-986205, and shIDO-ST, EOS-200271, KHK-2455, LY-3381916.

[0368] Janus kinase (JAK) inhibitors

[0369] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of Janus kinase 1 (JAK1, JAK1A, JAK1B, JTK3; NCBI gene ID: 3716); Janus kinase 2 (JAK2, JTK10; THCYT3; NCBI gene ID: 3717); and / or Janus kinase 3 (JAK3, JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK; NCBI gene ID: 3718). Examples of JAK inhibitors include, but are not limited to, AT9283, AZD1480, baricitinib, BMS-911543, fedratinib, filgotinib (GLPG0634), gandotinib (LY2784544), INCB039110 (itacitinib), lestaurtinib, momelotinib (CYT0387), NS-018, pacritinib (SB1518), peficitinib (ASP015K), ruxolitinib, tofacitinib (formerly known as tasocitinib), INCB052793, and XL019.

[0370] Matrix metalloproteinase (MMP) inhibitors

[0371] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an inhibitor of matrix metalloproteinases (MMPs), such as inhibitors of MMP1 (NCBI gene ID: 4312), MMP2 (NCBI gene ID: 4313), MMP3 (NCBI gene ID: 4314), MMP7 (NCBI gene ID: 4316), MMP8 (NCBI gene ID: 4317), MMP9 (NCBI gene ID: 4318), MMP10 (NCBI gene ID: 4319), MMP11 (NCBI gene ID: 4320), MMP12 (NCBI gene ID: 4321), MMP13 (NCBI gene ID: 4322), MMP14 (NCBI gene ID: 4323), MMP15 (NCBI gene ID: 4324), MMP16 (NCBI gene ID: 4325), MMP17 (NCBI gene ID: 4326), MMP18 (NCBI gene ID: 4327), MMP19 (NCBI gene ID: 4330), MMP20 (NCBI gene ID: 4331), MMP21 (NCBI gene ID: 4332), MMP22 (NCBI gene ID: 4333), MMP23 (NCBI gene ID: 4334), MMP24 (NCBI gene ID: 4335), MMP25 (NCBI gene ID: 4336), MMP26 (NCBI gene ID: 4337), MMP27 (NCBI gene ID: 4338), MMP2 4321), MMP13 (NCBI Gene ID: 4322), MMP14 (NCBI Gene ID: 4323), MMP15 (NCBI Gene ID: 4324), MMP16 (NCBI Gene ID: 4325), MMP17 (NCBI Gene ID: 4326), MMP19 (NCBI Gene ID: 4327), MMP20 (NCBI Gene ID: 9313), MMP21 (NCBI Gene ID: 118856), MMP24 (NCBI Gene ID: 10893), MMP25 (NCBI Gene ID: 64386), MMP26 (NCBI Gene ID: 56547), MMP27 (NCBI Gene ID: 64066), and / or MMP28 (NCBI Gene ID: 79148). Examples of MMP9 inhibitors include, but are not limited to, marimastat (BB-2516), simaxastat (Ro 32-3555), GS-5745 (andecaliximab), and those described in WO 2012 / 027721 (Gilead Biologics).

[0372] RAS and RAS pathway inhibitors

[0373] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of the following: KRAS proto-oncogene, GTPase (KRAS; also known as NS; NS3; CFC2; RALD; K-Ras; KRAS1; KRAS2; RASK2; KI-RAS; CK-RAS; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; c-Ki-ras2; NCBI Gene ID: 3845); NRAS proto-oncogene GTPase (NRAS; also known as NS6; CMNS; NCMS; ALPS4; N-ras; NRAS1; NCBI Gene ID: 4893); HRas proto-oncogene GTPase (HRAS; also known as CTLO; KRAS; HAMSV; HRAS1; KRAS2; RASH1; RASK2; Ki-Ras; p21ras; CH-RAS; cK-ras; H-RASIDX; c-Ki-ras; C-BAS / HAS; C-HA-RAS1; NCBI Gene ID: 3265). Ras inhibitors can inhibit Ras at the polynucleotide (e.g., transcription inhibitor) or polypeptide (e.g., GTPase inhibitor) level. In some embodiments, the inhibitor targets one or more proteins in the Ras pathway, for example, inhibiting one or more of EGFR, Ras, Raf (A-Raf, B-Raf, C-Raf), MEK (MEK1, MEK2), ERK, PI3K, AKT, and mTOR.

[0374] In various embodiments, the agents described herein that inhibit binding between CD47 and SIRPα (eg, mololimab); and VEGFA / VEGFR inhibitors (eg, bevacizumab) are further combined with an inhibitor of KRAS. Examples of KRAS inhibitors include AMG-510, COTI-219, MRTX-1257, ARS-3248, ARS-853, WDB-178, BI-3406, BI-1701963, ARS-1620 (G12C), SML-8-73-1 (G12C), compound 3144 (G12D), Kobe0065 / 2602 (RasGTP), RT11, MRTX-849 (G12C), and K-Ras (G12D)-selective inhibitory peptides, including KRpep-2 (Ac-RRCPLYISYDPVCRR-NH2) (SEQ ID NO: 256) and KRpep-2d (Ac-RRRRCPLYISYDPVCRRRR-NH2) (SEQ ID NO: 257).

[0375] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of KRAS mRNA. Illustrative KRAS mRNA inhibitors include anti-KRAS U1 aptamers, AZD-4785, siG12D-LODER ™ and siG12D exosomes.

[0376] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of MEK. Illustrative MEK inhibitors that can be co-administered include bimetinib, cobimetinib, PD-0325901, pimatinib, RG-7304, selumetinib, trametinib, and selumetinib.

[0377] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of AKT. Exemplary AKT inhibitors that can be co-administered include RG7440, MK-2206, ipatritinib, afusetinib, AZD5363, ARQ-092, capasitinib, triciribine, ABTL-0812 (PI3K / Akt / mTOR).

[0378] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of Raf. Exemplary Raf inhibitors that can be co-administered include BGB-283 (Raf / EGFR), HM-95573, LXH-254, LY-3009120, RG7304, TAK-580, dabrafenib, vemurafenib, connefenib (LGX818), PLX8394, RAF-265 (Raf / VEGFR), ASN-003 (Raf / PI3K).

[0379] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of ERK. Exemplary ERK inhibitors that can be co-administered include LTT-462, LY-3214996, MK-8353, ravoxertinib, GDC-0994, and uritinib.

[0380] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an inhibitor of PI3K. Illustrative PI3K inhibitors that can be co-administered include Zydelig ® ), aboliciib, bupariciib, pictilisib, IPI-549. Illustrative PI3K / mTOR inhibitors that can be co-administered include dactolisib, omipalisib, voxtalisib, gedatolisib, GSK2141795, RG6114.

[0381] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of mTOR. Illustrative mTOR inhibitors that can be co-administered include: sapacerti, vistusertib (AZD2014), ME-344, sirolimus (oral nanoamorphous formulation, cancer), TYME-88 (mTOR / cytochrome P450 3A4).

[0382] In certain embodiments, Ras-driven cancers (e.g., NSCLC) with CDKN2A mutations can be inhibited by co-administering the MEK inhibitor selumetinib and the CDK4 / 6 inhibitor palbociclib. See, e.g., Zhou et al., Cancer Lett. 2017 Nov 1;408:130-137. Moreover, K-RAS and mutant N-RAS can be reduced by the irreversible ERBB1 / 2 / 4 inhibitor neratinib. See, e.g., Booth et al., Cancer Biol Ther. 2018 Feb 1;19(2):132-137.

[0383] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of RAS. Examples of RAS inhibitors include NEO-100 and reglucoserti.

[0384] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an antagonist of EGFR, such as AMG-595, necitumumab, ABBV-221, depatuxizumab mafodotin (ABT-414), tomuzotuximab, ABT-806, vectibix, modotuximab, RM-1929.

[0385] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an inhibitor of protein tyrosine phosphatase non-receptor type 11 (PTPN11; BPTP3, CFC, JMML, METCDS, NS1, PTP-1D, PTP2C, SH-PTP2, SH-PTP3, SHP2; NCBI gene ID: 5781). Examples of SHP2 inhibitors include TNO155 (SHP-099), RMC-4550, JAB-3068, RMC-4630, SAR442720, and those described in WO2018172984 and WO2017211303.

[0386] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an inhibitor of mitogen-activated protein kinase 7 (MAP2K7, JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7, SAPKK-4, SAPKK4; NCBI Gene ID: 5609). Examples of MEK inhibitors include: antroquinol, binimetinib, CK-127, cobimetinib (GDC-0973, XL-518), MT-144, selumetinib (AZD6244), sorafenib, trametinib (GSK1120212), uprosertib + trametinib, PD-0325901, pimasertib, LTT462, AS703988, CC-90003, refametinib, TAK-733, CI-1040, RG7421.

[0387] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, such as phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA, CLAPO, CLOVE, CWS5, MCAP, MCM, MCMTC, PI3K, PI3K-α, p110-α; NCBI Gene ID: 5290); phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA, CLAPO, CLOVE, CWS5, MCAP, MCM, MCMTC, PI3K, PI3K-α, p110-α; NCBI Gene ID: 5290); Kinase catalytic subunit beta (PIK3CB, P110BETA, PI3K, PI3KBETA, PIK3C1; NCBI gene ID: 5291); phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG, PI3CG, PI3K, PI3Kγ, PIK3, p110γ, p120-PI3K; gene ID: 5494); and / or phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (PIK3CD, APDS, IMD14, P110DELTA, PI3K, p110D, NCBI gene ID: 5293). In some embodiments, the PI3K inhibitor is a pan-PI3K inhibitor. Examples of PI3K inhibitors include, but are not limited to, ACP-319, AEZA-129, AMG-319, AS252424, AZD8186, BAY 1082439, BEZ235, belimumab (PQR309), buparlisib (BKM120), BYL719 (alpelisib), carboxyamidotriazole orotate (CTO), CH5132799, CLR-457, CLR-1401, copanlisib (BAY 80-6946), DS-7423, datolisib, duvelisib (IPI-145), fimepinostat (CUDC-907), gedatolisib (PF-05212384), GDC-0032, GDC-0084 (RG7666), GDC-0077, pictilisib (GDC-0941), GDC-0980, GSK2636771, GSK2269577, GSK2141795, idelalisib (Zydelig ® ), INCB040093, INCB50465, IPI-443, IPI-549, KAR4141, LY294002, LY3023414, NERLYNX® (neratinib), nemiralisib (GSK2269557), omipalisib (GSK2126458, GSK458), OXY111A, panulisib (P7170, AK151761), PA799, perifosine (KRX-0401), pilarisib (SAR245408; XL147), puquitinib mesylate mesylate)(XC-302), SAR260301, seletalisib (UCB-5857), serabelisib (INK-1117, MLN-1117, TAK-117), SF1126, sonolisib (PX-866), RG6114, RG7604, rigosertibsodium (ON-01910 sodium), RP5090, tenal isib) (RP6530), RV-1729, SRX3177, taselisib, TG100115, umbralisib (TGR-1202), TGX221, voxtalisib (SAR245409), VS-5584, WX-037, X-339, X-414, XL499, XL756, wortmannin, ZSTK474, and compounds described in the following patents: WO 2005 / 113556 (ICOS), WO 2013 / 052699 (Gilead Calistoga), WO 2013 / 116562 (Gilead Calistoga), WO 2014 / 100765 (Gilead Calistoga), WO 2014 / 100767 (Gilead Calistoga) and WO 2014 / 201409 (GileadSciences).

[0388] Spleen tyrosine kinase (SYK) inhibitors

[0389] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with an inhibitor of spleen-associated tyrosine kinase (SYK, p72-Syk, Gene ID: 6850). Examples of SYK inhibitors include, but are not limited to, 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine, BAY-61-3606, cerdulatinib (PRT-062607), entospletinib, fostamatinib (R788), HMPL-523, NVP-QAB 205 AA, R112, R343, tamatinib (R406), and those described in US 8450321 (Gilead Connecticut) and those described in US 2015 / 0175616.

[0390] Tyrosine kinase inhibitors (TKIs)

[0391] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with tyrosine kinase inhibitors (TKIs). TKIs can target the receptors for epidermal growth factor receptor (EGFR) as well as fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). Examples of TKIs include, but are not limited to: axitinib, afatinib, ARQ-087 (derazantinib), asp5878, AZD3759, AZD4547, bosutinib, brigatinib, cabozantinib, cediranib, crenolanib, crizotinib, dacomitinib, dasatinib, dovitinib, E-6201, erdafitinib, erlotinib, gefitinib, ASP-2215, FP-1039, HM61713, icotinib , imatinib, KX2-391 (Src), lapatinib, lestautinib, lenvatinib, midostaurin, nintedanib, ODM-203, olmutinib, osimertinib (AZD-9291), pazopanib, ponatinib, poziotinib, quizartinib, radotinib, rociletinib, sulfatinib (HMPL-012), sunitinib, MAC-4, tivoanib, TH-4000, and MEDI-575 (anti-PDGFR antibody), and TAK-659.

[0392] Chemotherapeutic agents (standard of care)

[0393] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (eg, mololimab); and VEGFA / VEGFR inhibitors (eg, bevacizumab) are further combined with a chemotherapeutic agent or an anti-tumor agent.

[0394] As used herein, the term "chemotherapeutic agent" or "chemotherapeutic agent" (or "chemotherapy" in the case of treatment with a chemotherapeutic agent) is intended to encompass any non-proteinaceous (e.g., non-peptide) compound that can be used to treat cancer. Examples of chemotherapeutic agents include, but are not limited to, alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN ®); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodepa, carboquinone, metodepa and uredepa; ethyleneimines and methylmelamines, including hexamethylmelamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimemylolomelamine; lactones such as brassic acid and brassinone; camptothecins, including the synthetic analogue topotecan; bryostatin, callystatin; CC-1065, including its synthetic analogues adolesin, carzelesin and biszelesin; scutellarin, especially scutellarin 1 and scutellarin 8; caudate phytosine; duocarmycins, including the synthetic analogues KW -2189 and CBI-TMI; eleutherobin; 5-azacytidine; pancratistatin; sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, naphthyl mustard, cyclophosphamide, glufosfamide, ivophosphamide, bendamustine, estramustine, ifosfamide, dichloromethyl diethylamine, dichloromethyl diethylamine hydrochloride, melphalan, nembixin, phenamic acid, prednimustine, trolofosamide and uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine and ranimustine; antibiotics such as Edenediyne antibiotics (e.g., calicheamicins, especially calicheamicin gamma II and calicheamicin phiI), danimycins (including danimycin A), bisphosphonates (such as clodronate), espammycins, neostatin chromophores and related chromophores, enediyne antibiotic chromophores, aclarubicin, actinomycin, authramycin, azaserine, bleomycin, actinomycin, carabicin, carrninomycin, carzinophilin, chromomycin, dactinomycin, daunorubicin, detopicin, 6-diazo-5-oxo-L-norleucine acid, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolo-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, mexilomycin, mitomycin (such as mitomycin C), mycophenolic acid, nogamycin, olivetomycin, peplomycin, porfibrinocin, puromycin, quinamycin, rhodorubicin, streptomycin, streptozotocin, tuberculocidin, ubenimex, zoloft and daunorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as norpterin, methotrexate, pteropterin and trimetrexate; purine analogs such as cladribine, pentostatin, fludarabine, 6-mercaptopurine, thiabendazole and thioguanine;Pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens such as caprotestosterone, drostanolone propionate, cyclothiocarb, melastane, and testolactone; antiadrenal agents such as aminoglutethimide, mitotane, and trilostane; folic acid supplements such as folinic acid; radiotherapeutic agents such as radium-223; 177-Lu-PSMA-617; trichothecenes, especially T-2 toxin, verracurin A, roridin A, and anguidine; taxanes such as paclitaxel; ® ), albumin-bound / nab-paclitaxel (ABRAXANE ® ), docetaxel (TAXOTERE ® ), cabazitaxel, BIND-014, tesetaxel; platinum analogs such as cisplatin and carboplatin, NC-6004 nanoplatin; acetoglucuronide; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; hestrabucil; bisantrene; edatrexate; phosphamide; colcemid; diazocone; elformthine; elliptolide; epothilone; etoglucosamine; gallium nitrate; hydroxyurea; lentinan; leucovorin; lonidamine; maytansine alkaloids such as maytansine and ansamitocin; mitoguanidine; mitoxantrone; toxantrone; mopidarol; diamine nitrazol; methamine nitrogen mustard; pirarubicin; losoxantrone; fluoropyrimidine; folinic acid; podophyllic acid; 2-ethylhydrazide; procarbazine; polysaccharide-K (PSK); razoxane; rhizoxin; sizoran; spirogermanamine; tricholomaric acid; trabectedin, triazoquinone; 2,2',2''-trichlorotrimethylamine; carbamate; vindesine; dacarbazine; mannomustine; dibromomannitol; dibromodulanol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; chlorambucil; gemcitabine (GEMZAR ® ); 6-thioguanine; mercaptopurine; methotrexate; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine (NAVELBINE ®)。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。 )。

[0395] The definition of "chemotherapeutic agent" also includes anti-hormonal agents, such as antiestrogens and selective estrogen receptor modulators (SERMs), aromatase inhibitors, anti-androgens, and pharmaceutically acceptable salts, acids, or derivatives of any of the above substances, which are used to regulate or inhibit the effects of hormones on tumors. Examples of antiestrogens and SERMs include, for example, tamoxifen (including NOLVADEX™), raloxifene, droloxifene, 4-hydroxytamoxifen, troloxifene, raloxifene hydrochloride, LY117018, onapristone, and toremifene (FARESTON ® ). Inhibitors of aromatase regulate the production of estrogen in the adrenal glands. Examples include 4(5)-imidazole, aminoglutethimide, megestrol acetate (MEGACE ® ), exemestane, formestane, fadrozole, vorazole (RIVISOR ® ), letrozole (FEMARA ® ) and anastrozole (ARIMIDEX ® ). Examples of antiandrogens include apalutamide, abiraterone, enzalutamide, flutamide, galeterone, nilutamide, bicalutamide, leuprolide, goserelin, ODM-201, APC-100, ODM-204. Examples of progesterone receptor antagonists include onapristone.

[0396] Anti-angiogenic agents

[0397] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-angiogenic agents. Anti-angiogenic agents that can be co-administered include, but are not limited to, retinoic acid and its derivatives, 2-methoxyestradiol, ANGIOSTATIN ® ENDOSTATIN ® , regorafenib, nivolumab, suramin, squalamine, tissue inhibitor of metalloproteinase-1, tissue inhibitor of metalloproteinase-2, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, cartilage-derived inhibitor, paclitaxel (nab-paclitaxel), platelet factor 4, protamine sulfate (herring protamine), sulfated chitin derivatives (prepared from snow crab shells), sulfated polysaccharide peptidoglycan complex (sp-pg), staurosporine, matrix metabolism regulators (including proline analogs such as l-azetidine-2-carboxylic acid (LACA), cis-hydroxyproline, d,I-3,4-dehydroproline, thioproline), α,α'-bipyridine, β-amino Propionitrile fumarate, 4-propyl-5-(4-pyridinyl)-2(3h)-oxazolone, methotrexate, mitoxantrone, heparin, interferon, 2-macroglobulin-serum, chicken inhibitor of metalloproteinase-3 (ChIMP-3), chymostatin, beta-cyclodextrin tetradesulfate, epothilone, fumaricin, gold sodium thiomalate, dextrorotatory penicillamine, beta-1-anticollagenase-serum, alpha-2-antiplasmin, bisantrene, lobenzarit disodium, disodium n-2-carboxyphenyl-4-chloroanthrone or "CCA", thalidomide, angiostatic steroids, carboxyaminoimidazoles, metalloproteinase inhibitors (such as BB-94), inhibitors of S100A9 (such as tasquinimod). Other anti-angiogenic agents include antibodies, preferably monoclonal antibodies, to these angiogenic growth factors: β-FGF, α-FGF, FGF-5, VEGF isoforms, VEGF-C, HGF / SF, and Ang-1 / Ang-2.

[0398] Antifibrotic agents

[0399] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with anti-fibrotic agents. Anti-fibrotic agents that can be co-administered include, but are not limited to, compounds such as β-aminopropionitrile (BAPN), and compounds disclosed in US 4965288 involving lysyl oxidase inhibitors and their use in treating diseases and conditions associated with abnormal collagen deposition and US 4997854 involving compounds that inhibit LOX to treat various pathological fibrotic states, which are incorporated herein by reference. Additional exemplary inhibitors are described in US 4943593, directed to compounds such as 2-isobutyl-3-fluoro-, chloro- or bromo-allylamine, US 5021456, directed to 2-(1-naphthyloxymethyl)-3-fluoroallylamine, US 5059714, US 5120764, US 5182297, US 5252608 and US 2004-0248871, which are incorporated herein by reference.

[0400] Exemplary anti-fibrotic agents also include primary amines that react with the carbonyl group of the active site of lysyl oxidase, and more specifically, those that produce products stabilized by resonance upon binding to the carbonyl group, such as the following primary amines: ethylenediamine, hydrazine, phenylhydrazine, and their derivatives; semicarbazide and urea derivatives; aminonitriles, such as BAPN or 2-nitroethylamine; unsaturated or saturated halogenated amines, such as 2-bromo-ethylamine, 2-chloroethylamine, 2-trifluoroethylamine, 3-bromopropylamine, and p-halobenzylamine; and selenohomocysteine ​​lactone.

[0401] Other anti-fibrotic agents are copper chelators that infiltrate or do not infiltrate cells. Exemplary compounds include indirect inhibitors that block aldehyde derivatives derived from lysyl oxidase to lysyl and hydroxylysyl residues oxidative deamination. Examples include thiolamines (particularly D-penicillamine) and analogs thereof, such as 2-amino-5-mercapto-5-methylhexanoic acid, D-2-amino-3-methyl-3-((2-acetylaminoethyl) dithio) butyric acid, p-2-amino-3-methyl-3-((2-aminoethyl) dithio) butyric acid, 4-((p-1-dimethyl-2-amino-2-carboxylethyl) dithio) butane sodium sulfate, 2-acetylaminoethyl-2-acetylaminoethanethiol sulfate and 4-mercaptobutanesulfinate sodium trihydrate.

[0402] Anti-inflammatory agents

[0403] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (eg, mololimab); and VEGFA / VEGFR inhibitors (eg, bevacizumab) are further combined with an anti-inflammatory agent. Exemplary anti-inflammatory agents include, but are not limited to, inhibitors of one or more of the following: arginase (ARG1 (NCBI Gene ID: 383), ARG2 (NCBI Gene ID: 384)), carbonic anhydrase (CA1 (NCBI Gene ID: 759), CA2 (NCBI Gene ID: 760), CA3 (NCBI Gene ID: 761), CA4 (NCBI Gene ID: 762), CA5A (NCBI Gene ID: 763), CA5B (NCBI Gene ID: 11238), CA6 (NCBI Gene ID: 765), CA7 (NCBI Gene ID: 766), CA8 (NCBI Gene ID: 767), CA9 (NCBI Gene ID: 768), CA10 (NCBI Gene ID: 56934), CA11 (NCBI Gene ID: 770), C A12 (NCBI Gene ID: 771), CA13 (NCBI Gene ID: 377677), CA14 (NCBI Gene ID: 23632), prostaglandin-endoperoxide synthase 1 (PTGS1, COX-1; NCBI Gene ID: 5742), prostaglandin-endoperoxide synthase 2 (PTGS2, COX-2; NCBI Gene ID: 5743), secreted phospholipase A2, prostaglandin E synthase (PTGES, PGES; Gene ID: 9536), arachidonic acid 5-lipoxygenase (ALOX5, 5-LOX; NCBI Gene ID: 240), soluble epoxide hydrolase 2 (EPHX2, SEH; NCBI Gene ID: 2053), and / or mitogen-activated protein kinase kinase kinase 8 (MAP3K8, TPL2; NCBI Gene ID: 1326). In some embodiments, the inhibitor is a dual inhibitor, such as a dual inhibitor of COX-2 / COX-1, COX-2 / SEH, COX-2 / CA, COX-2 / 5-LOX.

[0404] Examples of inhibitors of prostaglandin-endoperoxide synthase 1 (PTGS1, COX-1; NCBI Gene ID: 5742) that may be co-administered include, but are not limited to, mofezolic acid, GLY-230, and TRK-700.

[0405] Examples of inhibitors of prostaglandin-endoperoxide synthase 2 (PTGS2, COX-2; NCBI Gene ID: 5743) that may be co-administered include, but are not limited to, diclofenac, meloxicam, parecoxib, etoricoxib, AP-101, celecoxib, AXS-06, diclofenac potassium, DRGT-46, AAT-076, methosulide, lumiracoxib, meloxicam, valdecoxib, zaltoprofen, nimesulide, anizafine, alicoxib, cimicoxib, deracoxib, fluumidazole, firocoxib, mavalocoxib, NS-398, pamigrelbrine, parecoxib, robacoxib, rofecoxib, evodiamine, temoxib, and zaltoprofen. Examples of dual COX1 / COX2 inhibitors that may be co-administered include, but are not limited to, HP-5000, lornoxicam, ketorolac tromethamine, bromfenac sodium, ATB-346, HP-5000. Examples of dual COX-2 / carbonic anhydrase (CA) inhibitors that may be co-administered include, but are not limited to, pomacoxib and ericoxib.

[0406] Examples of inhibitors of secretory phospholipase A2, prostaglandin E synthase (PTGES, PGES; Gene ID: 9536) that can be co-administered include, but are not limited to, LY3023703, GRC 27864, and WO2015158204, WO2013024898, WO2006063466, WO2007059610, WO2007124589, WO2010100249, WO2010034796, WO2010034797, WO2012022793, WO2012076673, WO2012076672, WO2010034798, WO2010034799, WO2012022792, WO2009103778, WO2011048004, WO2012087771, WO2012161965, WO2013 The compounds described in WO2013072825, WO2014167444, WO2009138376, WO2011023812, WO2012110860, WO2013153535, WO2009130242, WO2009146696, WO2013186692, WO2015059618, WO2016069376, WO2016069374, WO2009117985, WO2009064250, WO2009064251, WO2009082347, WO2009117987 and WO2008071173. Metformin has also been found to inhibit the COX2 / PGE2 / STAT3 axis and can be co-administered. See, e.g., Tong et al., Cancer Lett. (2017) 389:23-32; and Liu et al., Oncotarget. (2016) 7(19):28235-46.

[0407] Examples of inhibitors of carbonic anhydrase (e.g., one or more of CA1 (NCBI Gene ID: 759), CA2 (NCBI Gene ID: 760), CA3 (NCBI Gene ID: 761), CA4 (NCBI Gene ID: 762), CA5A (NCBI Gene ID: 763), CA5B (NCBI Gene ID: 11238), CA6 (NCBI Gene ID: 765), CA7 (NCBI Gene ID: 766), CA8 (NCBI Gene ID: 767), CA9 (NCBI Gene ID: 768), CA10 (NCBI Gene ID: 56934), CA11 (NCBI Gene ID: 770), CA12 (NCBI Gene ID: 771), CA13 (NCBI Gene ID: 377677), CA14 (NCBI Gene ID: 23632)) that can be co-administered include, but are not limited to, acetazolamide, methazolamide, dorzolamide, zonisamide, brinzolamide, and diclofenac. Dual COX-2 / CA1 / CA2 inhibitors that may be co-administered include CG100649.

[0408] Examples of inhibitors of arachidonic acid 5-lipoxygenase (ALOX5, 5-LOX; NCBI Gene ID: 240) that may be co-administered include, but are not limited to, meclofenamic acid sodium, zileuton.

[0409] Examples of inhibitors of soluble epoxide hydrolase 2 (EPHX2, SEH; NCBI Gene ID: 2053) that may be co-administered include, but are not limited to, compounds described in WO2015148954. Dual inhibitors of COX-2 / SEH that may be co-administered include compounds described in WO2012082647. Dual inhibitors of SEH and fatty acid amide hydrolase (FAAH; NCBI Gene ID: 2166) that may be co-administered include compounds described in WO2017160861.

[0410] Examples of inhibitors of mitogen-activated protein kinase kinase kinase 8 (MAP3K8, tumor progression site 2, TPL2; NCBI Gene ID: 1326) that may be co-administered include, but are not limited to, GS-4875, GS-5290, BHM-078, and those described in, for example, WO2006124944, WO2006124692, WO2014064215, WO2018005435; Teli et al., J Enzyme Inhib Med Chem. (2012) 27(4):558-70; Gangwall et al., Curr Top Med Chem. (2013) 13(9):1015-35; Wu et al., Bioorg Med Chem Lett. (2009) 19(13):3485-8; Kaila et al., Bioorg Med Chem. (2007) 15(19):6425-42; and Hu et al., Bioorg MedChem Lett. (2011) 21(16):4758-61.

[0411] Tumor oxygenator

[0412] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with agents that promote or increase tumor oxygenation or reoxygenation, or prevent or reduce tumor hypoxia. Exemplary agents that can be co-administered include, for example, hypoxia inducible factor-1α (HIF-1α) inhibitors such as PT-2977, PT-2385; VEGF inhibitors such as bevasizumab, IMC-3C5, GNR-011, tanibirumab, LYN-00101, ABT-165; and / or oxygen carrier proteins (e.g., heme nitric oxide and / or oxygen binding protein (HNOX)), such as OMX-302 and HNOX proteins described in WO 2007 / 137767, WO 2007 / 139791, WO 2014 / 107171, and WO 2016 / 149562.

[0413] Immunotherapeutic agents

[0414] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (eg, mololimab); and VEGFA / VEGFR inhibitors (eg, bevacizumab) are further combined with an immunotherapeutic agent.Exemplary immunotherapeutic agents that may be co-administered include, but are not limited to, abagovomab, ABP-980, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab biosimilars, and bivac. Bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, CC49, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, dacetuzumab, dalotuzumab, daratumumab daratumumab, detumomab, dinutuximab, drozitumab, duligotumab, dusigitumab, ecoromeximab, emibetuzumab, ensituximab, ertumaxomab, etaracizumab, farletuzumab, figitu mumab, flanvotumab, futuximab, gemtuzumab, girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab, ipilimumab (YERVOY). ®, MDX-010, BMS-734016, and MDX-101), iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab, moxetumomab pasudotox, naptumomab, narnatumab, necitumumab, nimotuzumab, nofetumomab, OB I-833, obinutuzumab, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, panitumumab, parsatuzumab, pasudotox, patritumab, pemtumomab, pertuzumab, pintumomab, pritumumab, racotumomab, radretumab, ramucirumab (Cyramza ®), rilotumumab, rituximab, robatumumab, samalizumab, satumomab, sibrotuzumab, siltuximab, solitomab, simtuzumab, tacatuzumab, tapitumomab, tenatuzumab The drugs include rituximab, teprotumumab, tigatuzumab, tositumomab, trastuzumab, trastuzumab biosimilars, tucotuzumab, ubilituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, and 3F8. Rituximab can be used to treat indolent B-cell cancers, including marginal zone lymphoma, WM, CLL, and small lymphocytic lymphoma. Combinations of rituximab and chemotherapeutic agents are particularly effective.

[0415] The exemplified therapeutic antibodies may be further labeled or combined with radioactive isotope particles such as indium-111, yttrium-90 (90Y-clituzumab), or iodine-131.

[0416] In some embodiments, the immunotherapeutic agent is an antibody-drug conjugate (ADC). Exemplary ADCs that can be co-administered include, but are not limited to, drug-conjugated antibodies, fragments thereof, or antibody mimetics targeting proteins or antigens listed above and herein (e.g., in Table B). Exemplary ADCs that may be co-administered include, but are not limited to, gemtuzumab ozogamicin, brentuximab, trastuzumab, inotuzumab, glenbatuzumab, anetuzumab, mirvetuximab, depatuxizumab, rovacpitumab, vadatuximab, labetuzumab, certolizumab pegol, rifatuzumab, indostatumab, potuzumab, pinatuzumab, cotuximab, indostatin, milatuzumab, rovacpitumab, ABBV-011, ABBV-2029, ABBV-321, ABBV-647, MLN0264 (anti-GCC, guanylate cyclase C), T-DM1 (enmetuzumab trastuzumab), emtansine, Kadcycla); SYD985 (anti-HER2, duocarcin), milatuzumab doxorubicin (hCD74-DOX), DCDT2980S, belantamab mofortin (GSK2857916), polotuzumab vedotin (RG-7596), SGN-CD70A, SGN-CD19A, inotuzumab ozogamicin (CMC-544), lorotuzumab emtansine, SAR3419, certolizumab gavitalin (TRODELVY ®), esatuzumab govitecan, enfutumab vedotin (ASG-22ME), ASG-15ME, DS-8201 (trastuzumab drutecan), 225Ac-lintuzumab, U3-1402, 177Lu-tetraxetan-tetuloma, tesotumab vedotin, anetuzumab revitacin, CX-2009, SAR-566658, W-0101, ABBV-085, gemtuzumab ozogamicin, ABT-414, glenbarumab vedotin (C DX-011), labetuzumab govenotecan (IMMU-130), rifatuzumab vedotin (RG-7599), doxorubicin milatuzumab (IMMU-110), indalatuzumab revitaxin (BT-062), pinatuzumab vedotin (RG-7593), SGN-LIV1A, SGN-CD33A, SAR566658, MLN2704, SAR408701, rovaccum tixil, ABBV-399, AGS-16C3F, ASG-22ME, AGS67E, AMG 172, AMG 595, AGS-15E, BAY1129980, BAY1187982, BAY94-934 (anituzumab revituxin), GSK2857916, Humax-TF-ADC (tesuzumab vedotin), IMGN289, IMGN529, IMGN853 (milvetuximab revituxin), LOP628, PCA062, MDX-1203, MEDI-547, PF-0626350 7, PF-06647020, PF-06647263, PF-06664178, PF-06688992, PF-06804103, RG7450, RG7458, RG7598, SAR566658, SGN-CD33A, DS-1602 and DS-7300, DS-6157, DS-6000, TAK-164, MEDI2228, MEDI7247, AMG575. ADCs that can be co-administered are described, for example, in Lambert et al., Adv Ther (2017) 34:1015–1035 and de Goeij, Current Opinion in Immunology (2016) 40:14–23.

[0417] Exemplary therapeutic agents (e.g., anticancer agents or antitumor agents) that can be conjugated to the drug-conjugated antibody, fragment thereof, or antibody mimetic include, but are not limited to, monomethylreoxetine E (MMAE), monomethylreoxetine F (MMAF), calicheamicin, ansamitocin, maytansine or its analogs (e.g., mertansine / emtansine (DM1), ravtansine / soravtansine (DM2), sirolimus / ... M4)), anthracyclines (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin), pyrrolobenzodiazepine (PBD) DNA cross-linker SC-DR002 (D6.5), duocarmycin, microtubule inhibitors (MTI) (e.g., taxanes, vinca alkaloids, epothilones), pyrrolobenzodiazepine (PBD) or its dimer, duocarmycin (A, B1, B2, C1, C2, D, SA, CC-1065), and other anticancer agents or antitumor agents described herein.

[0418] Cancer gene therapy and cell therapy

[0419] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with cancer gene therapy and cell therapy. Cancer gene therapy and cell therapy include inserting normal genes into cancer cells to replace mutated or altered genes; genetic modification of silent mutant genes; genetic methods that directly kill cancer cells; including infusions of immune cells that are designed to replace most of the patient's own immune system to enhance the immune response to cancer cells, or activate the patient's own immune system (T cells or natural killer cells) to kill cancer cells, or find and kill cancer cells; genetic methods that change cell activity to further change the endogenous immune response to cancer.

[0420] Cell therapy

[0421] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with one or more cell therapies. Illustrative cell therapies include, but are not limited to, co-administration of one or more immune cell populations. In some embodiments, the immune cells are natural killer (NK) cells, NK-T cells, T cells, γδ T cells, B cells, cytokine-induced killer (CIK) cells, macrophages (MAC), tumor infiltrating lymphocytes (TIL), granulocytes, innate lymphoid cells, megakaryocytes, monocytes, macrophages, platelets, thymocytes, bone marrow cells, and / or dendritic cells (DC). In some embodiments, cell therapy requires T cell therapy, for example, co-administration of α / β TCR T cells, γ / δ TCR T cells, regulatory T (Treg) cells, and / or TRuC ™ A population of T cells. In some embodiments, cell therapy requires NK cell therapy, such as co-administration of NK-92 cells or JK500 cells. Depending on the circumstances, cell therapy may require co-administration of cells that are autologous, syngeneic, or allogeneic to the subject.

[0422] In some embodiments, cell therapy requires co-administration of immune cells engineered to express a chimeric antigen receptor (CAR) or a T cell receptor (TCR) TCR. In a specific embodiment, the immune cell population is engineered to express a CAR, wherein the CAR comprises a tumor antigen binding domain. In other embodiments, the immune cell population is engineered to express a T cell receptor (TCR) engineered to target a tumor-derived peptide presented on the surface of a tumor cell. In one embodiment, the immune cell engineered to express a chimeric antigen receptor (CAR) or a T cell receptor (TCR) TCR is a T cell. In another embodiment, the immune cell engineered to express a chimeric antigen receptor (CAR) or a T cell receptor (TCR) TCR is a NK cell.

[0423] With regard to the structure of CAR, in some embodiments, CAR comprises an antigen binding domain, a transmembrane domain and an intracellular signaling domain. In some embodiments, the intracellular domain comprises a primary signaling domain, a costimulatory domain or both a primary signaling domain and a costimulatory domain.In some embodiments, the primary signaling domain comprises a functional signaling domain of one or more proteins selected from the group consisting of CD3ζ, CD3γ, CD3δ, CD3ε, common FcRγ (FCERIG), FcRβ (Fcε Rlb), CD79a, CD79b, FcγRIIa, DAP10, and DAP12. 4-1BB / CD137, activated NK cell receptor, immunoglobulin, B7-H3, BAFFR, BLAME (SLAMF8), BTLA, CD100 (SEMA4D), CD103, CD160 (BY55), CD18, CD19, CD19a, CD2, CD247, CD27, CD276 (B7-H3), CD28, CD29, CD3δ, CD3ε, CD3γ, CD30, CD4, CD40, CD49a, CD49D, CD49f, CD69, CD7, CD84, CD8α, CD8β, CD96 (Tactile), CD11a, CD11b, CD11c, CD11d, CDS, CEACAM1, CRT AM, cytokine receptor, DAP-10, DNAM1 (CD226), Fcγ receptor, GADS, GITR, HVEM (LIGHTR), IA4, ICAM-1, ICAM-1, Igα (CD79a), IL-2Rβ, IL-2Rγ, IL-7Rα, inducible T cell co-stimulator (ICOS), integrin, ITGA4, ITGA4, ITGA6, ITGAD, ITGAE, ITGAL, ITGAM, ITGAX, ITGB2, ITGB7, ITGB1, KIRDS2, LAT, LFA-1, LFA-1, ligand binding to CD83, LIGHT, LIGHT, LTBR, ​​Ly9 (CD229), Ly108, lymphocyte function-associated antigen-1 (LFA-1; CD1-1a / CD18), MHC Class 1 molecules, NKG2C, NKG2D, NKp30, NKp44, NKp46, NKp80 (KLRF1), OX-40, PAG / Cbp, programmed death-1 (PD-1), PSGL1, SELPLG (CD162), signaling lymphocyte activation molecule (SLAM protein), SLAM (SLAMF1; CD150; IPO-3), SLAMF4 (CD244; 2B4), SLAMF6 (NTB-A), SLAMF7, SLP-76, TNF receptor protein, TNFR2, TNFSF14, Toll ligand receptor, TRANCE / RANKL, VLA1 or VLA-6, or fragments, truncated forms or combinations thereof.

[0424] In some embodiments, the co-stimulatory domain comprises a functional domain of one or more proteins selected from the group consisting of CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, CD2, CD7, LIGHT, NKG2C, lymphocyte function-associated antigen-1 (LFA-1), MYD88, B7-H3, a ligand specifically binding to CD83, CDS, ICAM-1, GITR, BAFFR, HVEM ( LIGHTR), SLAMF7, NKp80 (KLRFI), CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA 4. CD49D, ITGA6, VLA-6, CD49f, ITGAD, ITGAE, CD103, ITGAL, CD1A (NCBI gene ID: 909), CD1B (NCBI gene ID: 910), CD 1C (NCBI gene ID: 911), CD1D (NCBI gene ID: 912), CD1E (NCBI gene ID: 913), ITGAM, ITGAX, ITGB1, CD29, ITGB2 (CD18, LFA-1), ITGB7, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD15 0, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​LAT, GADS, SLP-76, PAG / Cbp, NKp44, NKp30, NKp46 and NKG2D.

[0425] In some embodiments, the transmembrane domain comprises a transmembrane domain derived from a protein selected from the group consisting of: the alpha, beta, or zeta chain of a T-cell receptor, CD28, CD3 epsilon, CD3 delta, CD3 gamma, CD45, CD4, CD5, CD7, CD8 alpha, CD8 beta, CD9, CD11a, CD11b, CD11c, CD11d, CD16, CD18, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD19, CD19a, IL2Rβ, IL2Rγ, IL7R α, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD1A, CD1B, CD1C, CD1D, CD1E, ITGAE, CD103, ITGAL, ITGAM, ITGAX, ITGB1, ITGB2, ITGB7, CD29, ITGB2 (LFA-1, CD18), ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (TACTILE), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF 1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, ​​PAG / Cbp, NKp44, NKp30, NKp46, NKG2D and NKG2C activating NK cell receptors, immunoglobulins, BTLA, CD247, CD276 (B7-H3), CD30, CD84, CDS, cytokine receptors, Fcγ receptors, GADS, ICAM-1, Igα (CD79a), integrins, LAT, ligands that bind to CD83, LIGHT, MHC class 1 molecules, PAG / Cbp, TNFSF14, Toll ligand receptors, TRANCE / RANKL, or fragments, truncated forms, or combinations thereof.

[0426] In some embodiments, the CAR comprises a hinge domain. The hinge domain may be derived from a protein selected from the group consisting of CD2, CD3δ, CD3ε, CD3γ, CD4, CD7, CD8.α, CD8.β, CD11a (ITGAL), CD11b (ITGAM), CD11c (ITGAX), CD11d (ITGAD), CD18 (ITGB2), CD19 (B4), CD27 (TNFRSF7), CD28, CD28T, CD29 (ITGB1), CD30 (TNFRSF8), CD40 (TNFRSF5), CD48 (SLAMF2), CD49a (ITGA1), CD49d (ITGA4), CD49f (ITGA 6), CD66a (CEACAM1), CD66b (CEACAM8), CD66c (CEACAM6), CD66d (CEACAM3), CD66e (CEACAM5), CD69 (CLEC2), CD79A (B cell antigen receptor complex-associated α chain), CD79B (B cell antigen receptor complex-associated β chain), CD84 (SLAMF5), CD96 (Tactile), CD100 (SEMA4D), CD103 (ITGAE), CD134 (OX40), CD137 (4-1BB), CD150 (SLAMF1), CD158A (KIR2DL1), CD 158B1 (KIR2DL2), CD158B2 (KIR2DL3), CD158C (KIR3DP1), CD158D (KIRDL4), CD158F1 (KIR2DL5A), CD158F2 (KIR2DL5B), CD158K (KIR3DL2), CD160 (B Y55), CD162 (SELPLG), CD226 (DNAM1), CD229 (SLAMF3), CD244 (SLAMF4), CD247 (CD3-ζ), CD258 (LIGHT), CD268 (BAFFR), CD270 (TNFSF14), CD272 (BT LA), CD276 (B7-H3), CD279 (PD-1), CD314 (NKG2D), CD319 (SLAMF7), CD335 (NK-p46), CD336 (NK-p44), CD337 (NK-p30), CD352 (SLAMF6), CD353 (SLAMF8), CD355 (CRTAM), CD357 (TNFRSF18), inducible T cell co-stimulator (ICOS), LFA-1 (CD11a / CD18), NKG2C, DAP-10, ICAM-1, NKp80 (KLRF1), IL-2Rβ, IL-2Rγ, IL-7Rα,LFA-1, SLAMF9, LAT, GADS (GrpL), SLP-76 (LCP2), PAG1 / CBP, CD83 ligand, Fcγ receptor, MHC class 1 molecule, MHC class 2 molecule, TNF receptor protein, immunoglobulin, cytokine receptor, integrin, activated NK cell receptor or Toll ligand receptor, IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM, or fragments or combinations thereof.

[0427] In some embodiments, a TCR or CAR antigen binding domain or an immunotherapeutic described herein (e.g., a monospecific or multispecific antibody or antigen-binding fragment thereof, or an antibody mimetic) binds a tumor-associated antigen (TAA). In some embodiments, the tumor-associated antigen is selected from the group consisting of: CD19; CD123; CD22; CD30; CD171; CS-1 (also known as CD2 subset 1, CRACC, SLAMF7, CD319 and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECLI); CD33; epidermal growth factor receptor variant III (EGFRvlll); ganglioside G2 (GD2); ganglioside GD3 (αNeuSAc(2-8)αNeuSAc(2-3)βDGaip(1-4)bDGIcp(1-1)Cer); ganglioside GM3 (αNeuSAc(2-3)βDGalp(1-4)βDGlcp(1-1)Cer); GM-CSF receptor; TNF receptor superfamily member 17 (TNFRSF17, BCMA); B-lymphocyte cell adhesion molecule; Tn antigen ((Tn Ag) or (GaINAcu-Ser / Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (RORI); tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; carcinoembryonic antigen (CEA); epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); mesothelin; interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); testisin or PRSS21; vascular endothelial growth factor receptor 2 (VEGFR2); HLA Class I antigen A-2α; HLA antigen; Lewis (Y) antigen; CD24; platelet-derived growth factor receptor beta (PDGFR-β); stage-specific embryonic antigen-4 (SSEA-4); CD20; delta-like 3 (DLL3); folate receptor α; folate receptor beta, GDNFα 4 receptor, receptor tyrosine protein kinase, ERBB2 (Her2 / neu); cell surface-associated mucin 1 (MUC1); APRIL receptor; ADP-ribosyl cyclase-1; Ephb4 tyrosine kinase receptor, DCAMKL1 serine threonine kinase, aspartate beta-hydroxylase, epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); prostatic enzyme; prostatic acid phosphatase (PAP); mutated elongation factor 2 (ELF2M); ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX);Proteasome (Prosome, Macropain) subunit beta type 9 (LMP2); glycoprotein 100 (gp100); oncogene fusion protein composed of cleavage cluster region (BCR) and Abelson murine leukemia virus oncogene homolog 1 (Abl) (bcr-abl); tyrosinase; ephrin type A receptor 2 (EphA2); ephrin type A receptor 3 (EphA3), fucosyl GM1; sialyl Lewis adhesion molecule (sLe); transglutaminase 5 (TGS5); high molecular weight melanoma associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); folate receptor beta; tumor endothelial marker 1 (TEM1 / CD248); tumor endothelial marker 7 related (TEM7R); prostate six transmembrane epithelial antigen I (ST EAP1); occludin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5 member D (GPRCSD); interleukin-15 receptor (IL-15); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); hexasaccharide moiety of globoH glycoceramide (GloboH); breast differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); hepatitis A virus cellular receptor 1 (HAVCR1); adrenal receptor beta 3 (ADRB3); pan-nexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); olfactory receptor 51E2 (ORS IE2); TCRγ alternate reading frame protein (TARP); Wilms tumor protein (WT1); cancer / testis antigen 1 (NY-ESO-1); cancer / testis antigen 2 (LAGE-la); melanoma-associated antigen 1 (MAGE-A1); melanoma-associated antigen 3 (MAGE-A3); melanoma-associated antigen 4 (MAGE-A4); T cell receptor β2 chain C; ETS translocation variant gene 6 located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family member 1A (XAGE1); angiopoietin binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MADCT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53, (p53); p53 mutants; prostein; survivin; telomerase; prostate cancer tumor antigen-1 (PCTA-1 or galectin 8), melanoma antigen recognized by T cells 1 (MelanA or MARTI); rat sarcoma (Ras) mutants; human telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints;Melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-acetylglucosamine transferase V (NA17); paired box protein Pax-3 (PAX3); androgen receptor; cyclin-A1; cyclin B1; v-myc avian myelocytoma viral oncogene neuroblastoma-derived homolog (MYCN); Ras homolog family member C (RhoC); tyrosinase-related protein 2 (TRP-2); cytochrome P450 1B1 (CYP IBI); CCCTC-binding factor (zinc finger protein)-like (BORIS or brother of regulator of imprinted sites factor), squamous cell carcinoma antigen recognized by T cells 3 (SART3); paired box protein Pax-5 (PAX5); pre-acrosome binding protein sp32 (OY-TES I); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchoring protein 4 (AKAP-4); peptidoglycan recognition protein, synovial sarcoma, breakpoint X 2 (SSX2); receptor for advanced glycation end products (RAGE-I); renal ubiquitin 1 (RUI); renal ubiquitin 2 (RU2); legumin; human papillomavirus E6 (HPV E6); human papillomavirus E7 (HPV E7); intestinal carboxylesterase; mutant heat shock protein 70-2 (mut hsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIRI); Fc fragment of IgA receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module containing mucin-like hormone receptor 2 (EMR2); lymphocyte antigen 75 (LY75); glypican-2 (GPC2); glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1). In some embodiments, the target is an epitope of a tumor-associated antigen presented in MHC. ;

[0428] In some embodiments, the tumor antigen is selected from CD150, 5T4, ActRIIA, B7, TNF receptor superfamily member 17 (TNFRSF17, BCMA), CA-125, CCNA1, CD123, CD126, CD138, CD14, CD148, CD15, CD19, CD20, CD200, CD21, CD22, CD23, CD24, CD25, CD26, CD261, CD262, CD30, CD33, CD362, CD37, CD38, CD4, CD40, CD40L, CD44, CD46, CD5, CD52, CD53, CD54, CD56, CD66a-d, CD74, CD8, CD80, CD92, CE7, CS-1, CSPG4, ED-B fibronectin, EGFR, EGFRvIII, EGP-2, EGP-4, EPHa2, ErbB2, ErbB3, ErbB4, FBP, HER1-HER2 combination, HER2-HER3 combination, HERV-K, HIV-1 envelope glycoprotein gp120, HIV-1 envelope glycoprotein gp41, HLA-DR, HLA class I antigen αG, HM1.24, K-Ras GTPase, HMW-MAA, Her2, Her2 / neu, IGF-1R, IL-11Rα, IL-13R-α2, IL-2, IL-22R-α, IL-6, IL-6R, Ia, Ii, L1-CAM, L1 cell adhesion molecule, Lewis Y, Ll-CAM, MAGE A3, MAGE-A1, MART-1, MUC1, NKG2C ligand, NKG2D ligand, NYESO-1, OEPHa2, PIGF, PSCA, PSMA, ROR1, T101, TAC, TAG72, TIM-3, TRAIL-R1, TRAIL-R1 (DR4), TRAIL-R2 (DR5), VEGF, VEGFR2, WT-I, G protein-coupled receptor, alpha-fetoprotein (AFP), angiogenic factor, exogenous cognate binding molecule (ExoCBM), oncogene product, antifolate receptor, c-Met, carcinoembryonic antigen (CEA), cyclin (D1), ephrin B2, upper mesenchymal tumor antigen, estrogen receptor, fetal acetylcholine e receptor, folate binding protein, gp100, hepatitis B surface antigen, Epstein-Barr nuclear antigen 1, latent membrane protein 1, secretory protein BARF1, P2X7 purinergic receptor, syndecan-1, kappa chain, kappa light chain, kdr, lambda chain, activin, melanoma-associated antigen, mesothelin, mouse double minute 2 homolog (MDM2), mucin 16 (MUC16), mutant p53, mutant ras, necrosis antigen, carcinoembryonic antigen, ROR2, progesterone receptor, prostate specific antigen, tEGFR, tenascin, P2-Microgiobuiin, Fc receptor-like 5 (FcRL5). .

[0429] Examples of cell therapies include, but are not limited to: AMG-119, Algenpantucel-L, ALOFISEL ®, Sipuleucel-T, (BPX-501)rivogenlecleucel US9089520, WO2016100236, AU-105, ACTR-087, activated allogeneic natural killer cells CNDO-109-AANK, MG-4101, AU-101, BPX-601, FATE-NK100, LFU-835 hematopoietic stem cells, Imilecleucel-T, baltaleucel-T, PNK-007, UCARTCS1, ET-1504, ET-1501, ET-1502, ET-190, CD19-ARTEMIS, ProHema, bone marrow stem cell therapy treated with FT-1050, CD4CARNK-92 cells, SNK-01, NEXI-001, CryoStim, AlloStim, lentivirally transduced huCART meso cells, CART-22 cells, EGFRt / 19-28z / 4-1BBL CAR T cells, autologous 4H11-28z / fIL-12 / EFGRt T cells, CCR5-SBC-728-HSPC, CAR4-1BBZ, CH-296, dnTGFbRII-NY-ESOc259T, Ad-RTS-IL-12, IMA-101, IMA-201, CARMA-0508, TT-18, CMD-501, CMD-503, CMD-504, CMD-502, CMD-601, CMD-602, CSG-005, LAAP T cell therapy, PD-1 knockout T cell therapy (esophageal cancer / NSCLC), anti-MUC1 CAR T cell therapy (esophageal cancer / NSCLC), anti-MUC1 CAR T cell therapy + PD-1 knockout T cell therapy (esophageal cancer / NSCLC), anti-KRASG12D mTCR PBL, anti-CD123 CAR T cell therapy, anti-mutated neoantigen TCR T cell therapy, tumor lysate / MUC1 / survivin loaded PepTivator dendritic cell vaccine, autologous dendritic cell vaccine (metastatic malignant melanoma,dermal / intravenous), anti-LeY-scFv-CD28-ζ CAR T cells, PRGN-3005, iC9-GD2-CAR-IL-15 T cells, HSC-100, ATL-DC-101, MIDRIX4-LUNG, MIDRIXNEO, FCR-001, PLX stem cell therapy, MDR-101, GeniusVac-Mel4, ilixadencel, allogeneic mesenchymal stem cell therapy, romyelocel L, CYNK-001, ProTrans, ECT-100, MSCTRAIL, dilanubicel, FT-516, ASTVAC-2, E-CEL UVEC, CK-0801, allogeneic α / β CD3+T cell and CD19+B cell depleted stem cells (hematological diseases, TBX-1400, HLCN-061, umbilical cord-derived Hu-PHEC cells (hematological malignancies / aplastic anemia), AP-011, apceth-201, apceth-301, SENTI-101, stem cell therapy (pancreatic cancer), ICOVIR15-cBiTE, CD33HSC / CD33 CAR-T, PLX-Immune, SUBCUVAX, CRISPR-based allogeneic gamma-delta T cell gene therapy (cancer), ex vivo CRISPR-based allogeneic healthy donor NK cell gene therapy (cancer), ex vivo allogeneic induced pluripotent stem cell-derived NK cell gene therapy (solid tumors), and anti-CD20 CAR T cell therapy (non-Hodgkin lymphoma).

[0430] Additional agents to target tumors

[0431] Additional agents for targeting tumors include, but are not limited to, alpha-fetoprotein modulators, such as ET-1402 and AFP-TCR; anthrax toxin receptor 1 modulators, such as anti-TEM8 CAR T cell therapy; TNF receptor superfamily member 17 (TNFRSF17, BCMA), such as bb-2121 (ide-cel), bb-21217, JCARH125, UCART-BCMA, ET-140, MCM-998, LCAR-B38M, CART-BCMA, SEA-BCMA, BB212, ET-140, P-BCMA-101, AUTO-2 (APRIL-CAR), JNJ-68284528; anti-CLL-1 antibodies (see, e.g., PCT / US2017 / 025573); anti-PD-L1-CAR tank cell therapy, such as KD-045; anti-PD-L1 t-haNK, such as PD-L1 t-haNK; anti-CD45 antibodies, such as 131I-BC8 (lomab-B); anti-HER3 antibodies, such as LJM716, GSK2849330; APRIL receptor modulators, such as anti-BCMA CAR T cell therapy, Descartes-011; ADP-ribosyl cyclase-1 / APRIL receptor modulators, such as dual anti-BCMA / anti-CD38 CAR T cell therapy; CART-ddBCMA; B7 homolog 6, such as CAR-NKp30 and CAR-B7H6; B lymphocyte antigen CD19, such as TBI-1501, CTL-119 huCART-19 T cells, l iso-cel, JCAR-015 US7446190, JCAR-014, JCAR-017 (WO2016196388, WO2016033570, WO2015157386), Akirunsa (KTE-C19, Yescarta ®), KTE-X19, US7741465, US6319494, UCART-19, EBV-CTL, T tisagenlecleucel-T (CTL019), WO2012079000, WO2017049166, T cells expressing CD19CAR-CD28-CD3ζ-EGFRt, armored CD19 / 4-1BBL CAR T cell therapy, C-CAR-011, CIK-CAR.CD19, CD19CAR-28-ζ T cells, PCAR-019, MatchCART, DSCAR-01, IM19 CAR-T, TC-110; anti-CD19 CAR T cell therapy (B-cell acute lymphoblastic leukemia, Universiti Kebangsaan Malaysia); anti-CD19 CAR T cell therapy (acute lymphoblastic leukemia / non-Hodgkin's lymphoma, University Hospital Heidelberg), anti-CD19 CAR T cell therapy (IL-6 expression silencing, cancer, Shanghai Unicar-Therapy Bio-medicine Technology), MB-CART2019.1 (CD19 / CD20), GC-197 (CD19 / CD7), CLIC-1901, ET-019003, anti-CD19-STAR-T cells, AVA-001, BCMA-CD19 cCAR (CD19 / APRIL), ICG-134, ICG-132 (CD19 / CD20), CTA-101, WZTL-002, dual anti-CD19 / anti-CD20 CAR T cells (chronic lymphocytic leukemia / B-cell lymphoma), HY-001, ET-019002, YTB-323, GC-012 (CD19 / APRIL), GC-022 (CD19 / CD22), Tn / mem expressing CD19CAR-CD28-CD3ζ-EGFRt; UCAR-011, ICTCAR-014, GC-007F, PTG-01, CC-97540; allogeneic anti-CD19 CART cells, such as GC-007G; APRIL receptor modulators; SLAM family member 7 modulator BCMA-CS1 cCAR; autologous dendritic cell tumor antigen (ADCTA), such as ADCTA-SSI-G; B-lymphocyte antigen CD20, such as ACTR707 ATTCK-20, PBCAR-20A; expressing CD20 Allogeneic T cells of CAR, such as LB-1905; B lymphocyte antigen CD19 / B lymphocyte antigen 22, such as TC-310;B lymphocyte antigen 22 cell adhesion, such as UCART-22, JCAR-018 WO2016090190; NY-ESO-1 regulators, such as GSK-3377794, TBI-1301, GSK3537142; carbonic anhydrase, such as DC-Ad-GMCAIX; caspase 9 suicide gene, such as CaspaCIDe DLI, BPX-501; CCR5, such as SB-728; CCR5 gene inhibitor / TAT gene / TRIM5 gene stimulator, such as autologous CD34-positive hematopoietic progenitor cells transduced with lentiviral vector CCR5 shRNA / TRIM5α / TAR decoy; CDw123, such as MB-102, IM-23, JEZ-567, UCART-123; CD4, such as ICG-122; CD5 regulators, such as CD5.28z CART cells; anti-CD22, such as anti-CD22 CART; anti-CD30, such as TT-11; dual anti-CD33 / anti-CLL1, such as LB-1910; CD40 ligand, such as BPX-201, MEDI5083; CD56, such as allogeneic CD56-positive CD3-negative natural killer cells (myeloid malignancies); CD19 / CD7 modulators, such as GC-197; T cell antigen CD7 modulators, such as anti-CD7 CAR T cell therapy (CD7-positive hematological malignancies); CD123 modulators, such as UniCAR02-T-CD123; anti-CD276, such as anti-CD276 CART; CEACAM protein 5 modulators, such as MG7-CART; Occludin 6, such as CSG-002; Occludin 18.2, such as LB-1904; Chlorotoxin, such as CLTX-CART; EBV targeting, such as CMD-003; MUC16EGFR, such as autologous 4H11-28z / fIL-12 / EFGRt T cells; endonucleases, such as PGN-514, PGN-201; Epstein-Barr virus-specific T lymphocytes, such as TT-10; Epstein-Barr nuclear antigen 1 / latent membrane protein 1 / secreted protein BARF1 regulators, such as TT-10X; Erbb2, such as CST-102, CIDeCAR; ganglioside (GD2), such as 4SCAR-GD2; γδT cells, such as ICS-200; folate hydrolase 1 (FOLH1, glutamate carboxypeptidase II, PSMA; NCBI gene ID: 2346), such as CIK-CAR.PSMA, CART-PSMA-TGFβRDN, P-PSMA-101; phosphatidylinositol proteoglycan-3 (GPC3), such as TT-16, GLYCAR; hemoglobin, such as PGN-236;Hepatocyte growth factor receptor, such as anti-cMet RNA CAR T; HLA class I antigen A-2 alpha modulator, such as FH-MCVA2TCR; HLA class I antigen A-2 alpha / melanoma associated antigen 4 modulator, such as ADP-A2M4CD8; HLA antigen modulator, such as FIT-001, NeoTCR-P1; human papillomavirus E7 protein, such as KITE-439 (see, e.g., PCT / US2015 / 033129); ICAM-1 modulator, such as AIC-100; immunoglobulin gamma Fc receptor III, such as ACTR087; IL-12, such as DC-RTS-IL-12; IL-12 agonist / mucin 16, such as J CAR-020; IL-13α2, such as MB-101; IL-15 receptor agonists, such as PRGN-3006, ALT-803; interleukin-15 / Fc fusion protein (e.g., XmAb24306); recombinant interleukin-15 (e.g., AM0015, NIZ-985); pegylated IL-15 (e.g., NKTR-255); IL-2, such as CST-101; interferon α ligands, such as autologous tumor cell vaccine + systemic CpG-B + IFN-α (cancer); K-Ras GTPases, such as anti-KRAS G12V mTCR cell therapy; neural cell adhesion molecule L1 L1CAM (CD171), such as JCAR-023; latent membrane protein 1 / latent membrane protein 2, such as autologous dendritic cells transduced with Ad5f35-LMPd1-2; MART-1 melanoma antigen modulators, such as MART-1 F5 TCR-engineered PBMCs; melanoma associated antigen 10, such as MAGE-A10C796T MAGE-A10 TCR; melanoma associated antigen 3 / melanoma associated antigen 6 (MAGE A3 / A6), such as KITE-718 (see, e.g., PCT / US2013 / 059608); mesothelin, such as CSG-MESO, TC-210; mucin 1 modulators, such as ICTCAR-052, Tn MUC-1 CAR-T, ICTCAR-053; anti-MICA / MICB, such as CYAD-02; NKG2D, such as NKR-2; Ntrkr1 tyrosine kinase, such as JCAR-024; PRAMET cell receptor, such as BPX-701; prostate stem cell antigen modulators, such as MB-105; Roundabout homolog 1 modulators, such as ATCG-427; peptidoglycan recognition protein modulators, such as Tag-7 gene-modified autologous tumor cell vaccines; PSMA, such as PSMA-CAR T cell therapy (lentiviral vector, castration-resistant prostate cancer); SLAM family member 7 modulators, such as IC9-Luc90-CD828Z;TGFβ receptor modulators, such as DNR.NPC T cells; T lymphocytes, such as TT-12; T lymphocyte stimulators, such as ATL-001; TSH receptor modulators, such as ICTCAR-051; tumor infiltrating lymphocytes, such as LN-144, LN-145; and / or Wilms tumor protein, such as JTCR-016, WT1-CTL, ASP-7517. ;

[0432] MCL1 apoptosis regulator, BCL2 family member (MCL1) inhibitor

[0433] In various embodiments, an anti-CD47 agent or anti-SIRPα agent as described herein is combined with an inhibitor of MCL1 apoptosis regulator (BCL2 family member) (MCL1, TM; EAT; MCL1L; MCL1S; Mcl-1; BCL2L3; MCL1-ES; bcl2-L-3; mcl1 / EAT; NCBI Gene ID: 4170). Examples of MCL1 inhibitors include AMG-176, AMG-397, S-64315 and AZD-5991, 483-LM, A-1210477, UMI-77, JKY-5-037, and those described in WO2018183418, WO2016033486, WO2019222112, and WO2017147410.

[0434] Cytokine-inducible SH2-containing protein (CISH) inhibitor

[0435] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with inhibitors of cytokine-inducible SH2-containing proteins (CISH; CIS; G18; SOCS; CIS-1; BACTS2; NCBI gene ID: 1154). Examples of CISH inhibitors include those described in WO2017100861, WO2018075664, and WO2019213610.

[0436] Gene editing

[0437] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab); and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with a gene editor. Exemplary gene editing systems that can be co-administered include, but are not limited to, CRISPR / Cas9 systems, zinc finger nuclease systems, TALEN systems, homing endonuclease systems (e.g., ARCUS), and homing meganuclease systems.

[0438] Other drugs with unspecified targets

[0439] In various embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab) and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are further combined with the following substances: human immunoglobulin (10% liquid preparation), Cuvitru (human immunoglobulin (20% solution)), disodium leucovorin, IMSA-101, BMS-986288, IMUNO BGC Moreau RJ, R-OKY-034F, GP-2250, AR-23, calcium leucovorin, porfimer sodium (porfimer sodium), RG6160, ABBV-155, CC-99282, polyphenprosan 20 with carmustine, Veregen, gadoxetate disodium, gadobutrol, gadoterate meglumine, gadoteridol, 99mTc-sestamibi, pomalidomide, pacibanil, and / or valrubicin.

[0440] Exemplary Combination Therapies

[0441] In various embodiments, the agents described herein that inhibit binding between CD47 and SIRPα (eg, mololimab) and VEGFA / VEGFR inhibitors (eg, bevacizumab) are further combined with standard of care regimens for treating colorectal cancer.

[0442] Therapeutic agents used to treat CRC include bevacizumab, capecitabine, cetuximab, fluorouracil, irinotecan, leucovorin, oxaliplatin, panitumumab, ziv-aflibercept, and any combination thereof. In some embodiments, the therapeutic agent used to treat CRC includes bevacizumab (AVASTIN ® ), leucovorin, 5-FU, oxaliplatin (FOLFOX), pembrolizumab (KEYTRUDA ® ), FOLFIRI, regorafenib (STIVARGA ® ), Aflibercept (ZALTRAP ® ), Cetuximab (ERBITUX ® )、Lonsurf(ORCANTAS ®), XELOX, FOLFOXIRI, or a combination thereof. In some embodiments, therapeutic agents for treating CRC include bevacizumab + leucovorin + 5-FU + oxaliplatin (FOLFOX), bevacizumab + FOLFIRI, bevacizumab + FOLFOX, aflibercept + FOLFIRI, cetuximab + FOLFIRI, bevacizumab + XELOX, and bevacizumab + FOLFOXIRI. In some embodiments, therapeutic agents for treating CRC include bimetinib + encorafenib + cetuximab, trametinib + dabrafenib + panitumumab, trastuzumab + pertuzumab, nabucasin + FOLFIRI + bevacizumab, nivolumab + ipilimumab.

[0443] Additional Exemplary Combination Therapies

[0444] In some embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab) and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are co-administered with one or more therapeutic agents selected from the following: PI3K inhibitors, FLT3R agonists, PD-1 antagonists, PD-L1 antagonists, MCL1 inhibitors, CCR8 binders, HPK1 antagonists, DGKα inhibitors, CISH inhibitors, PARP-7 inhibitors, Cbl-b inhibitors, KRAS inhibitors (e.g., KRASG12C or G12D inhibitors), KRAS degraders, β-catenin degraders, helios degraders, CD73 inhibitors, adenosine receptor antagonists, TIGIT antagonists, TREM1 binders, TREM2 binders, CD137 agonists, GITR binders, OX40 binders, and CAR-T cell therapy.

[0445] In some embodiments, the agent described herein that inhibits the binding between CD47 and SIRPα (e.g., mololimab) and the VEGFA / VEGFR inhibitor (e.g., bevacizumab) are co-administered with one or more therapeutic agents selected from the following: a PI3Kδ inhibitor (e.g., idealisib), a FLT3L-Fc fusion protein (e.g., GS-3583), an anti-PD-1 antibody (pembrolizumab, nivolumab, sepalimumab), a small molecule PD-L1 inhibitor (e.g., GS-4224), an anti-PD-L1 antibody (e.g., atezolizumab, avelumab), a small molecule MCL1 inhibitor (e.g., GS-9716), a small molecule HPK1 inhibitor (e.g., GS-6451), an HPK1 degrader (PROTAC; e.g., ARV- 766), small molecule DGKα inhibitors, small molecule CD73 inhibitors (e.g., quemliclustat (AB680)), anti-CD73 antibodies (e.g., olelumab), dual A2a / A2b adenosine receptor antagonists (e.g., etrumadenant (AB928)), anti-TIGIT antibodies (e.g., tisleliumab, vebollimumab, dunalimab, AB308), anti-TREM1 antibodies (e.g., PY159), anti-TREM2 antibodies (e.g., PY314), CD137 agonists (e.g., AGEN-2373), GITR / OX40 binders (e.g., AGEN-1223), and CAR-T cell therapies (e.g., axicabtagene ciloleucel, brexucabtagene autoleucel, tisagenlecleucel).

[0446] In some embodiments, the agents described herein that inhibit the binding between CD47 and SIRPα (e.g., mololimab) and VEGFA / VEGFR inhibitors (e.g., bevacizumab) are co-administered with one or more therapeutic agents selected from the group consisting of idealisib, GS-3583, sepalizumab, GS-4224, GS-9716, GS-6451, quilibrium (AB680), edrinan (AB928), dunalimab, AB308, PY159, PY314, AGEN-1223, AGEN-2373, akilencil, and brikielencil.

[0447] 5. Dosage and Timing

[0448] The methods described herein include administering a therapeutically effective amount of a composition, for example, a therapeutically effective amount of an agent that inhibits binding between CD47 and SIRPα and a therapeutically effective amount of a VEGFA / VEGFR inhibitor.

[0449] As described above, the composition is administered to the patient in an amount sufficient to substantially ablate the target cells. An amount sufficient to achieve this is defined as a "therapeutically effective dose," which can provide an improvement in overall survival. The term "therapeutically effective dose" is an amount that effectively improves the symptoms of a disease (e.g., a cancer described herein). A therapeutically effective dose can be a "prophylactically effective dose," since prevention can be considered a treatment. Depending on the dose and frequency required and tolerated by the patient, the composition can be administered in a single or multiple doses. The specific dose used for treatment will depend on the physical condition and medical history of the mammal, as well as other factors such as age, weight, sex, route of administration, efficiency, etc.

[0450] In some embodiments, a combined therapeutic amount of an agent described herein that inhibits the binding between CD47 and SIRPα; and a VEGFA / VEGFR inhibitor, optionally together with one or more additional therapeutic agents described herein, can (i) reduce the number of diseased cells; (ii) reduce tumor size; (iii) inhibit, block, slow down and preferably prevent to some extent the infiltration of diseased cells into peripheral organs; (iv) inhibit (e.g., slow down and preferably prevent to some extent) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay tumor occurrence and / or recurrence; and / or (vii) alleviate to some extent one or more of the symptoms associated with cancer or myeloproliferative diseases. In some embodiments, a combined therapeutic amount of an agent described herein that inhibits the binding between CD47 and SIRPα; and a VEGFA / VEGFR inhibitor, optionally together with one or more additional therapeutic agents described herein, can (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, block, slow down, and preferably prevent cancer cells from infiltrating peripheral organs to a certain extent; (iv) inhibit (e.g., slow down and preferably prevent to a certain extent) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay tumor occurrence and / or recurrence; and / or (vii) alleviate one or more of the symptoms associated with cancer to a certain extent. In various embodiments, the amount is sufficient to improve, alleviate, reduce, and / or delay one or more of the symptoms of cancer.

[0451] By "increasing" or "enhancing" an amount (e.g., with respect to cancer cell proliferation or expansion, anti-tumor response, cancer cell metastasis) is meant an increase of 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, or 50 times or more (e.g., 100 times, 500 times, 1000 times) (including all integers and decimal points between them and greater than 1, e.g., 2.1, 2.2, 2.3, 2.4, etc.) of an amount or level described herein. It may also include an increase of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 150%, at least 200%, at least 500%, or at least 1000% of an amount or level described herein.

[0452] "Reduced" or "decreased" or a "smaller" amount (e.g., with respect to tumor size, cancer cell proliferation or growth) refers to a decrease of about 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, or 50 times or more (e.g., 100, 500, 1000) (including all fractions between them and less than 1, e.g., 1.5, 1.6, 1.7, 1.8, etc.) of the amounts or levels described herein. It may also include a decrease of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%, at least 100%, at least 150%, at least 200%, at least 500%, or at least 1000% of the amounts or levels described herein. In various embodiments, tumor burden is determined using a linear dimensional method, such as Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Eisenhauer et al., Eur J Cancer. (2009) 45(2):228–47). In various embodiments, tumor burden is determined using volumetric analysis (e.g., positron emission tomography (PET) / computed tomography (CT) scan). See, e.g., Paydary et al., Mol Imaging Biol. (2019) 21(1):1-10; Li et al., AJR Am J Roentgenol. (2021) 217(6):1433-1443; and Kerner et al., EJNMMI Res. (2016) Dec; 6(1):33.

[0453] As used herein, "anti-tumor effect" refers to a biological effect that can be manifested as a reduction in tumor volume, a reduction in the number of tumor cells, a reduction in tumor cell proliferation, a reduction in the number of metastases, an extension of overall survival or progression-free survival, an extension of life expectancy, or an improvement in various physiological symptoms associated with tumors. Anti-tumor effect can also refer to the prevention of the occurrence or recurrence of a tumor, for example, recurrence after remission.

[0454] The effective dosage of the combination of agents for treating cancer varies depending on many different factors, including the mode of administration, the target site, the physiological state of the patient, whether the patient is a human or an animal, other drugs being administered, and whether the treatment is prophylactic or therapeutic. Typically, the patient is a human, but non-human mammals, e.g., companion animals (such as dogs, cats, horses, etc.), laboratory mammals (such as non-human primates, rabbits, mice, rats, etc.), etc., can also be treated. The therapeutic dose can be titrated to optimize safety and efficacy.

[0455] A therapeutically effective dose of an anti-CD47 antibody can depend on the specific agent used, but is typically about 10 mg / kg body weight or more (e.g., about 10 mg / kg or more, about 15 mg / kg or more, 20 mg / kg or more, about 25 mg / kg or more, about 30 mg / kg or more, about 35 mg / kg or more, about 40 mg / kg or more, about 45 mg / kg or more, about 50 mg / kg or more, or about 55 mg / kg or more, or about 60 mg / kg or more, or about 65 mg / kg or more, or about 70 mg / kg or more) or about 10 mg / kg, about 15 mg / kg to about 70 mg / kg (e.g., about 10 mg / kg to about 67.5 mg / kg, or about 10 mg / kg, about 15 mg / kg to about 60 mg / kg).

[0456] In some embodiments, the therapeutically effective dose of the anti-CD47 antibody is 10 mg / kg, 15 mg / kg, 20 mg / kg, 25 mg / kg, 30 mg / kg, 35 mg / kg, 40 mg / kg, 45 mg / kg, 50 mg / kg, 55 mg / kg, 60 mg / kg, 65 mg / kg, or 67.5 mg / kg. In some embodiments, the therapeutically effective dose of the anti-CD47 antibody is 10 mg / kg to 60 mg / kg. In some embodiments, the therapeutically effective dose of the anti-CD47 antibody is 10 mg / kg to 67.5 mg / kg. In some embodiments, the anti-CD47 antibody is administered at a dose of at least 10 mg-30 mg, 20 mg-30 mg, 15 mg-60 mg, 30 mg-60 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 50 mg, or 60 mg of antibody per kg of body weight.

[0457] The therapeutic dose of the anti-CD47 antibody can be a fixed dose. For example, a fixed dose can be administered without regard to the weight of a particular subject. Alternatively, a fixed dose can be administered based on the weight of a particular subject falling within a particular weight range (e.g., a first range of less than or equal to 100 kg; or a second range of greater than 100 kg). The fixed dose can be, for example, 1000 mg-5000 mg, 2000 mg-4000 mg, 2000 mg-3500 mg, 2400 mg-3500 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, 1500 mg, 1600 mg, 1700 mg, 1800 mg, 1900 mg, 2000 mg, 2100 mg, 2200 mg, 2300 mg, 2400 mg, 2500 mg, 2600 4700mg, 4800mg, 4900mg, 5000mg, or intermediate mg numbers thereof.

[0458] The method may include the step of administering a priming agent to the subject, followed by the step of administering a therapeutically effective dose of anti-CD47 to the subject. In some embodiments, the step of administering a therapeutically effective dose is performed at least about 3 days (e.g., at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 8 days, at least about 9 days, or at least about 10 days) after the start of administration of the priming agent. This period of time is, for example, sufficient to increase the reticulocyte production of the individual. In some embodiments, the anti-CD47 agent is an isolated anti-CD47 antibody.

[0459] The administration of a therapeutically effective dose of anti-CD47 can be achieved in many different ways. In some cases, two or more therapeutically effective doses are administered after the administration of the priming agent. Appropriate administration of a therapeutically effective dose may require administration of a single dose, or may require administration of multiple doses once a day, half a week, once a week, once every two weeks, once a month, once a year, etc. In some cases, the therapeutically effective dose is administered as two or more increasing concentration doses (i.e., gradually increasing doses), wherein (i) all doses are therapeutic doses, or wherein (ii) a subtherapeutic dose (or two or more subtherapeutic doses) is initially administered and the therapeutic dose is achieved by the increasing. As a non-limiting example illustrating increasing concentrations (i.e., gradually increasing doses), a therapeutically effective dose can be initiated with a subtherapeutic dose (e.g., a dose of less than 10 mg / kg, e.g., a dose of 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg) for weekly administration, and each subsequent dose can be increased by a specific increment (e.g., by 5 mg / kg, 10 mg / kg, 15 mg / kg), or by variable increments, until a therapeutic dose (e.g., 15 mg / kg, 30 mg / kg, 45 mg / kg, 60 mg / kg) is reached, at which point administration can be discontinued, or one or more additional therapeutic doses can continue to be administered (e.g., continuous therapeutic doses or increasing therapeutic doses, e.g., doses of 15 mg / kg, 30 mg / kg, 45 mg / kg, 60 mg / kg). As another non-limiting example illustrating increasing concentrations (i.e., gradually increasing doses), the therapeutically effective dose can be administered weekly starting with one or more relatively low therapeutic doses (e.g., a dose of 10 mg / kg, 15 mg / kg, or 30 mg / kg), and each subsequent dose can be increased by a specific increment (e.g., by 10 mg / kg or 15 mg / kg), or by variable increments, until a relatively high therapeutic dose (e.g., 30 mg / kg, 45 mg / kg, 60 mg / kg, 100 mg / kg, etc.) is reached, at which point administration can be discontinued, or administration can continue (e.g., one or more consecutive therapeutic doses or increasing therapeutic doses, e.g., doses of 30 mg / kg, 45 mg / kg, 60 mg / kg, 100 mg / kg, etc.). In various embodiments, a relatively lower therapeutic dose is administered more frequently (e.g., two or more 15 mg / kg doses administered weekly (Q1W), or two or more 30 mg / kg doses administered every two weeks (Q2W)), and a relatively higher therapeutic dose is administered less frequently (e.g., two or more 45 mg / kg doses administered every 3 weeks (Q3W), or two or more 60 mg / kg doses administered monthly or every 4 weeks (Q4W)).In some embodiments, administration of a therapeutically effective dose can be a continuous infusion, and the dose can be varied (eg, escalated) over time.

[0460] The dosage required to reach and / or maintain a specific serum level of the administered composition is directly proportional to the amount of time between doses and inversely proportional to the number of doses administered. Therefore, as the frequency of administration increases, the required dosage decreases. One of ordinary skill in the art will readily understand and practice the optimization of dosing strategies. Exemplary treatment regimens require administration once every two weeks or once a month or once every 3 to 6 months. The therapeutic entities described herein are generally administered multiple times. The intervals between single doses may be weekly, monthly, or annual. The intervals may also be irregular, as indicated by measuring the blood levels of the therapeutic entity in the patient. Alternatively, the therapeutic entities described herein may be administered as sustained-release formulations, in which case they are administered at a lower frequency. Dosage and frequency vary according to the half-life of the polypeptide in the patient. In some embodiments, the interval between each single dose is one week. In some embodiments, the interval between each single dose is two weeks. In some embodiments, the interval between each single dose is three weeks. In some embodiments, the interval between each single dose is four weeks. In some embodiments, the interval between each single dose of anti-CD47 antibodies is one week. In some embodiments, the interval between each single dose of anti-CD47 antibody is two weeks. In some embodiments, the interval between each single dose of anti-CD47 antibody is three weeks. In some embodiments, the interval between each single dose of anti-CD47 antibody is four weeks. In some embodiments, the interval between each single dose of mololimab is one week. In some embodiments, the interval between each single dose of mololimab is two weeks. In some embodiments, the interval between each single dose of mololimab is three weeks. In some embodiments, the interval between each single dose of mololimab is four weeks.

[0461] A "maintenance dose" is a dose that is intended to be a therapeutically effective dose. For example, in an experiment to determine a therapeutically effective dose, multiple different maintenance doses may be administered to different subjects. Thus, some maintenance doses may be therapeutically effective doses, while other maintenance doses may be subtherapeutic doses.

[0462] In preventive applications, relatively low doses may be administered at relatively infrequent intervals over a longer period of time. Some patients continue to receive treatment for the rest of their lives. In other therapeutic applications, relatively high doses at relatively short intervals are sometimes used until the progression of the disease is reduced or terminated, and preferably until the patient shows partial or complete improvement in symptoms of the disease. Thereafter, a preventive regimen may be administered to the patient.

[0463] The term "priming dose" or as used herein refers to the following dose of anti-CD47 antibody: it primes the subject to administer a therapeutically effective dose of anti-CD47 antibody so that the therapeutically effective dose does not result in severe RBC loss (reduced hematocrit or decreased hemoglobin). The specific appropriate priming dose of anti-CD47 antibody can vary depending on the nature of the agent used and many subject-specific factors (e.g., age, weight, etc.). Examples of suitable priming doses of anti-CD47 antibodies include about 0.5 mg / kg to about 5 mg / kg, about 0.5 mg / kg to about 4 mg / kg, about 0.5 mg / kg to about 3 mg / kg, about 1 mg / kg to about 5 mg / kg, about 1 mg / kg to about 4 mg / kg, about 1 mg / kg to about 3 mg / kg, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg. In some embodiments, the priming dose is preferably 1 mg / kg.

[0464] In some embodiments of the methods described herein, the anti-CD47 antibody is administered to the subject as a priming dose in the range of about 0.5 mg to about 10 mg, such as about 0.5 to about 5 mg / kg of antibody, optionally 4 mg / kg, 3 mg / kg, 2 mg / kg, or 1 mg / kg of antibody. In some embodiments, the anti-CD47 antibody is administered to the subject as a therapeutic dose in the range of about 20 mg / kg to about 67.5 mg / kg of antibody, optionally 15 mg / kg to 60 mg / kg of antibody, optionally 30 mg / kg to 60 mg / kg of antibody, optionally 15 mg / kg of antibody, 20 mg / kg of antibody, 30 mg / kg of antibody, 45 mg / kg of antibody, 60 mg / kg of antibody, or 67.5 mg / kg of antibody.

[0465] The priming dose of the anti-CD47 antibody can be a fixed priming dose. For example, a fixed priming dose can be administered without regard to the weight of a particular subject. Alternatively, a fixed priming dose can be administered based on the weight of a particular subject falling within a specific weight range (e.g., a first range of less than or equal to 100 kg; or a second range of greater than 100 kg). The fixed priming dose can be, for example, 10 mg-200 mg, 50 mg-100 mg, 80 mg-800 mg, 80 mg-400 mg, 80 mg-200 mg, 70 mg-90 mg, 75 mg-85 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 240 mg, 300 mg, 320 mg, 400 mg, 500 mg, 600 mg, 700 mg or 800 mg, or intermediate mg numbers thereof.

[0466] In some embodiments, an effective priming dose of mololimab is provided, wherein the effective priming dose for humans is about 1 mg / kg, e.g., at least about 0.5 mg / kg to a maximum of no more than about 5 mg / kg; at least about 0.75 mg / kg to a maximum of no more than about 1.25 mg / kg; at least about 0.95 mg / kg to a maximum of no more than about 1.05 mg / kg; and may be about 1 mg / kg.

[0467] In some embodiments, the initial dose of the CD47 or SIRPα binding agent is infused over a period of at least about 2 hours, at least about 2.5 hours, at least about 3 hours, at least about 3.5 hours, at least about 4 hours, at least about 4.5 hours, at least about 5 hours, at least about 6 hours, or longer. In some embodiments, the initial dose is infused over a period of about 2.5 hours to about 6 hours; for example, about 3 hours to about 4 hours. In some such embodiments, the dose of the agent in the infusion is about 0.05 mg / ml to about 0.5 mg / ml; for example, about 0.1 mg / ml to about 0.25 mg / ml.

[0468] In other embodiments, the initial dose (e.g., priming dose) of the CD47 or SIRPα binding agent is administered by continuous fusion (e.g., as an osmotic pump, delivery patch, etc.), wherein the dose is administered over a period of at least about 6 hours, at least about 12 hours, at least about 24 hours, at least about 2 days, at least about 3 days. Many such systems are known in the art. For example, the DUROS technology provides a dual compartment system separated by a piston. One of the compartments includes an osmotic power system that is specifically formulated with an excess of solid NaCl so that it remains present throughout the delivery period and results in a constant osmotic gradient. The compartment also includes a semipermeable membrane at one end, through which water is drawn into the osmotic power system, and a large and constant osmotic gradient is established between tissue water and the osmotic power system. The other compartment includes a drug solution and a hole, from which the drug is released due to the osmotic gradient. This helps to provide site-specific and systemic drug delivery when implanted in the human body. The preferred implant site is subcutaneous placement on the inner side of the upper arm.

[0469] After the priming agent is administered and a period of time is allowed to pass that is effective in increasing reticulocyte production, a therapeutic dose of anti-CD47 or anti-SIRPα agent is administered. The therapeutic dose can be administered in a variety of different ways. In some embodiments, two or more therapeutically effective doses are administered after the priming agent is administered, for example, with a weekly dosing schedule. In some embodiments, a therapeutically effective dose of an anti-CD47 agent is administered as two or more increasing concentration doses, and in other cases the doses are equal. Hemagglutination is reduced after the priming dose.

[0470] The therapeutically effective dose of the anti-SIRPα antibody may depend on the specific agent used, but is generally about 10 mg or more, for example, about 30 mg, 50 mg, 100 mg, 200 mg, 400 mg or 800 mg or more. Multiple administrations of the anti-SIRPα antibody (e.g., without Fc effector function) can be performed over an extended period of time, for example, within 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, at regular intervals, for example, every 2 weeks (Q2W), every 3 weeks (Q3W), every 4 weeks (Q4W).

[0471] Regarding administration of VEGFA / VEGFR inhibitors (e.g., bevacizumab), in some embodiments, bevacizumab is administered at one or more doses within the range of 5 mg / kg to 15 mg / kg, e.g., 5 mg / kg to 7.5 mg / kg or 7.5 mg / kg to 15 mg / kg. In some embodiments, VEGFA / VEGFR inhibitors (e.g., bevacizumab) are administered at one or more doses of 5 mg / kg.

[0472] In some embodiments, mololimab is first administered at a priming dose of 1 mg / kg, then at one or more therapeutic doses of 30 mg / kg, and then at one or more therapeutic doses of 60 mg / kg. In some embodiments, mololimab is first administered at a priming dose of 1 mg / kg, then at one or more therapeutic doses of 20 mg / kg, and then at one or more therapeutic doses of 45 mg / kg. In some embodiments, mololimab is first administered at a priming dose of 1 mg / kg, then at one or more therapeutic doses of 15 mg / kg, and then at one or more therapeutic doses of 30 mg / kg.

[0473] In some embodiments, mololimab and bevacizumab are administered in the first, second, and third 28-day cycles, wherein:

[0474] a) For the first 28-day cycle, mololimab was administered at a dose of 1 mg / kg on day 1 and 30 mg / kg weekly (QW) starting on day 8; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15;

[0475] b) for the second 28-day cycle, mololimab at a dose of 30 mg / kg weekly (QW); and bevacizumab at a dose of 5 mg / kg on days 1 and 15; and

[0476] c) For the third 28-day cycle, mololimab was administered at a dose of 30 mg / kg Q2W; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15.

[0477] In some embodiments, mololimab and bevacizumab are administered in the first, second, and third 28-day cycles, wherein:

[0478] a) For the first 28-day cycle, mololimab was administered at a dose of 1 mg / kg on day 1 and 20 mg / kg weekly (QW) starting on day 8; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15;

[0479] b) for the second 28-day cycle, mololimab at a dose of 20 mg / kg weekly (QW); and bevacizumab at a dose of 5 mg / kg on days 1 and 15; and

[0480] c) For the third 28-day cycle, mololimab was administered at a dose of 20 mg / kg Q2W; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15.

[0481] In some embodiments, mololimab and bevacizumab are administered in the first, second, and third 28-day cycles, wherein:

[0482] a) For the first 28-day cycle, mololimab was administered at a dose of 1 mg / kg on day 1 and 15 mg / kg weekly (QW) starting on day 8; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15;

[0483] b) for the second 28-day cycle, mololimab at a dose of 15 mg / kg weekly (QW); and bevacizumab at a dose of 5 mg / kg on days 1 and 15; and

[0484] c) For the third 28-day cycle, mololimab was administered at a dose of 15 mg / kg Q2W; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15.

[0485] In some embodiments, an agent that inhibits the binding between CD47 and SIRPα is administered in a combined synergistic amount; and a VEGFA / VEGFR inhibitor. As used herein, a "synergistic amount of a combination" refers to the sum of a first amount (e.g., the amount of an agent that inhibits the binding between CD47 and SIRPα) and a second amount (e.g., the amount of a VEGFA / VEGFR inhibitor) that results in a synergistic effect (i.e., an effect greater than the additive effect). Therefore, the terms "synergy," "synergy," "synergy," "synergy," "synergistic amount of a combination," and "synergistic therapeutic effect" used interchangeably herein refer to the measured effect of a compound administered in combination, wherein the measured effect is greater than the sum of the individual effects of each compound administered separately as a single agent.

[0486] Co-administration of an agent that inhibits the binding between CD47 and SIRPα and a VEGFA / VEGFR inhibitor can allow for lower doses of one or both therapeutic agents. In embodiments, the synergistic amount can be about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the amount of the agent that inhibits the binding between CD47 and SIRPα when used separately from the VEGFA / VEGFR inhibitor. In embodiments, a synergistic amount may be about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the amount of a VEGFA / VEGFR inhibitor when used separately with an agent that inhibits binding between CD47 and SIRPα.

[0487] The dosage and frequency may vary depending on the half-life of the therapeutic agent in the patient. It will be understood by those skilled in the art that such guidelines will be adjusted for the molecular weight of the active agent in the following processes: for example, in the use of antibody fragments, in the use of antibody conjugates, in the use of SIRPα agents, in the use of soluble CD47 peptides, etc. The dosage may also vary for local administration (e.g., intranasal, inhalation, etc.), or for systemic administration (e.g., intramuscular (im), intraperitoneal (ip), intravenous (iv), subcutaneous (sc), intratumoral, intracranial, as appropriate). In some embodiments, an agent that inhibits the binding between CD47 and SIRPα; and a VEGFA / VEGFR inhibitor are administered simultaneously. In some embodiments, an agent that inhibits the binding between CD47 and SIRPα; and a VEGFA / VEGFR inhibitor are administered sequentially. For example, the agent that inhibits the binding between CD47 and SIRPα described herein may be administered within seconds, minutes, hours, or days of administering a VEGFA / VEGFR inhibitor. In some embodiments, a unit amount of an agent that inhibits the binding between CD47 and SIRPα is first administered, and then a unit amount of a VEGFA / VEGFR inhibitor is administered within seconds, minutes, hours, or days. Alternatively, a unit amount of a VEGFA / VEGFR inhibitor is first administered, and then a unit amount of an agent that inhibits the binding between CD47 and SIRPα is administered within seconds, minutes, hours, or days. In other embodiments, a unit amount of an agent that inhibits the binding between CD47 and SIRPα is first administered, and then a unit dose of a VEGFA / VEGFR inhibitor is administered after a period of several hours (e.g., 1 hour to 12 hours, 1 hour to 24 hours, 1 hour to 36 hours, 1 hour to 48 hours, 1 hour to 60 hours, 1 hour to 72 hours). In yet other embodiments, a unit dose of a VEGFA / VEGFR inhibitor is administered first, and then a unit dose of an agent that inhibits the binding between CD47 and SIRPα is administered after a period of several hours (e.g., 1 hour to 12 hours, 1 hour to 24 hours, 1 hour to 36 hours, 1 hour to 48 hours, 1 hour to 60 hours, 1 hour to 72 hours).

[0488] 6. Conditions for receiving treatment

[0489] The present invention provides a method for treating, ameliorating, alleviating, preventing or delaying the recurrence or metastasis of colorectal cancer (CRC) in a subject, the method comprising co-administering to the subject: (a) an agent that inhibits the binding between CD47 and SIRPα; and (b) a VEGFA / VEGFR inhibitor. In various embodiments, CRC is adenocarcinoma, a digestive tract carcinoid, a primary colorectal lymphoma, a squamous cell carcinoma, a gastrointestinal stromal tumor (GIST), a leiomyosarcoma or a melanoma. In some embodiments, CRC is a familial or hereditary colorectal cancer, such as hereditary non-polyposis colorectal cancer (HNPCC) or familial adenomatous polyposis (FAP). Other types of colorectal cancer that can be treated by the methods described herein include, for example, Turcot syndrome, Peutz-Jeghers syndrome (PJS), familial colorectal cancer (FCC), and juvenile colon polyposis. In some embodiments, the subject is a human.

[0490] As used herein, "treatment" is a method for obtaining beneficial or desired results (including clinical results). For example, beneficial or desired clinical results may include one or more of the following: (i) reducing one or more symptoms caused by the disease; (ii) reducing the extent of the disease, stabilizing the disease (e.g., preventing or delaying the worsening of the disease); (iii) preventing or delaying the spread of the disease (e.g., metastasis); (iv) preventing or delaying the occurrence or recurrence of the disease, delaying or slowing the progression of the disease; (v) improving the disease state, providing relief from the disease (whether partial or total relief), reducing the dose of one or more other drugs required to treat the disease; (vi) delaying the progression of the disease, improving the quality of life, and / or (vii) prolonging survival. Beneficial or desired clinical results may be observed in more patients or subjects who have received the methods or treatments described herein.

[0491] In various embodiments, the methods described herein relate to treating, ameliorating, alleviating, reducing, preventing or delaying colorectal cancer (CRC), such as metastatic CRC, such as inoperable CRC, such as recurrence or metastasis of CRC that has progressed after at least one prior therapy. In some embodiments, the cancer has progressed after at least one prior anti-cancer therapy. In some embodiments, the cancer has progressed after at least one prior anti-cancer therapy selected from: anti-VEGFA therapy (e.g., bevacizumab, aflibercept), a chemotherapy regimen comprising a platinum coordination complex (e.g., FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin); FOLFIRI (folinic acid, 5-fluorouracil, irinotecan); FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan); FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, oxaliplatin); XELIRI (capecitabine, irinotecan); XELOXIRI (capecitabine, oxaliplatin, irinotecan)), a platinum coordination complex therapy (e.g., cisplatin, oxaliplatin, and carboplatin), an immune checkpoint inhibitor therapy (e.g., anti-PD1 antibody therapy or anti-PD-L1 antibody therapy). In some embodiments, the CRC has progressed following treatment with one or more of the following therapeutic agents in the absence of mololimab: bevacizumab, capecitabine, cetuximab, fluorouracil, irinotecan, leucovorin, oxaliplatin, panitumumab, ziv-aflibercept, and any combination thereof. In some embodiments, the therapeutic agent used to treat CRC includes bevacizumab (AVASTIN ® ), leucovorin, 5-FU, oxaliplatin (FOLFOX), pembrolizumab (KEYTRUDA ® ), FOLFIRI, regorafenib (STIVARGA ® ), Aflibercept (ZALTRAP ® ), Cetuximab (ERBITUX ® )、Lonsurf(ORCANTAS ®), XELOX, FOLFOXIRI, or a combination thereof. In some embodiments, therapeutic agents for treating CRC include bevacizumab + leucovorin + 5-FU + oxaliplatin (FOLFOX), bevacizumab + FOLFIRI, bevacizumab + FOLFOX, aflibercept + FOLFIRI, cetuximab + FOLFIRI, bevacizumab + XELOX, and bevacizumab + FOLFOXIRI. In some embodiments, therapeutic agents for treating CRC include bimetinib + encorafenib + cetuximab, trametinib + dabrafenib + panitumumab, trastuzumab + pertuzumab, nabucasin + FOLFIRI + bevacizumab, nivolumab + ipilimumab.

[0492] In various embodiments, CRC is classified as stage I, i.e., according to the TNM classification system. In various embodiments, CRC is classified as stage II (e.g., IIA, IIB, or IIC), i.e., according to the TNM classification system. In various embodiments, CRC is classified as stage III (e.g., IIIA, IIIB, or IIIC), i.e., according to the TNM classification system. In various embodiments, CRC is classified as stage IV (e.g., IVA, IVB, or IVC), i.e., according to the TNM classification system. See Delattre et al., Cancer Treat Rev. (2022) Feb;103:102325.

[0493] In some embodiments, the subject is treatment naive, ie, the combined administration of an agent that inhibits binding between CD47 and SIRPα (eg, mololimab) and a VEGFA / VEGFR inhibitor (eg, bevacizumab) is a first-line cancer therapy.

[0494] "Prevention" means any treatment (i.e., drug, medication, therapy) of a disease or condition (i.e., cancer) such that clinical symptoms of the disease or condition do not develop. In some embodiments, the compounds may be administered to subjects (including humans) who are at risk or have a family history of the disease or condition.

[0495] "Delaying" the development of cancer means postponing, hindering, slowing down, slowing down, stabilizing and / or delaying the development of the disease. Delays can have different lengths of time, depending on the history of the disease and / or the subject being treated. It is obvious to those skilled in the art that sufficient or significant delays can actually cover prevention because the individual does not develop the disease. A method of "delaying" the development of cancer is a method that reduces the likelihood of disease development within a given time frame and / or reduces the extent of the disease within a given time frame (compared to not using the method). Such comparisons are generally based on clinical studies using statistically significant numbers of subjects. Disease development can be detected using standard methods (such as routine physical examination, blood draw, mammography, imaging or biopsy). Development can also refer to disease progression that may not be detected initially, and includes occurrence, recurrence and onset.

[0496] The term "amelioration" refers to any therapeutically beneficial outcome of treating a disease state (eg, a cancer disease state), including prevention, lessening of its severity or progression, remission, or cure.

[0497] 7. Test kit

[0498] Also described herein are kits comprising one or more unit doses of active agents, such as agents that inhibit the binding between CD47 and SIRPα (e.g., mololimab) and VEGFA / VEGFR inhibitors (e.g., bevacizumab) as described herein and formulations thereof, and instructions for use. In various embodiments, the agent that inhibits the binding between CD47 and SIRPα and the VEGFA / VEGFR inhibitor may be in the same or different containers. The kit may also contain at least one additional agent, such as an agent for a chemotherapy regimen (e.g., FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin); FOLFIRI (folinic acid, 5-fluorouracil, irinotecan); FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan); FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, oxaliplatin); XELIRI (capecitabine, irinotecan); XELOXIRI (capecitabine, oxaliplatin, irinotecan)), an immune checkpoint inhibitor. The kit typically includes a label indicating the intended use of the contents of the kit. The term "label" includes any written or recorded material provided on or with the kit, or otherwise accompanying the kit.

[0499] In some embodiments, one or both of the agent that inhibits the binding between CD47 and SIRPα (e.g., mololimab) and the VEGFA / VEGFR inhibitor (e.g., bevacizumab) are provided in a dosage form (e.g., a therapeutically effective dosage form). In some embodiments, one or both of the agent that inhibits the binding between CD47 and SIRPα (e.g., mololimab) and the VEGFA / VEGFR inhibitor (e.g., bevacizumab) are provided in two or more different dosage forms (e.g., two or more different therapeutically effective dosage forms). In the context of a kit, one or both of the agent that inhibits the binding between CD47 and SIRPα (e.g., mololimab) and the VEGFA / VEGFR inhibitor (e.g., bevacizumab) can be provided in a liquid or in any convenient packaging (e.g., stick pack, pharmaceutical pack, etc.) for sale.

[0500] An agent that inhibits the binding between CD47 and SIRPα (e.g., mololimab) and a VEGFA / VEGFR inhibitor (e.g., bevacizumab) may be provided in the same or separate containers, as appropriate. In different embodiments, an agent that inhibits the binding between CD47 and SIRPα (e.g., mololimab) and a VEGFA / VEGFR inhibitor (e.g., bevacizumab) are provided in separate containers. A composition comprising one or both of an agent that inhibits the binding between CD47 and SIRPα (e.g., mololimab) and a VEGFA / VEGFR inhibitor (e.g., bevacizumab) is provided in one or more containers, the container having a label. Suitable containers include, for example, bottles, vials, ampoules, syringes (including preloaded syringes) and test tubes. The container may be formed of a variety of materials, such as glass or plastic. The container holds a composition that is effective in treating a condition and may have a sterile access port (e.g., the container may be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle). The active agent in one composition is an agent that inhibits the binding between CD47 and SIRPα (e.g., an anti-CD47 antibody, such as mololimab). The active agent in the second composition is a VEGFA / VEGFR inhibitor (e.g., bevacizumab). A label on or associated with the container indicates that the composition is used to treat a selected condition. The article of manufacture may also include one or more containers containing a pharmaceutically acceptable buffer, such as for use as a diluent. Exemplary buffers include, but are not limited to, phosphate-buffered saline, Ringer's solution, and / or dextrose solution. The kit may also include other materials desired from a commercial and user perspective, including other buffers, diluents, filters, needles, syringes, and a package insert with instructions for use.

[0501] In various embodiments, the kits of the invention include a primer agent (e.g., an erythropoiesis stimulating agent (ESA)) and an anti-CD47 agent. In some embodiments, the kit includes two or more primer agents. In some embodiments, the kit includes two or more anti-CD47 agents. In some embodiments, the priming agent is provided in a dosage form (e.g., a priming dosage form). In some embodiments, the priming agent is provided in two or more different dosage forms (e.g., two or more different priming dosage forms).

[0502] In addition to the above-mentioned components, the subject test kit can also include (in certain embodiments) instructions for implementing the subject method. These instructions can be present in the subject test kit in various forms, one or more of which can be present in this test kit. A form in which these instructions can exist is as the following printed information: printed information on suitable medium or substrate (for example, one or more sheets of paper on which this information is printed), printed information in the packaging material of test kit, printed information in package instructions etc. Another form of these instructions is the computer-readable medium on which this information has been recorded, for example, disk, CD (CD), flash drive etc. Another form in which these instructions can exist is the website address that can be used to access the information at the remote site via the Internet.

[0503] Example

[0504] The following examples are provided to illustrate but not to limit the claimed invention.

[0505] Example 1

[0506] A phase 2, randomized, open-label study evaluating the safety and efficacy of mololimab in combination with bevacizumab and FOLFIRI versus bevacizumab and FOLFIRI in previously treated advanced inoperable metastatic colorectal cancer (mCRC)

[0507] Goals and End Points

[0508] Table 1 presents the study objectives and end points.

[0509] Table 1. Study objectives and endpoints

[0510]

[0511]

[0512] Study Design

[0513] A schematic diagram of this study is provided in Figure 1 middle.

[0514] This is a phase 2, randomized, open-label, multicenter study to evaluate morolimab in combination with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable mCRC who have progressed after one prior systemic therapy and do not have a BRAF V600E mutation or high microsatellite instability (MSI-H).

[0515] This study will involve the following 2 groups:

[0516] Safety trial cohort: Morolimab in combination with bevacizumab and FOLFIRI in previously treated patients with advanced inoperable mCRC.

[0517] After completion of the safety trial cohort, the randomized cohort will be open for recruitment.

[0518] Randomization cohort: Morolimab in combination with bevacizumab and FOLFIRI (experimental arm A) versus bevacizumab and FOLFIRI alone (control arm B) in previously treated patients with advanced inoperable mCRC.

[0519] Safety test group :

[0520] Initially, 6 patients will be enrolled in the safety trial cohort at the starting dose level. A 28-day DLT assessment period will be conducted.

[0521] Even if no dose-dependent toxicity is observed with mololimab, in order to maintain the effective dose of the combination partner drug, dose reductions will occur for mololimab as follows:

[0522] If 2 or fewer of the 6 DLT-evaluable patients experience a DLT during the first 28 days, enrollment into the randomized cohort will begin at this dose level as the RP2D.

[0523] If more than 2 patients experience at least one DLT during the first 28-day cycle, enrollment at the current dose level will be stopped immediately and dose reduction will occur. Up to 6 additional patients will then be enrolled and evaluated in the same manner at the lower dose level.

[0524] ●Once the RP2D is determined, the sponsor will open the randomization group.

[0525] Approximately 6 patients will be enrolled in the safety trial cohort. Additional patients may be added to the safety trial cohort or to the dose reduction cohort.

[0526] Dose-Limiting Toxicity (DLT) Evaluation Period for Safety Trial Cohorts: The DLT Evaluation Period will be the first 28 days and will apply to the Safety Trial Cohort. Patients will be considered evaluable for DLT if any of the following criteria are met during the DLT Evaluation Period:

[0527] ●The patient experienced a DLT at any time after starting the first infusion of mololimab.

[0528] ●Patients did not experience a DLT and completed at least 3 infusions of mololimab and at least 2 doses of bevacizumab and FOLFIRI in the safety trial cohort.

[0529] If a patient experiences a DLT during the DLT evaluation period, the patient will discontinue treatment. Patients who are not evaluable for DLT evaluation in the safety trial cohort will be replaced.

[0530] Randomization Cohort: Once the safety trial cohort is completed and the RP2D of mololimab in combination with bevacizumab and FOLFIRI is determined, the sponsor will open the randomization cohort. In this open-label, randomized, 2-arm study, patients with mCRC will be randomized in a 2:1 ratio to receive mololimab in combination with bevacizumab and FOLFIRI (experimental arm A) and bevacizumab and FOLFIRI (control arm B). The primary efficacy assessment will be investigator-assessed PFS, and the primary analysis will be performed after 85 PFS events. Stratification factors for randomization include the following: (1) Kirsten rat sarcoma (KRAS) mutation versus wild-type status, (2) geographic region (United States [US] versus European Union [EU] / rest of the world [ROW]), and (3) presence versus absence of liver metastases.

[0531] Duration of treatment

[0532] All patients will continue study treatment unless they meet study treatment discontinuation criteria. Survival follow-up will be conducted by telephone every 2 months until death or end of study. The duration of survival follow-up will be limited to 3 years.

[0533] Target Group

[0534] Prior treatment of patients with advanced inoperable mCRC who have progressed after 1 prior systemic therapy and do not have a BRAF V600E mutation or MSI-H. Patients with mismatch repair deficiency will be excluded. However, patients may be included regardless of KRAS mutation status. The mololimab mechanism of action is thought to support development in both KRAS wild-type and mutant backgrounds. Data from the 5F9004 study (ie, NCT02953782) did not identify a subpopulation that would specifically benefit from mololimab. KRAS-mutated CRCs are present in 45% of patients, indicate a poor prognosis, and are challenging to target.

[0535] Diagnosis and major eligibility criteria :

[0536] Inclusion criteria

[0537] All patients must meet all of the following inclusion criteria to be eligible for participation in this study:

[0538] 1) The patient has provided informed consent.

[0539] 2) The patient is willing and able to comply with the clinical visits and procedures outlined in the study protocol.

[0540] 3) Male or female, at least 18 years old.

[0541] 4) Prior treatment patients with inoperable mCRC who have progressed on or after 1 prior systemic therapy and are not eligible for checkpoint inhibitor therapy (patients eligible for checkpoint inhibitor therapy are defined as MSI-H or mismatch repair deficiency [dMMR] and are excluded). Note: Maintenance therapy is not counted as a separate line of treatment.

[0542] 5) At least 3 weeks of chemotherapy-free and bevacizumab (if applicable) interval.

[0543] 6) Histologically or cytologically confirmed adenocarcinoma originating from the colon or rectum (excluding appendix and anal canal cancer) that has progressed on or after 1 prior systemic therapy without indication for curative resection. This therapy must include 5-fluorouracil (5-FU)-based chemotherapy with oxaliplatin and bevacizumab, or for patients with RAS wild-type and left-sided tumors, bevacizumab or cetuximab or panitumumab.

[0544] 7) Measurable disease (at least 1 measurable metastatic lesion according to RECIST v1.1 criteria, the lesion is not located in the previously irradiated area). Previous radiation damage can only be considered as measurable disease if disease progression in that site after radiation is clearly documented.

[0545] 8) Patients must have an ECOG performance status of 0 or 1.

[0546] 9) Life expectancy of at least 12 weeks.

[0547] 10) Laboratory measurements, blood cell count:

[0548] a. Prior to the initial dose of study treatment, hemoglobin (Hb) must be ≥9 g / dL. Note: Blood transfusions are allowed to meet Hb eligibility.

[0549] b. Absolute neutrophil count of at least 1.5 × 10 9 / L

[0550] c. Platelet count at least 100×10 9 / L

[0551] 11) Adequate liver function, as demonstrated by:

[0552] a. AST less than or equal to 2.5×ULN or less than or equal to 5×ULN in patients with liver metastases

[0553] b. ALT less than or equal to 2.5×ULN or less than or equal to 5×ULN in patients with liver metastases

[0554] c. Bilirubin less than or equal to 1.5×ULN or less than or equal to 3.0×ULN and predominantly unconjugated bilirubin if the patient has a documented history of Gilbert's syndrome or genetic equivalent.

[0555] 12) Patients must have adequate renal function as demonstrated by a creatinine clearance of at least 30 mL / min; calculated by the Cockcroft Gault formula.

[0556] 13) Pre-treatment blood cross-matching is completed.

[0557] 14) Male and female patients of reproductive potential who engage in heterosexual intercourse must agree to use the contraceptive method specified in the protocol.

[0558] Exclusion criteria

[0559] Patients who met any of the following exclusion criteria were not included in this study:

[0560] 1) Prior anticancer therapy (including chemotherapy, hormone therapy, or administration of study agent) within 3 weeks or at least 4 half-lives (up to a maximum of 4 weeks) before administration of mololimab, whichever is shorter.

[0561] 2) Known BRAF V600E or MSI-H mutation or dMMR.

[0562] 3) Persistent grade 2 or higher gastrointestinal bleeding.

[0563] 4) Patients who received a dose-reduction regimen (e.g., LV / 5-FU with bevacizumab, followed by FOLFOX or FOLFIRI with bevacizumab) and / or were intolerant to bevacizumab.

[0564] 5) Patients who received previous irinotecan therapy.

[0565] 6) Colorectal cancer patients who have not received prior bevacizumab therapy.

[0566] 7) Patients with known allergy or hypersensitivity to monoclonal antibodies (bevacizumab, mololimab) or Chinese hamster ovary cell products or any other humanized or recombinant antibodies or any other chemotherapy under study and their excipients.

[0567] 8) Clinically significant coronary artery disease or myocardial infarction within 6 months prior to inclusion.

[0568] 9) Peripheral neuropathy greater than grade 1 (CTCAE version 5.0).

[0569] 10) Known dihydropyrimidine dehydrogenase deficiency.

[0570] 11) History of acute intestinal obstruction or sub-obstruction, inflammatory bowel disease, or extended small bowel resection. Presence of colon prosthesis.

[0571] 12) Unhealed wounds, active gastric or duodenal ulcers, or fractures.

[0572] 13) History of abdominal fistula, tracheoesophageal fistula, any other grade 4 gastrointestinal perforation, non-gastrointestinal fistula, or intra-abdominal abscess within 6 months prior to screening.

[0573] 14) Uncontrolled arterial hypertension (systolic blood pressure >150 mm Hg and / or diastolic blood pressure >100 mm Hg) with and without antihypertensive medication.

[0574] 15) History of hypertensive crisis or hypertensive encephalopathy.

[0575] 16) Thromboembolic events (e.g., transient ischemic stroke, stroke, subarachnoid hemorrhage) within 6 months before study inclusion, except for peripheral deep vein thrombosis treated with anticoagulants.

[0576] 17) Positive serum pregnancy test.

[0577] 18) Breastfeeding women.

[0578] 19) Active central nervous system (CNS) disease. Patients with asymptomatic and stable, treated CNS damage (radiation and / or surgery and / or other CNS-directed therapies who have not received corticosteroids for at least 4 weeks) are allowed.

[0579] 20) RBC transfusion dependence, defined as the need for more than 2 units of concentrated RBC transfusions during the 4-week period prior to screening. RBC transfusions were allowed during the screening period and prior to recruitment to meet the Hb inclusion criteria

[0580] 21) History of hemolytic anemia, autoimmune thrombocytopenia or Evans syndrome in the past 3 months.

[0581] 22) Known hypersensitivity to any study drug, metabolite, or formulation excipient.

[0582] 23) Prior treatment with CD47 or signal regulatory protein α targeting agents.

[0583] 24) Currently participating in another interventional clinical study.

[0584] 25) Known inherited or acquired bleeding disorder.

[0585] 26) Major illness or medical condition that, as assessed by the investigator and sponsor, would significantly increase the risk-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the past 6 months, unstable angina, uncontrolled diabetes, significant active infection, and New York Heart Association Class III-IV congestive heart failure.

[0586] 27) Second malignancies, except for treated basal cell or localized squamous cell skin cancer, localized prostate cancer, or other malignancies, for whom no active anticancer treatment has been given and complete remission has been achieved for more than 2 years.

[0587] 28) History of known active or chronic hepatitis B or C infection, or HIV infection

[0588] 29) Uncontrolled pleural effusion.

[0589] 30) Uncontrolled hypercalcemia (ionized calcium >1.5mmol / L) or symptomatic hypercalcemia requiring continued bisphosphonate treatment.

[0590] 31) Uncontrolled tumor-related pain.

[0591] 32) Severe / serious systemic infection within 4 weeks of randomization.

[0592] Note: Local non-CNS radiotherapy, prior hormonal therapy for breast cancer with luteinizing hormone-releasing hormone agonists, and treatment with bisphosphonates and receptor activator of nuclear factor κB ligand (RANKL) inhibitors are not exclusion criteria. There is no minimum washout period required for these therapies. Patients should have recovered from the effects of radiation.

[0593] FOLFIRI as a chemotherapy backbone

[0594] The decision to incorporate FOLFIRI was based on biology / MOA, treatment prospects, and standard of care (SOC) for advanced colorectal cancer. FOLFIRI is the preferred chemotherapy backbone in second-line mCRC in the United States and is interchangeable with FOLFOX in the European Union (EU). Fluorouracil, a fluoropyrimidine, is reported to alleviate immunosuppression by reducing myeloid-derived immunosuppressive cells, such as myeloid-derived suppressor cells. Irinotecan has also been shown to upregulate the expression of immunogenic cell death markers and promote phagocytosis of tumor cells by phagocytes (Pozzi et al., Nat Med (2016) 22 (6): 624-31).

[0595] The data presented here are consistent with the conclusion that irinotecan is more effective than oxaliplatin in increasing cell surface expression of prophagocytic receptors and promoting phagocytosis of colorectal cancer cells, regardless of their mutational profile (Figure 2). CRC cells treated with irinotecan were also more likely to experience growth inhibition ( Figure 3 In immunocompromised mice bearing subcutaneous HT-29 tumors, the combination of mololimab and irinotecan provided superior tumor growth control compared with mololimab and oxaliplatin alone ( Figure 4 ). These findings support the use of FOLFIRI as a chemotherapeutic backbone for mololimab.

[0596] Dosing and administration

[0597] The mololimab dosing schedules for the safety trial and randomized cohorts are presented in Tables 2 and 3 .

[0598]

[0599]

[0600] It should be understood that the embodiments and implementations described herein are for illustrative purposes only, and those skilled in the art will propose various modifications or changes based on these embodiments and implementations, and include these modifications or changes within the spirit and authority of this application and the scope of the appended claims. All publications, patents and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

Claims

1. A method of treating previously treated advanced inoperable metastatic colorectal cancer in a subject, the method comprising co-administering to the subject an effective amount of: a) an agent that inhibits the binding between CD47 and SIRPα; and b) An agent that inhibits the binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA cognate receptors.

2. The method of claim 1, wherein the one or more VEGFA cognate receptors are selected from fms-related receptor tyrosine kinase 1 (FLT1, also known as VEGFR1) and kinase insert domain receptor (KDR, also known as VEGFR2).

3. The method of any one of claims 1 to 2, further comprising co-administering a chemotherapy regimen.

4. The method according to claim 3, comprising co-administering the FOLFOX regimen, the FOLFIRI regimen, the XELIRI (also known as CAPIRI) regimen, the FOLFOXIRI regimen, the XELOXIRI regimen, or the FOLFIRINOX regimen.

5. The method according to any one of claims 3 to 4, comprising co-administering the FOLFIRI regimen or the XELIRI regimen.

6. The method of any one of claims 1 to 5, wherein the cancer has CD47 cell surface expression.

7. The method of any one of claims 1 to 6, wherein the cancer does not comprise a BRAF V600E mutation.

8. The method of any one of claims 1 to 7, wherein the cancer does not comprise high microsatellite instability.

9. The method of any one of claims 1 to 8, wherein the cancer has one or more KRAS mutations and the subject is unresponsive to anti-EGFR antibody therapy.

10. The method of any one of claims 1 to 9, wherein the cancer is an adenocarcinoma originating from the colon or rectum.

11. The method of any one of claims 1 to 10, wherein the cancer has progressed following one or more prior systemic therapies.

12. The method of claim 11, wherein the one or more prior therapies comprise administration of one or more agents selected from the group consisting of 5-fluorouracil (5-FU), oxaliplatin, bevacizumab, cetuximab, and panitumumab.

13. The method of any one of claims 1 to 12, wherein the treatment results in a reduction in overall tumor burden of at least 15%, at least 20%, at least 30%, or at least 40% as determined using a linear dimensional method (e.g., RECIST v1.1).

14. A method according to any one of claims 1 to 13, comprising reducing the size or eliminating transfers. 15 . The method according to any one of claims 1 to 14 , wherein the agent that inhibits the binding between CD47 and SIRPα comprises an antibody that binds to CD47.

16. The method of claim 15, wherein the antibody that binds to CD47 is selected from mololimab, leszolimab, leterlimab, lefalimab, AO-176, sirelimab (IBI-322), gentolizumab, ZL-1201, IMC-002, SRF-231, CC-90002 (also known as INBRX-103), NI-1701 (also known as TG-1801), and STI-6643. 17 . The method according to any one of claims 1 to 14 , wherein the agent that inhibits the binding between CD47 and SIRPα comprises an antibody that binds to SIRPα.

18. The method of claim 15, wherein the antibody that binds to SIRPα is selected from GS-0189 (also known as FSI-189), CC-95251, BI-765063, and APX-700. 19 . The method according to any one of claims 1 to 14 , wherein the agent that inhibits the binding between CD47 and SIRPα comprises a SIRPα-Fc fusion protein.

20. The method according to claim 19, wherein the SIRPα-Fc fusion protein is selected from the group consisting of ivolipide (ALX-148), tedapeptide, TTI-621, TTI-622, JMT601 (CPO107) and SL-172154.

21. The method of any one of claims 1 to 20, wherein the agent that inhibits binding between VEGFA and one or more VEGFA cognate receptors comprises an antibody that binds to VEGFA.

22. The method of claim 21, wherein the antibody that binds to VEGFA is selected from bevacizumab, ranibizumab, brucelluzumab, evocizumab, suvicitumab, and faricitumab.

23. The method of any one of claims 1 to 20, wherein the agent that inhibits binding between VEGFA and one or more VEGFA cognate receptors comprises an antibody that binds to VEGFR2.

24. The method of claim 23, wherein the antibody that binds to VEGFR2 is ramucirumab.

25. The method of any one of claims 1 to 20, wherein the agent that inhibits binding between VEGFA and one or more VEGFA cognate receptors comprises a VEGFA-Fc fusion protein.

26. The method of claim 25, wherein the VEGFA-Fc fusion protein is selected from Conbercept and Aflibercept.

27. The method of any one of claims 1 to 20, wherein the agent that inhibits binding between VEGFA and one or more VEGFA cognate receptors comprises a small molecule inhibitor.

28. The method of claim 27, wherein the small molecule is selected from surufatinib, anlotinib hydrochloride, fruquintinib, tivozanib, regorafenib, axitinib, vandetanib, sioronib, pazopanib hydrochloride, sunitinib malate, and pegaptanib sodium.

29. The method of any one of claims 1 to 28, further comprising administering one or more therapeutic antibodies.

30. The method of any one of claims 1 to 29, further comprising co-administering an antibody that binds to epidermal growth factor receptor (EGFR).

31. The method of claim 30, wherein the antibody that binds to EGFR is selected from cetuximab and panitumumab.

32. The method of any one of claims 1 to 31, further comprising co-administering one or more blockers or inhibitors of one or more T cell stimulatory immune checkpoint proteins or receptors.

33. The method of claim 32, wherein the one or more immune checkpoint inhibitors comprise a protein (eg, antibody) inhibitor of PD-L1 (CD274), PD-1 (PDCD1), or CTLA4.

34. The method of any one of claims 32 to 33, wherein the one or more immune checkpoint proteins or receptors are selected from: CD274 (CD274, PDL1, PD-L1) and programmed cell death 1 (PDCD1, PD1, PD-1).

35. The method of claim 33, wherein the protein (e.g., antibody) inhibitor of CTLA4 is selected from ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884 (zeflimab), BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-11 55. KN-044, CG-0161, ATOR-1144, PBI-5D3H5, FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4) and AK-104 (CTLA4 / PD-1).

36. The method of any one of claims 32 to 34, wherein the protein (e.g., antibody) inhibitor of programmed cell death 1 (PDCD1; NCBI gene ID: 5133; CD279, PD-1, PD1) is selected from the group consisting of sepalizumab (AB122, GLS-010, WBP-3055), pembrolizumab (KEYTRUDA®, MK-3475, SCH900475), nivolumab (OPDIVO®, BM S-936558, MDX-1106), cemiprilimab (LIBTAYO®; cemiprilimab-rwlc, REGN-2810), pidilizumab (CT-011), AMG-404, MEDI0680 (AMP-514), spartalizumab (PDR001), tislelizumab (BGB-A317), toripalizumab (JS-001), genoluzumab (CBT-501, APL-501, GB 226), SHR-1201, carrelizumab (SHR-1210), sintilimab (TYVYT®; IBI-308), dotalimumab (TSR-042, WBP-285), lanrolizumab (MK-3475); saxanthlimab (PF-06801591), silimab (JNJ-63723283), slulizumab (HLX-10), rivolimab (MGA-012), bastimumab (AGEN2034), palolizumab (BCD 100), brigatinib (ABBV-181), woprelizumab (JTX-4014), AK-103 (HX-008), AK-105, CS-1003, BI-754091, LZM-009, Sym-021, BAT-1306, PD1-PIK, tepolizumab (MGD013; PD-1 / LAG-3), RO-7247669 (PD-1 / LAG-3), FS-118 (LAG-3 / PD -L1), RO-7121661 (PD-1 / TIM-3), RG7769 (PD-1 / TIM-3), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTL A4), KN-046 (PD-1 / CTLA4), XmAb-20717 (PD-1 / CTLA4), AK-104 (CTLA4 / PD-1) and MEDI-5752 (CTLA4 / PD-1).

37. The method according to any one of claims 32 to 34, wherein the protein (e.g., antibody) inhibitor of the CD274 molecule (NCBI gene ID: gene ID: 29126; B7-H, B7H1, PD-L1) is selected from atezolizumab (TECENTRIQ®), avelumab (BAVENCIO®; MSB0010718C), envolimab (ASC22), durvalumab (IMFINZI®; MEDI-4736), BMS-936559 (MDX1105), coxilimab (CK-301), lodalimab (LY 3300054), galivizumab (BGB A333), envolimab (KN035), oclimab (HLX 20), Manelimab (BCD135), CX-072, CBT-502 (TQB2450), MSB-2311, SHR-1316, Sugelimumab (CS-1001; WBP3155), A167 (KL-A167, HBM 9167), STI-A1015 (IMC-001), FAZ-053, BMS-936559 (MDX1105), INCB086550, GEN-1046 (PD-L1 / 4-1BB), FPT-155 (CTLA4 / PD-L1 / CD28), M7824 (PD-L1 / TGFβ-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM-3 / PDL1), INBRX-105 (4-1BB / PDL1), and GNS-1480 (PD-L1 / EGFR).

38. The method of any one of claims 1 to 37, further comprising co-administering an agonist of fms-related receptor tyrosine kinase 3 (FLT3).

39. The method of claim 38, wherein the agonist of FLT3 is selected from GS-3583 and CDX-301.

40. The method of any one of claims 1 to 39, wherein the agent that inhibits binding between CD47 and SIRPα and the agent that inhibits binding between VEGFA and one or more VEGFA cognate receptors are administered in a combined synergistic amount.

41. The method of any one of claims 1 to 40, wherein administration of the agent that inhibits binding between CD47 and SIRPα and the agent that inhibits binding between VEGFA and one or more VEGFA cognate receptors provides a synergistic effect.

42. The method of claim 41, wherein the synergistic effect is increased cancer cell death and / or decreased cancer cell growth when the effect of the combination is compared to the effect of either the agent that inhibits binding between CD47 and SIRPα or the agent that inhibits binding between VEGFA and one or more VEGFA cognate receptors alone.

43. The method of claim 41, wherein the synergistic effect is increased phagocytosis of cancer cells by macrophages when the effect of the combination is compared to the effect of either the agent that inhibits binding between CD47 and SIRPα or the agent that inhibits binding between VEGFA and one or more VEGFA cognate receptors alone.

44. The method of claim 41, wherein the synergistic effect is an increase or enhancement in tumor burden reduction when the effect of the combination is compared to the effect of either the agent that inhibits binding between CD47 and SIRPα or the agent that inhibits binding between VEGFA and one or more VEGFA cognate receptors alone.

45. The method of any one of claims 1 to 44, wherein the subject is a human.

46. ​​A method for treating, alleviating, reducing, preventing or delaying the recurrence or metastasis of colorectal cancer in a subject, the method comprising co-administering to the subject an effective amount of mololimab and bevacizumab.

47. The method of claim 46, wherein the cancer is (i) unresectable, locally advanced, or (ii) metastatic.

48. The method of any one of claims 46 to 47, wherein the cancer is unresectable, locally advanced and the subject is treatment naive.

49. A method of treating previously treated advanced inoperable metastatic colorectal cancer in a subject, the method comprising co-administering to the subject an effective amount of: a) Mololimab; and b) Bevacizumab.

50. The method of any one of claims 46 to 49, further comprising co-administering a chemotherapy regimen.

51. The method of any one of claims 46 to 50, comprising co-administering a FOLFOX regimen, a FOLFIRI regimen, a XELIRI (also known as CAPIRI) regimen, a FOLFOXIRI regimen, a XELOXIRI regimen, or a FOLFIRINOX regimen.

52. The method of any one of claims 46 to 51, comprising co-administering a FOLFIRI regimen or a XELIRI regimen.

53. The method of any one of claims 46 to 52, wherein the cancer has CD47 cell surface expression.

54. The method of any one of claims 46 to 53, wherein the cancer does not comprise a BRAF V600E mutation.

55. The method of any one of claims 46 to 54, wherein the cancer does not comprise high microsatellite instability.

56. The method of any one of claims 46 to 55, wherein the cancer has one or more KRAS mutations and the subject is unresponsive to anti-EGFR antibody therapy.

57. The method of any one of claims 46 to 56, wherein the cancer is an adenocarcinoma originating from the colon or rectum.

58. The method of any one of claims 46 to 57, wherein the cancer has progressed following one or more prior systemic therapies.

59. The method of claim 58, wherein the one or more prior therapies comprise administration of one or more agents selected from the group consisting of 5-fluorouracil (5-FU), oxaliplatin, bevacizumab, cetuximab, and panitumumab.

60. The method of any one of claims 46 to 59, wherein the treatment results in a reduction in overall tumor burden of at least 15%, at least 20%, at least 30%, or at least 40% as determined using a linear dimensional method (e.g., RECIST v1.1).

61. A method according to any one of claims 47 to 60 comprising reducing the size or eliminating metastases.

62. The method of any one of claims 46 to 61, further comprising administering one or more therapeutic antibodies.

63. The method of any one of claims 46 to 62, further comprising co-administering an antibody that binds to epidermal growth factor receptor (EGFR).

64. The method of claim 63, wherein the antibody that binds to EGFR is selected from cetuximab and panitumumab.

65. The method of any one of claims 46 to 64, further comprising co-administering one or more blockers or inhibitors of one or more T cell stimulatory immune checkpoint proteins or receptors.

66. The method of claim 65, wherein the one or more immune checkpoint inhibitors comprise a protein (eg, antibody) inhibitor of PD-L1 (CD274), PD-1 (PDCD1), or CTLA4.

67. The method of any one of claims 65 to 66, wherein the one or more immune checkpoint proteins or receptors are selected from: CD274 (CD274, PDL1, PD-L1) and programmed cell death 1 (PDCD1, PD1, PD-1).

68. The method of claim 66, wherein the protein (e.g., antibody) inhibitor of CTLA4 is selected from ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884 (zeflimab), BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-11 55. KN-044, CG-0161, ATOR-1144, PBI-5D3H5, FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4) and AK-104 (CTLA4 / PD-1).

69. The method of any one of claims 65 to 67, wherein the protein (e.g., antibody) inhibitor of programmed cell death 1 (PDCD1; NCBI gene ID: 5133; CD279, PD-1, PD1) is selected from the group consisting of sepalizumab (AB122, GLS-010, WBP-3055), pembrolizumab (KEYTRUDA®, MK-3475, SCH900475), nivolumab (OPDIVO®, BM S-936558, MDX-1106), cemiprilimab (LIBTAYO®; cemiprilimab-rwlc, REGN-2810), pidilizumab (CT-011), AMG-404, MEDI0680 (AMP-514), spartalizumab (PDR001), tislelizumab (BGB-A317), toripalizumab (JS-001), genoluzumab (CBT-501, APL-501, GB 226), SHR-1201, carrelizumab (SHR-1210), sintilimab (TYVYT®; IBI-308), dotalimumab (TSR-042, WBP-285), lanrolizumab (MK-3475); saxanthlimab (PF-06801591), silimab (JNJ-63723283), slulizumab (HLX-10), rivolimab (MGA-012), bastimumab (AGEN2034), palolizumab (BCD 100), brigatinib (ABBV-181), woprelizumab (JTX-4014), AK-103 (HX-008), AK-105, CS-1003, BI-754091, LZM-009, Sym-021, BAT-1306, PD1-PIK, tepolizumab (MGD013; PD-1 / LAG-3), RO-7247669 (PD-1 / LAG-3), FS-118 (LAG-3 / PD -L1), RO-7121661 (PD-1 / TIM-3), RG7769 (PD-1 / TIM-3), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTL A4), KN-046 (PD-1 / CTLA4), XmAb-20717 (PD-1 / CTLA4), AK-104 (CTLA4 / PD-1) and MEDI-5752 (CTLA4 / PD-1).

70. The method according to any one of claims 65 to 67, wherein the protein (e.g., antibody) inhibitor of the CD274 molecule (NCBI Gene ID: Gene ID: 29126; B7-H, B7H1, PD-L1) is selected from atezolizumab (TECENTRIQ®), avelumab (BAVENCIO®; MSB0010718C), envolimab (ASC22), durvalumab (IMFINZI®; MEDI-4736), BMS-936559 (MDX1105), coxilimab (CK-301), lodalimab (LY 3300054), galivizumab (BGB A333), envolimab (KN035), oclimab (HLX 20), Manelimab (BCD135), CX-072, CBT-502 (TQB2450), MSB-2311, SHR-1316, Sugelimumab (CS-1001; WBP3155), A167 (KL-A167, HBM 9167), STI-A1015 (IMC-001), FAZ-053, BMS-936559 (MDX1105), INCB086550, GEN-1046 (PD-L1 / 4-1BB), FPT-155 (CTLA4 / PD-L1 / CD28), M7824 (PD-L1 / TGFβ-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM-3 / PDL1), INBRX-105 (4-1BB / PDL1), and GNS-1480 (PD-L1 / EGFR).

71. The method of any one of claims 46 to 70, further comprising co-administering an agonist of fms-related receptor tyrosine kinase 3 (FLT3).

72. The method of claim 71, wherein the agonist of FLT3 is selected from GS-3583 and CDX-301.

73. The method of any one of claims 46 to 72, wherein the mololimab and the bevacizumab are administered in a combined synergistic amount.

74. The method of any one of claims 46 to 73, wherein administration of the mololimab and the bevacizumab provides a synergistic effect.

75. The method of claim 74, wherein the synergistic effect is increased cancer cell death and / or decreased cancer cell growth when the effect of the combination is compared to the effect of the mololimumab or the bevacizumab alone.

76. The method of claim 74, wherein the synergistic effect is increased phagocytosis of cancer cells by macrophages when the effect of the combination is compared to the effect of either mololimab or bevacizumab alone.

77. The method of claim 74, wherein the synergistic effect is an increase or enhancement in tumor burden reduction when the effect of the combination is compared to the effect of either the mololimab or the sabevazumab alone.

78. The method of any one of claims 46 to 77, wherein the mololimab is first administered at a priming dose of less than 10 mg / kg and then administered at one or more therapeutic doses of at least 15 mg / kg, e.g., at least 30 mg / kg, 45 mg / kg, 60 mg / kg.

79. The method according to any one of claims 46 to 78, wherein the mololimab is first administered at a priming dose of less than 5 mg / kg and then at one or more therapeutic doses of at least 30 mg / kg, such as 45 mg / kg, 60 mg / kg.

80. The method of any one of claims 46 to 79, wherein the mololimab is first administered at a priming dose of 1 mg / kg, then at one or more therapeutic doses of 30 mg / kg, and subsequently at one or more therapeutic doses of 60 mg / kg.

81. The method of any one of claims 46 to 79, wherein the mololimab is first administered at a priming dose of 1 mg / kg, then at one or more therapeutic doses of 20 mg / kg, and subsequently at one or more therapeutic doses of 45 mg / kg.

82. The method of any one of claims 46 to 79, wherein the mololimab is first administered at a priming dose of 1 mg / kg, then at one or more therapeutic doses of 15 mg / kg, and subsequently at one or more therapeutic doses of 30 mg / kg.

83. The method of any one of claims 46 to 82, wherein the mololimab is administered intravenously, subcutaneously, or intratumorally.

84. The method of any one of claims 46 to 83, wherein the bevacizumab is administered at one or more doses in the range of 5 mg / kg to 15 mg / kg, e.g., 5 mg / kg to 7.5 mg / kg or 7.5 mg / kg to 15 mg / kg.

85. The method of any one of claims 46 to 84, wherein the bevacizumab is administered at one or more doses of 5 mg / kg.

86. The method of any one of claims 46 to 85, wherein the bevacizumab is administered intravenously, subcutaneously, or intratumorally.

87. The method of any one of claims 46 to 86, wherein the mololimab and the bevacizumab are administered in a first, second, and third 28-day cycle, in: a) For the first 28-day cycle, mololimab was administered at a dose of 1 mg / kg on day 1 and 30 mg / kg weekly (QW) starting on day 8; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15; b) for the second 28-day cycle, mololimab at a dose of 30 mg / kg weekly (QW); and bevacizumab at a dose of 5 mg / kg on days 1 and 15; and c) For the third 28-day cycle, mololimab was administered at a dose of 30 mg / kg Q2W; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15.

88. The method of any one of claims 46 to 86, wherein the mololimab and the bevacizumab are administered in a first, second, and third 28-day cycle, in: a) For the first 28-day cycle, mololimab was administered at a dose of 1 mg / kg on day 1 and 20 mg / kg weekly (QW) starting on day 8; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15; b) for the second 28-day cycle, mololimab at a dose of 20 mg / kg weekly (QW); and bevacizumab at a dose of 5 mg / kg on days 1 and 15; and c) For the third 28-day cycle, mololimab was administered at a dose of 20 mg / kg Q2W; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15.

89. The method of any one of claims 46 to 86, wherein the mololimab and the bevacizumab are administered in a first, second, and third 28-day cycle, in: a) For the first 28-day cycle, mololimab was administered at a dose of 1 mg / kg on day 1 and 15 mg / kg weekly (QW) starting on day 8; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15; b) for the second 28-day cycle, mololimab at a dose of 15 mg / kg weekly (QW); and bevacizumab at a dose of 5 mg / kg on days 1 and 15; and c) For the third 28-day cycle, mololimab was administered at a dose of 15 mg / kg Q2W; and bevacizumab was administered at a dose of 5 mg / kg on days 1 and 15.

90. The method of any one of claims 46 to 77, wherein the subject is a human.

91. A kit comprising one or more unit doses of: (a) an agent that inhibits binding between CD47 and SIRPα; and (b) an agent that inhibits binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA cognate receptors.

92. The kit of claim 91, wherein the one or more VEGFA cognate receptors are selected from fms-related receptor tyrosine kinase 1 (FLT1, also known as VEGFR1) and kinase insert domain receptor (KDR, also known as VEGFR2).

93. The kit of any one of claims 91 to 92, further comprising one or more unit doses of a chemotherapy regimen.

94. The kit according to any one of claims 91 to 93, further comprising components for the FOLFOX regimen, the FOLFIRI regimen, the XELIRI (also known as CAPIRI) regimen, the FOLFOXIRI regimen, the XELOXIRI regimen or the FOLFIRINOX regimen.

95. The kit of any one of claims 91 to 94, comprising components for use with the FOLFIRI regimen or the XELIRI regimen.

96. The kit according to any one of claims 91 to 95, comprising components for the FOLFOX regimen, the FOLFIRI regimen, the XELIRI (also known as CAPIRI) regimen, the FOLFOXIRI regimen, the XELOXIRI regimen or the FOLFIRINOX regimen.

97. The kit of any one of claims 91 to 96, comprising components for use with the FOLFIRI regimen or the XELIRI regimen.

98. The kit of any one of claims 91 to 95, wherein the agent that inhibits binding between CD47 and SIRPα and the agent that inhibits binding between vascular endothelial growth factor A (VEGFA) and one or more VEGFA cognate receptors are in separate containers.

99. The kit of claim 98, wherein the separate container is selected from the group consisting of a vial, an ampoule, and a pre-loaded syringe. 100 . The kit according to any one of claims 91 to 99 , wherein the agent that inhibits the binding between CD47 and SIRPα comprises an antibody that binds to CD47.

101. The kit of claim 100, wherein the antibody that binds to CD47 is selected from mololimab, leszolimab, leterlimab, lefalimab, AO-176, sirelimab (IBI-322), gentolizumab, ZL-1201, IMC-002, SRF-231, CC-90002 (also known as INBRX-103), NI-1701 (also known as TG-1801), and STI-6643.

102. The kit according to any one of claims 91 to 99, wherein the agent that inhibits the binding between CD47 and SIRPα comprises an antibody that binds to SIRPα.

103. The kit of claim 102, wherein the antibody that binds to SIRPα is selected from GS-0189 (also known as FSI-189), CC-95251, BI-765063, and APX-700. 104 . The kit according to any one of claims 91 to 99, wherein the agent that inhibits the binding between CD47 and SIRPα comprises a SIRPα-Fc fusion protein.

105. The kit according to claim 104, wherein the SIRPα-Fc fusion protein is selected from ALX-148, TTI-621, TTI-622, JMT601 (CPO107) and SL-172154.

106. The kit of any one of claims 91 to 105, further comprising one or more therapeutic antibodies.

107. A kit according to any one of claims 91 to 106, further comprising one or more blockers or inhibitors of one or more T cell inhibitory immune checkpoint proteins or receptors.

108. The kit of any one of claims 91 to 107, comprising a protein (eg, antibody) inhibitor of PD-L1 (CD274), PD-1 (PDCD1), or CTLA4.

109. The kit of any one of claims 107 to 108, comprising a protein (eg, antibody) inhibitor of PD-L1 (CD274) or PD-1 (PDCD1).

110. The kit of claim 108, wherein the protein (e.g., antibody) inhibitor of CTLA4 is selected from ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884 (zeflimab), BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN2041, JHL-1 155. KN-044, CG-0161, ATOR-1144, PBI-5D3H5, FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4) and AK-104 (CTLA4 / PD-1).

111. The kit of claim 108, wherein the protein (e.g., antibody) inhibitor of programmed cell death 1 (PDCD1; NCBI gene ID: 5133; CD279, PD-1, PD1) is selected from the group consisting of sepalizumab (AB122, GLS-010, WBP-3055), pembrolizumab (KEYTRUDA®, MK-3475, SCH900475), nivolumab (OPDIVO®, BMS- 936558, MDX-1106), cemiprilimab (LIBTAYO®; cemiprilimab-rwlc, REGN-2810), pidilizumab (CT-011), AMG-404, MEDI0680 (AMP-514), spartalizumab (PDR001), tislelizumab (BGB-A317), toripalizumab (JS-001), genoluzumab (CBT-501, APL-501, GB 226), SHR-1201, carrelizumab (SHR-1210), sintilimab (TYVYT®; IBI-308), dotalimumab (TSR-042, WBP-285), lanrolizumab (MK-3475); saxanthlimab (PF-06801591), silimab (JNJ-63723283), slulizumab (HLX-10), rivolimab (MGA-012), bastimumab (AGEN2034), palolizumab (BCD 100), brigatinib (ABBV-181), woprelizumab (JTX-4014), AK-103 (HX-008), AK-105, CS-1003, BI-754091, LZM-009, Sym-021, BAT-1306, PD1-PIK, tepolizumab (MGD013; PD-1 / LAG-3), RO-7247669 (PD-1 / LAG-3), FS-118 (LAG-3 / PD -L1), RO-7121661 (PD-1 / TIM-3), RG7769 (PD-1 / TIM-3), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTL A4), KN-046 (PD-1 / CTLA4), XmAb-20717 (PD-1 / CTLA4), AK-104 (CTLA4 / PD-1) and MEDI-5752 (CTLA4 / PD-1).

112. The kit according to claim 108, wherein the protein (e.g., antibody) inhibitor of the CD274 molecule (NCBI gene ID: gene ID: 29126; B7-H, B7H1, PD-L1) is selected from atezolizumab (TECENTRIQ®), avelumab (BAVENCIO®; MSB0010718C), envolimab (ASC22), durvalumab (IMFINZI®; MEDI-4736), BMS-936559 (MDX1105), coxilimab (CK-301), lodalimab (LY 3300054), galivizumab (BGB A333), envolimab (KN035), oclimab (HLX 20), manellimab (BCD-4736), selegiline (selegiline ... 135), CX-072, CBT-502 (TQB2450), MSB-2311, SHR-1316, Sugelimumab (CS-1001; WBP3155), A167 (KL-A167, HBM 9167), STI-A1015 (IMC-001), FAZ-053, BMS-936559 (MDX1105), INCB086550, GEN-1046 (PD-L1 / 4-1BB), FPT-155 (CTLA4 / PD-L1 / CD28), M7824 (PD-L1 / TGFβ-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM-3 / PDL1), INBRX-105 (4-1BB / PDL1), and GNS-1480 (PD-L1 / EGFR).

113. The kit of any one of claims 91 to 112, further comprising co-administering an agonist of fms-related receptor tyrosine kinase 3 (FLT3).

114. The kit of claim 113, wherein the agonist of FLT3 is selected from GS-3583 and CDX-301.

Citation Information

Cited By

  • Application of RNF128 gene in prognosis of gastrointestinal stromal tumor

    CN120400348A

  • Dual-function nano-drug based on autophagy targeting chimera-T cell connector and preparation method and application of dual-function nano-drug

    CN121401215A